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Abstract 
Background 
Prostate cancer is the UK number one male cancer. Evidence from 
epidemiological studies suggests only age, race and family history as established 
risk factors. Other factors such as low dose diagnostic radiations and surrogate 
hormone markers such as baldness, finger length pattern and acne are 
hypothesized to have a potential role in the aetiology of prostate cancer. It is 
evident that genetics plays an important role in prostate cancer aetiology. 
This thesis focuses both environmental and genetic factors. The environmental 
factors include selected surrogate hormone markers, medical diagnostic radiation 
procedures and family history of prostate cancer. The genetic part explores 
genetic polymorphisms that could have implications for interactions with 
exposures studied. Single nucleotide polymorphisms (SNPs) involved in 
mechanistic pathways related to DNA repair genes and potential hormone 
marker genes were the main targets. 
Aims 
1. To extensively review and analyses of some important environmental 
factors such as family history, diagnostic radiations and hormone 
markers such as male pattern baldness, right hand pattern and acne. 
2. To evaluate the role of DNA repair genes involved in diagnostic radiation 
process in the aetiology of prostate cancer and the hormone genes such 
as male pattern baldness in prostate cancer risk. 
3. To assess gene environment interactions of selected genes and studied 
exposures. 
Methods 
The study was a nationwide population based case- control study, 1112 cases 
and 1872 controls were included. Data collection spanned over a ten year period 
from 1999-2009. The data collection tool was self completed postal 
questionnaire with ten sections on lifestyle and a separate section on diet. 
Biological samples including toenail clippings and 18ml blood samples were 
collected. Data on family history 
, 
diagnostic radiations and hormone markers 
such as baldness, right hand pattern and acne were analysed using multivariate 
logistic regression to obtain odds ratios (OR) and 95% confidence intervals (CI). 
Blood samples were processed and DNA was extracted for further genotyping. 
Sixteen selected SNPs from two groups of genes including DNA repair and 
balding genes were analysed to obtain their estimated risks. Gene and 
environment interaction analysis was carried out to assess the interactions 
between selected SNPs and environmental factors. 
Results 
Family history 
Family history of prostate cancer in first degree relatives (father and brother) 
was a strong risk factor for prostate cancer (OR 7.93,95% C. I. 6.17-10.20). 
Within subjects age <60 years with positive prostate cancer family history a 
highly significant association was observed as compared to risk seen in all ages 
(OR 12.55 compared to 7.93). 
A modest risk was observed in a group of subjects with the positive family 
history of breast cancer in their first degree female relatives (mother, sister and 
daughter) (OR 1.39,95% C. I. 1.07-1.79). 
Diagnostic radiation 
Hip / pelvic X-ray procedure increased the risk of developing prostate cancer in 
subjects who reported expose to procedure one time regardless time of the 
exposure (OR 3.15,95% C. I. 1.81-5.47). Furthermore when time of exposure 
was censored at > 5,10 or 15 years prior to case diagnoses or to control 
receiving questionnaire, all estimated risks were statistically significant (>5years 
OR 3.42,95% C. I. 1.56-7.50, >10years OR 4.18,95% C. I. 1.69-1.30 and >15 
years OR 4.69,95% C. I. 1.77-12.47) as compared to those who were 
unexposed. All other procedures such as barium meal, barium enema, IVP and 
Upper leg/thigh X-ray were non significant. 
Hormone markers 
Baldness: 
Prevalence of baldness increased with age in both case and control group, 
however there was no association between balding and prostate cancer risk at 
any age (20s, 30s and 40s) (all confidence intervals include 1). Subjects with 
positive family history of prostate cancer in their first degree relatives and who 
reported having had hair recession either frontal or vertex balding at age 30s 
show a positive association with prostate cancer risk (OR 2.06,95% C. I. 1.01- 
3.83 and OR 1.85,95% C. I. 1.03-3.31) respectively. 
Right hand pattern: 
Index longer than ring finger showed a borderline statistically significant risk 
reduction (OR 0.63 95% C. I 0.37-1.07) as compared to index finger shorter than 
ring (reference group). While Index finger equal to ring appeared to be non 
significant when compared with reference group (OR 1.01,95% C. I. 0.83-1.22). 
iv 
Acne: 
Acne was not associated with prostate cancer risk at puberty, age 20s, teens 
through 20s. However subjects who reported having had acne at age 30s and 
who reported having had acne from their teen through to age 30s are at greater 
risk as compared to subjects who never had acne (OR 1.59,95% C. I. 1.06-2.39 
and OR 1.60,95% C. I. 1.04-2.45 respectively). 
DNA repair genes 
The prevalence of all eleven polymorphism is very similar in both cases and 
controls. None of the analysed SNPs appeared to be a risk factor for prostate 
cancer. 
Baldness genes 
There was no associations between five SNPs and prostate cancer risk (all 
confidence interval include 1). 
V 
Gene-environment interaction 
Hip/pelvic X-ray, DNA repair genes and prostate cancer risk: 
Gene and environment interaction analysis using multiplicative model suggested 
a modest increased risk with (of Xeroderma Pigmentosum Group C (XPC 
Lys939G1n gene, rs2228001) (OR 1.66,95% C. I. 1.02-2.71). 
Universal X-ray exposure (expose to any of the 5 studied radiological 
procedures), DNA repair genes and prostate cancer risk: 
The negative interaction was suggested with SNP rs7003908 (XRCC7G6721T) 
(OR 0.60,95% C. I. 0.39-0.93). 
Baldness genes: 
There was no multiplicative interaction between "balding genes", baldness and 
prostate cancer. 
vi 
Conclusion 
In summary, family history was a strong risk factor for prostate cancer. The 
findings confirm the importance of low dose ionizing radiations in prostate cancer 
aetiology. Risk reduction seen in subjects with female phenotypic hand pattern 
and risk increased seen in subjects who reported appearance of acne at age 30s 
and from their teens to their 30s and also subjects with positive prostate cancer 
in their family who reported hair recession at age 30s supported the probable 
role of androgens in prostate carcinogenesis either linking with pre and post 
natal life exposure. 
Polymorphisms in DNA repair genes along with exposures to universal hip/pelvic 
and universal hip X-ray suggested some interactions between the genetic and 
environment exposure while polymorphisms in balding genes and balding 
phenotype did not support any interactions. The interaction analysis between 
gene and environment may help identifying genetically predisposed individuals 
who are more sensitive to environmental exposures compared to non genetically 
predisposed. 
Key words: non screen detected prostate cancer; family history; diagnostic 
radiation, male pattern baldness, right hand pattern, acne, gene and 
environmental interaction, prostate cancer risk. 
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Chapter 1 Prostate and it's cancer and general demographic 
features of study population 
1 
This chapter aims to describe basic structure and function of prostate gland 
along with its pathology. The review of the literature includes both clinical as 
well as epidemiological aspects of prostate cancer. Clinical aspects include 
symptoms and different diagnostic procedures including a brief review on 
prostate specific antigen (PSA). It also covers staging and grading of prostate 
cancer. The epidemiological part presents the recent incidence, prevalence, 
survival and mortality rates of prostate cancer. 
There is also overview of general demographic features of the study population. 
General demographic features are also discussed by comparing data with 
previous evidence from different epidemiological studies. 
1 Literature review 
1.1 Anatomy and physiology of the prostate 
The prostate is an encapsulated epithelial gland located under the urinary 
bladder and it surrounds the upper part of the urethra (see Figure 1-1). The 
prostate gland is divided into three zones, the peripheral, transition and central 
zones. The peripheral zone comprises the major portion of the prostate gland 
(Kirby et al, 1996). 
The main function of the prostate gland is to produce prostatic secretions. These 
secretions contribute about 20% of the volume of seminal fluid and have 
neutralizing effect on acidic vaginal secretions for increased sperm viability and 
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contain enzymes responsible for the formation of a seminal clot to retain sperm 
in the female reproductive tract (Sherwood, 2004). 
Figure 1-1 Anatomy of the prostate gland 
Prostate Gland 
Prostate 
gland 
Urethra 
Epididymis 
Bladder 
'5 dr_irn:, rlet, n: 
(Figure adopted from www. medicinenet. com/prostatecancer/article. htm) 
1.2 Pathogenesis of prostate cancer 
The majority of prostate cancers (>70%) are classified as adenocarcinoma or 
glandular cancer, arising from normal semen-secreting prostate gland cells near 
the capsule from the peripheral zone and nearly 5-10% arise from central zone 
and the remaining from the transition zone, which is a common site for benign 
prostatic hyperplasia (BPH) (Devita Jr et al, 2005; Kirby & Patel, 2009). The 
exact pathogenesis of prostate cancer is not known but it has been suggested 
that a condition known as carcinoma in situ or prostatic intraepithelial neoplasia 
(PIN) classified as low or high grade leads to the development of invasive 
carcinoma (Willis & Wians Jr, 2003). PIN is usually associated with cancers 
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zTesticle 
arising from the peripheral zone, the most common site for prostate cancer 
(Kirby et al, 1996). Number of factors affecting the process of oncogenesis of 
prostate cancer such as age, race, family history, environmental factors e. g. 
diet, radiations etc, steroid hormones (testosterone), but the process of 
oncogenesis yet to be cleared (see Figure 1-2). 
Figure 1-2 shows the probable factors involved and pathogenesis of 
prostate cancer 
Normal epithelium PIN (Gradel) PIN (Grade 2) PIN (Grade 3) Prostate cancer 
? 15-30 years ?4 years ?4 years ?9 years 
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1.3 Clinical features of prostate cancer 
Early and localised prostate cancer usually causes no symptoms and is often 
diagnosed during a routine investigation. The main symptoms of localised 
spread are increased frequency of urination, urgency, poor stream, haematuria 
and sometimes blood in the semen. Bone pain is often felt by patients with bone 
metastasis, the first and most common site of metastasis. Metastatic disease to 
the spinal cord produces weakness and numbness in the lower extremities due 
to cord compression (Tanagho & McAninch, 2004). 
1.4 Diagnosis of prostate cancer 
The important diagnostic investigations for detection of prostate cancer are: 
1. Digital rectal examination (DRE). 
2. Serum tumour markers such as PSA and prostatic acid phosphatase 
(PAP). 
3. Biopsy. 
4. Diagnostic imaging such as transrectal ultrasound (TRUS), computed 
tomography and bone scan. 
1.4.1 Prostate specific antigen 
PSA is secreted by glandular epithelial cells of the prostate as a glycoprotein and 
is currently the most important and widely used serum marker for prostate 
cancer. The main function is to liquefy semen after, ejaculation (Kirby & Patel, 
2009). There is no conventional cut off point for PSA as in the past the 4. Ong/ml 
was used as cut-off point, but new data showed that in men younger than 60 
years a cut-off of 2.5ng/rnl can double the cancer detection rate from 18-36% 
with minimal negative effect on specificity. As PSA is organ specific not cancer 
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specific, PSA level can also increase in the other conditions other than prostate 
cancer such as BPH, prostatitis, urinary tract infections (UTIs), perineal or 
prostatic trauma, recent ejaculation and even bicycle riding and can give false 
positive and false negative results. 
Since the start of PSA screening in 1986 the detection of early prostate cancer 
became much easier but the PSA sensitivity and specificity remain controversial 
and for that several other more specific PSA derivatives are now used to improve 
the clinical value of the test such as PSA density, PSA velocity, Age specific 
reference ranges and different molecular forms such as free PSA and free: bound 
ratio (Berger et al, 2007; Kirby & Patel, 2009; Potter & Carter, 2000). 
The clinical usefulness of PSA density and velocity has potential limitations such 
as in PSA density, volume calculation (usually measured by trans-rectal ultra 
sound [TRUS]), PSA variability (shows natural fluctuation) and sampling bias 
(Kirby & Patel, 2009) and in PSA velocity, is its too few measurements within 
short period of time (at least three values over one or two years) which could be 
inaccurate as PSA levels show natural fluctuations (Kirby & Patel, 2009). 
Age specific ranges to improve cancer detection in younger men are based on 
the concept of by lowering the normal range of PSA level and to have more age- 
specific references values. Based on evidence from different studies that there 
are variations in 
. 
PSA serum level of age-specific reference groups in different 
races such is lower in Japanese and higher in African-American as compared to 
white men. May be because of different genetic/physiological composition, it is 
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now crucial to have different age-specific cut-off points for different races 
(Morgan et al, 1996; Oesterling et al, 1995). 
Ratio of free (unbound) to total PSA helps in distinguishing between BPH and 
prostate cancer because, due to unknown reasons free PSA is lower in prostate 
cancer as compared to BPH (Elabbady & Khedr, 2006; Zucchelli et a/, 1997). 
However, many clinicians are still reluctant to adopt these modifications because 
of unclear benefits (Wilbur, 2008) and still 4. Ong/ml is used as standard cut-off 
point to consider biopsy. 
1.4.1.1 Screening for prostate cancer 
Screening of prostate cancer is based on DRE and serum PSA level (Stenman et 
al, 1994). PSA is the single most effective screening test available for early 
detection of prostate cancer and can detect twice the number of prostate cancer 
cases compared to DRE only. But its predictive value increases if combined with 
DRE (Kirby & Patel, 2009). In recent years, prostate cancer screening using the 
PSA has gained attention in many parts of the world and this may be one of the 
reasons for the steep rise in prostate cancer incidence (Coldman et al, 2003). 
Because it is evident from different reviews that the benefits of widespread use 
of this test are still unclear, the government policy in the UK for the National 
Health Service (NHS) prostate cancer programme, supports this view, with the 
addition of informed decision of the individual (Donovan et al, 2001). 
In the UK and other European countries, PSA testing is not recommended for 
screening because: 
", 
Some men with prostate cancer do not have a raised PSA level. 
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"2 out of 3 men with a raised PSA do not have prostate cancer. 
" 
Natural history of prostate cancer poorly understood. 
" 
There is uncertainty about the best way to treat early prostate cancer. 
" 
The treatments can cause unpleasant side effects (NHS, 2008; Schroder, 
2005; Selley et al, 1997; Thompson et al, 2004). 
PSA screening also results in overdetection and lead time bias (the difference in 
time between screen detection and clinical detection in the absence of 
screening). Lead-time bias is estimated to be 5-12 years, depending on men's 
age at screening (Draisma et al, 2003; Parker et al, 2006; Pashayan et al, 
2006). 
According to the American Urological Association and American Cancer Society 
(ACS) guidelines, the PSA and Digital rectal examination (DRE) should be 
suggested every year, starting from the age of fifty, to men who have a life 
expectancy of ten years. Prior to that informed choice with the help of a clinician 
must be obtained (Smith et al, 2003). 
Recently, the findings from a large European trial suggested that unnecessary 
biopsies can be avoided by using individual prostate cancer risk prediction. The 
risk can be calculated using the risk calculators combining for example the 
logarithmic transformations of prostate volume and prostate-specific antigen 
(PSA), digital rectal examination, previous biopsy status, and age (Cavadas et al, 
2010). Results from another recent European Randomized Study of Screening 
for Prostate Cancer evaluating the effect of screening with prostate-specific- 
antigen (PSA) testing on death rates from prostate cancer showed reduction in 
mortality rates by 20% but was associated with increased risk of over diagnosis 
(Schröder et al, 2009). 
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1.4.1.1.1 Active Surveillance 
Nearly 50-80% of all prostate cancer cases detected by PSA are over diagnosed 
and remained asymptomatic even without treatment. On the other hand it is 
also responsible for >9000 deaths/year in the UK. Therefore it is important to 
distinguish patients who actually need treatment from those who merely need 
careful monitoring. Active surveillance is relatively new method of closely 
monitoring low risk prostate cancer cases to avoid unnecessary treatment. It 
involves close monitoring of PSA, with repeat biopsy. The decision for starting 
treatment based on evidence of disease progression (PSA doubling time or by 
looking at grading `upgrading' at repeat biopsy). Active surveillance aims to 
reduce the burden of side effects from treatment without compromising survival. 
It is different approach as compare to watchful waiting, in which if treatment is 
required should be palliative (Hardie et a/, 2005). 
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1.4.2 Staging and grading of prostate cancer 
1.4.2.1 Staging 
There are two staging systems to evaluate the spread of prostate cancer, (1) the 
Jewett-Whitmore system and (2) the Tumour, Nodes, Metastasis (TNM) staging 
system. TNM is commonly used staging system in UK. This system assesses the 
tumour size, the number of lymph nodes involved and the presence of 
metastasis (Schroder et a!, 1992; Selley et a!, 1997). 
The TNM classification (Kirby & Patel, 2009; Wittekind. C et al, 2005) 
Primary tumour 
TX Primary tumour cannot be assessed 
TO No evidence of primary tumour 
Ti Clinically inapparent tumour not palpable or visible by imaging 
Tia Tumour incidental; histological finding in 5% or less of tissue 
resected 
T1b Tumour incidental; histological finding is more than 5% of tissue 
resected 
T1c Tumour identified by needle biopsy (e. g. because of elevated PSA) 
T2 Tumour confined within the prostate' 
T2a Tumour involves 50% or less of one lobe 
T2b Tumour involves more than 50% of one lobe but not both lobes 
T2c Tumour involves both lobes 
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T3 Tumour extends through the prostatic capsule2 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structure other than seminal vesicles, 
bladder neck, external sphincter, rectum, levator muscles and/or pelvic wall 
Regional lymph nodes 
Nx Regional lymph nodes cannot be assessed 
NO No regional lymph node metastasis 
Ni Regional lymph node metastasis 
Distant metastasis3 
Mx Distant metastasis cannot be assesed 
MO No distant metastasis 
Ml Distant metastasis 
Mia non-regional lymph node(s) 
Mib Bone(s) 
Mic Other site(s) 
1 Tumour found in one or both lobes by needle biopsy, but not palpable or visible by 
imaging, is classified as T1c. 
2 Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is not 
classified as T3, but as T2. 
3 When more than one site of metastasis is present, the most advanced category should be 
used. 
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1.4.2.2 Grading 
The Gleason grading is widely recognised and frequently used to classify the 
tumour because it is reproducible, simple and predictable. This system has 
prognostic significance and value in selecting the treatment of choice. This is the 
most common grading system used in the UK, based on the evaluation of cyto- 
architectural details of individual cancer cells (Miller & Torkko, 2001). 
Five distinct patterns of growth from well to poorly differentiated are described 
on a scale from pattern 1 to 5 (Kirby & Patel, 2009). 
Table 1-1 Five stages of Gleason grading for prostate cancer and their 
histological features 
Grade Histological features 
1 small, uniform glands with minimal nuclear changes 
2 medium size acini, More closely arranged but still separated by 
stromal tissue 
3 marked variation in glandular size and organization with infiltration of 
stromal and neighbouring tissues(most common finding) 
4 marked atypical cells with extensive infiltration 
5 sheets of undifferentiated cancer cells 
The final Gleason score is the sum of grades of the primary and secondary 
growth pattern. Mostly prostate tumours have a Gleason score of ?6 (True et 
al, 2006). 
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1.5 Epidemiology 
1.5.1 Incidence 
According to Cancer Research UK, more than 34,000 new cases are diagnosed 
every year, making it the most common cancer in men in the UK. It has been 
reported that there is significant increases in incidence of prostate cancer in 
many countries, including the UK (Hsing et al, 2000). From 1975 to 2007 there 
was threefold rise in prostate cancer incidence with 33/100,000 in 1975 to 
97/100,00 in 2007 (see Figure 1-3). This steep rise in the incidence may be due 
to widespread use of PSA in UK, it was estimated that around 5-6% of men over 
the age 40 have PSA test each year (Cancer Research UK, 2010c; N Ireland 
Cancer Registry, 2010; Office for National Statistics, 2010). 
Figure 1-3 Age standardized incidence rate, Prostate cancer GB, 1975- 
2008 
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Taken from the webpage of Cancer Research UK (2010) 
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There are wide international and inter-ethnic differences in prostate cancer 
incidence (Gronberg, 2003; Hass & Sakr, 1997). In 2008, an estimated 913,000 
men were diagnosed with prostate cancer worldwide and more than two third 
were in developed countries (Andriole et al, 2009; Ferlay. ] et al, 2010). These 
differences may be due to genetic variations, exposure to external risk factors or 
may be due to different diagnostic modalities and variations in cancer 
registration and differences in health care provision. Another important reason 
for these variations in incidence rate may be the differences in life expectancy, 
as the prostate cancer is an age related disease (Kirby et al, 1996). Though 
geographical variations in prostate cancer in England and Wales were not clear 
but the incidence rate is slightly higher in north England than in the south (Quinn 
& Babb, 2000). 
1.5.2 Prevalence 
In UK, the prevalence of prostate cancer is high because of high incidence and 
five-year survival rate after diagnosis. Nearly 215,000 prostate cancer cases are 
living in UK. There could be a variety of reasons for this high prevalence such as 
trans urethral resection of the prostate (TURP) and PSA testing revealing greater 
number of earlier, latent and slow growing tumours (Cancer Research UK, 
2010c). 
1.5.3 Survival rate 
Although the incidence of the disease has been on the rise during last 20 years, 
the survival rates have improved during this period with a relative five year 
survival rate of 77% during 2001-2006, compared with 31% during 1971-75. 
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The survival rate depends upon the stage of disease at the time of diagnosis 
, 
if 
it is metastatic by that time five-year survival rate become much lower (30%) 
(Cancer Research UK, 2010c; Office for National Statistics (ONS), 2007). 
1.5.4 Mortality rate 
There were about 10,168 deaths occur in UK from prostate cancer in 2008. 
Nearly 12% men died in UK from prostate cancer, making it most common cause 
of death after lung cancer. Mortality for prostate cancer in UK is 23.9/100,000 
in 2008 (Cancer Research UK, 2010d; Etzioni et al, 1999; ISD Online, 2010; 
Office for National Statistics, 2009). As the graph shows, mortality is on decline 
as compare to 1990's. This may be due early detection and improved treatment. 
Figure 1-4 Age standardized mortality rate, Prostate cancer GB, 1975- 
2008 
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1.6 Review of demographic factors of prostate cancer 
1.6.1 Age 
Age is an established risk factor for prostate cancer. It is common in the elderly 
population and with an increasing aging population, prostate cancer is becoming 
one of the major public health problems (Hass & Sakr, 1997). In 65% of men 
aged >80 years, prostate cancer remains symptomless and only revealed at the 
time of post mortem examination (Pienta & Esper, 1993). There is evidence 
from epidemiological studies that despite prostate cancer being an age related 
disease, its onset might start at a young age due to substantial increase in 
androgens at the time of puberty (Diamandis & Yu, 1996). Delongchamps et al, 
2006, however, stated age as a controversial risk factor, they suggested that it 
is not age directly that is responsible, but aging probably provided the time 
necessary for the cumulative effects of environmental exposures and cellular 
changes essential for the development of a carcinogenic lesion (Delongchamps et 
al, 2006). 
1.6.2 Ethnicity 
International variations in prostate cancer incidence have suggested the crucial 
role of a variety of environmental risk factors, including ethnicity. According to 
previous studies, three-quarters of all incident cases occur in developed 
countries with the highest incidence in North America and lowest rates in Asian 
countries. In the UK, black Caribbean and black Africans have 2-3 times more 
risk of developing prostate cancer than the white men (Ben-Shlomo et al, 2008; 
Cancer Research UK, 2007; Jack et al, 2007; Wild et al, 2006). Morton reported 
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racial differences in adenocarcinoma of the prostate in North American men. 
The disease is more frequently developed in black Americans and who also have 
a worse prognosis as compared to white Americans (Hass & Sakr, 1997). There 
could be a variety of explanations for these racial differences like genetic factors, 
dietary patterns, diagnostic approaches and access to care (Bostwick et a/, 
2004). 
1.6.3 Social class 
In UK social class is determined by considering the employment status and 
occupation. There are 6 categories of social class, class I-Professional, class II- 
Managerial and technical occupations, class III-(N) skilled non-manual and class 
III-(M) skilled manual, IV-Partly skilled occupations, V- Unskilled occupation 
(HMSO, 1991). Evidence that social class influences prostate cancer risk 
remains inconclusive. Evidence from previous studies suggested that prostate 
cancer incidence is higher in high social class but poorer outcome is associated 
with low social class (Gilligan & Gilligan, 2005). 
Occupation is of key importance in determining social class. There is evidence 
from epidemiological studies that few occupations have 7-12% increased risk of 
prostate cancer such as farmers and other agricultural workers and this may be 
due to high consumption of meat and fatty diet and exposure to certain 
chemicals used in agriculture. There is also high risk of prostate cancer in 
workers in heavy industry, news paper printing and rubber manufacturing. 
Possible explanation for high incidence may be chemical exposure or other 
hidden factors present in the working environment (Hsing & Chokkalingam, 
2006). 
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1.6.4 Education 
Evidence is very limited for education as a risk factor of prostate cancer and 
discussed in the discussion part of this chapter. 
1.6.5 Marital status 
Evidence from several previous epidemiological studies for marital status as a 
risk factor for prostate cancer is inconsistent (Newell et al, 1989; Newell et al, 
1987; Talaminil et al, 1986). But as a social indicator, marital status may help 
in alleviating different stresses of life by leading to more sober and disciplined 
lifestyle and help protecting against various social disparities, which may protect 
from prostate cancer risk (Nielsen et al, 2007). 
1.7 The study hypotheses and aims 
After close examination of literature presented in this thesis, this study proposes 
to meet following study hypotheses and aims: 
The study hypotheses 
1. Prostate cancer risk is increased with positive family history of prostate 
and breast cancer. 
2. Prostate cancer risk increased after an exposure* to low-dose ionising 
radiations. 
3. There is an association between surrogate markers of male hormones 
(hand pattern, acne, balding) and prostate cancer risk. 
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4. There are possible interactions between environmental exposures 
including low dose diagnostic radiation, balding, acne and selected single 
nucleotide polymorphisms. 
The study aims 
This study has 2 main aims. The first aim is to examine associations of selected 
environmental exposures such as family history of prostate cancer in the first 
degree relatives, low dose diagnostic radiation, surrogate markers of male 
hormones (hand pattern, acne, balding) and prostate cancer risk. The second 
aim is to start to explore possible interactions between environmental exposures 
including low dose diagnostic radiation, balding, acne and selected single 
nucleotide polymorphisms that are suggested to relate with disease 
aetiology/pathways. 
More specific hypotheses and aims for each of these investigations are described 
in each chapter. 
1.8 Demographic features of study population 
In this chapter, the following basic demographic features were analysed and 
discussed. 
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1.8.1 Response rate 
Case and control response rate was assessed individually and was calculated on 
the bases of returned questionnaires as compared to sent number of 
questionnaires. 
1.8.2 Age 
Data on age for cases was received from GPs and from Royal Marsden Hospital 
and for controls from different GP practices from where they had been selected. 
If age at diagnosis was missing due to any reason, age at diagnosis was 
calculated by subtracting diagnosis date (available with the case downloads) 
from date of birth. 
1.8.3 Ethnicity 
The questionnaire used in study has ten different ethnic groups white, Black- 
Caribbean, Black-African, Indian, Pakistani, Jewish, Sephardic, Ashkenazi, 
Chinese and Other. Due to very small number of subjects in last three groups 
(Sephardic, Ashkenazi and Chinese), they was merged in group "other". 
1.8.4 Social class 
Social class was determined using individual's longest held job and classified into 
6 classes class I-Professional, class II-Managerial and technical occupations, 
class III-(N) skilled non-manual and class III-(M) skilled manual, class IV-Partly 
skilled occupations, class V- Unskilled occupation (HMSO, 1991). For analysing 
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the risk of prostate cancer social class was used as trichotomous variable based 
on similarities of class. Social class I=I-II, 2= III-IV, 3=V-VI. 
1.8.5 Education 
Education level was classified into four groups. First group with no formal 
education, second GCSE, 0 level or equivalent, third group with A levels or 
equivalent and fourth group was higher and professional qualifications, this 
group also includes other with higher education. 
1.8.6 Marital status 
In marital status, married and common law partners were merged in one group 
and widowed, divorced or separated were merged in other group. Third group 
was single. 
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1.9 Results 
1.9.1 Response rate 
The response rates of study participants is shown in table 1-2 
Table 1-2 Response rate of cases and controls 
Study phase Case (%) Control (%) 
First phase 78.9 61.8 
Second phase 91.0 87.0 
Total 85.0 74.4 
The overall response rate for cases was 85.0% and for controls 74.4%. 
1.9.2 Age 
Table 1- 3 shows age statistics 
Table 1-3 Age at diagnosis 
Group Number Median Age range 
Case 
Control 
1112 
1872 
60 
59 
36-85 
36-76 
Cases on average are slightly older than control 
. 
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1.9.3 Ethnicity 
Table 1-4 below illustrated distribution values of ethnic groups 
Table 1-4 Distribution of ethnic groups 
Ethnic Group Case (%) Control (%) 
White 1055(96.4) 1829(98.7) 
Black-Caribbean 13(1.2) 2(0.1) 
Black-African 5(0.5) 3(0.2) 
Indian 7(0.6) 7(0.4) 
Pakistani 2(0.2) 0(0.0) 
Jewish 4(0.4) 5(0.3) 
Other 8(0.7) 7(0.4) 
Total 1094(100.0) 1853(100.0) 
Missing 18 19 
Chi-square test, p-value 0.000 
The majority of study subjects are Caucasian (over 90%). 
1.9.4 Social class 
Tables- 5 shows the distribution and estimated risk values of social class 
Table 1-5 Distribution and risk estimates of social class 
Social class Case (%) Control (%) ORt 95%CI Lower-upper 
I&II 577(53.9) 978(54.9) 1.00 
III & IV 401(37.4) 673(37.8) 1.04 0.88-1.22 
V& VI 93(8.7) 130(7.3) 
- 
1.26 0.94-1.67 
Total 1071(100.0) 1781(100.0) P for trend 0.23 
Missing 41 91 
tAdjusted for age 
Class I-Professional, Class II-Managerial and technical occupations, Class III-(N) skilled non-manual 
and class III-(M) skilled manual, Class IV-Partly skilled occupations, Class V- Unskilled occupation 
Results indicate that social class distribution is similar between case and control 
group and is not associated with prostate cancer risk (p for trend 0.23). 
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1.9.5 Education 
Table 1-6 shows distribution values and odds ratio of education 
Table 1-6 Education and prostate cancer risk 
Education level Case (%) Control (%) ORt 95%CI Lower-upper p-value 
None 294 (27.1) 531(28.7) 1.00 
GCSE or 0 level 198(18.3) 308(16.7) 1.25 0.98-1.59 0.07 
A level 74(6.8) 134(7.2) 1.05 0.75-1.48 0.76 
Higher or 
Professional 
518(47.8) 876(47.4) 1.16 0.94-1.43 0.18 
Total 1084(100.0) 1849(100.0) 
Missing 28 23 
tadjusted for age and social class 
Almost 50% of cases and controls reported having had achieved higher 
education or professional level. About a quarter of study subjects had no 
education. Odd ratios suggest that education level is not associated with 
prostate cancer risk. 
1.9.6 Marital status 
Table 1-7 shows the marital status and prostate cancer risk. 
Table 1-7 Marital status and prostate cancer risk 
Marital status Case (%) Control (%) ORt 95%CI Lower-upper 
Married or partner 906(82.6) 1572(84.8) 1.00 
widowed or divorced or 
separated 
140(12.8) 228(12.3) 1.05 0.83-132 
Single 51(4.6) 54(2.9) 1.63 1.10-2.41 
Total 1097(100.0) 1854(100.0) 
Missing 15 18 
tadjusted tor age and social class 
About 80% of both case and control were still married or living with their 
partner. Being Single shows a moderate increase risk with (OR 1.63 and 95% 
C. I. 1.10-2.41). 
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1.10 Discussion 
1.10.1 Response rate 
Response rate is one of the essential elements of epidemiological studies as it 
provides information on the proportion of the targeted population who has 
participated (Slattery et al, 1995). In this study, the response rate for the first 
phase was 78.9% for cases and 61.8% for controls and for the second phase 
response rate for cases 91.0% and 87.0% for controls. The overall response 
rate for cases was 85.0% and for controls 74.4%. Cases responded more than 
controls. This may be due to their illness and therefore are more receptive. 
Achieving high response rate is vital in case-control studies as it decreases the 
chance that selection bias have any impact on the results (Colt et al, 2005). 
In summary, the study has yielded a good response rate from both groups. 
1.10.2 Age 
Median age for cases was 60 years and for controls it was 59 years. The findings 
of most of the previous studies support increasing age as a strong risk factor for 
prostate cancer, though it can also occur at a young age (Veldhuizen et al, 
2006). Clinical prostate cancer is rare under fifty years of age as compare to 
higher incidence in men age over sixty (Kirby & Patel, 2009). After fifty years of 
age incidence increase steadily and it is at faster rate as compare to any other 
malignancy (Hass & Sakr, 1997). While Bostwick et al, 2004 stated that it is 
oxidative stress accumulate with aging may be the one of risk factor for the 
prostate cancer but evidence on this theory is limited (Bostwick et al, 2004). 
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In this study case and controls were age-frequency matched thus age was not 
computed for estimated risk. 
1.10.3 General characteristics 
1.10.3.1 Ethnicity 
The majority of the study population is Caucasian (>95%). There were no 
differences in the ethnicity in cases and controls. Globally, the incidence of 
prostate cancer varies with ethnicity, with highest incidence in black Americans 
with very poor prognosis and lowest incidence is among men in China and Japan 
(Whittemore et al, 1995). 
Though the previous data suggest that ethnicity is a well established risk factor 
for prostate cancer, it still needs to be investigated as to whether ethnicity is a 
direct cause or there are other factors which are closely related with different 
ethnic backgrounds that affect quality of life such as socioeconomic status, 
education, awareness and access to health care. 
1.10.3.2 Social class 
The proportion of cases and controls are fairly similar in each social class 
although the highest percentage was found in social class I and II. There was no 
significant association between social class and prostate cancer risk. Similar 
findings have been previously reported showing no association between social 
class and prostate cancer risk (Severson et al, 1989). The higher percentages in 
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upper classes may be due to overall improvement in socioeconomic status of UK 
population over the years. Possible explanation of almost similar percentages of 
cases and controls in each class is may be due to successful random selection 
procedure of controls. 
However, some studies showed that prostate cancer risk was associated with 
high socioeconomic status (Bouchardy et al, 2002; Harvei & Kravdal, 1997; Lund 
Nilsen et al, 2000). In contrast, some studies have demonstrated an increasing 
trend of prostate cancer with decreasing socioeconomic status (Hass & Sakr, 
1997). One study revealed that incidence is higher with high socioeconomic 
status on the other hand mortality was higher in low socioeconomic class (Cheng 
et al, 2009). 
The majority of earlier studies failed to demonstrate any association between 
social class and prostate cancer risk. One of the explanations for the high 
percentage in the upper social classes is that it may be possible that these 
people have more access to health care and have more positive attitudes 
towards health care. 
1.10.3.3 Education 
The results of this study indicate that there is no association between education 
level and prostate cancer risk (all confidence interval include 1). Reported 
evidence is limited and inconclusive for education and prostate cancer. risk. 
Similar findings have been previously reported (Ewings & Bowie, 1996; Ilic et al, 
1996; Key et al, 1997; Severson et al, 1989). 
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The results from the case-control study conducted by Newell et al, 1989 
however, had showed significant association between higher education level and 
prostate cancer (OR 2.10,95% C. I. 1.10-4.04) (Newell et al, 1989). Also the 
results of a large census-based cohort study showed positive association 
between higher education level and prostate cancer risk. Although the education 
classification they had used does not match our study, they classified education 
in three levels and reported standardized incidence ratios (SIRs). They found 
that higher education level is a potential risk factor for prostate cancer 
(SIR=1.17,95% C. I. 1.05-1.30). The three educational levels used in that study 
was basic education include only elementary education (9-10 years), shorter 
courses or did not complete elementary education. Second was medium 
education included college graduates and with vocational training a third was 
academic education comprising of university graduates (Vidarsdottir et al, 2008). 
These results are also supported by another cohort study in which lower 
education level was negatively associated with prostate cancer risk (RR 0.79, 
95% C. I. 0.74-0.85) (Mouw et al, 2008). 
As the education is one of the important indicators of social class and higher 
education as a risk factor for prostate cancer might not be a direct cause but 
suggestive of possible differences i. e. diet or other lifestyle factors and good 
quality health care. 
1.10.3.4 Marital status 
More than 80% of study population was married or has a common law partner. 
Being single appeared to be a heightened risk factor for prostate cancer (OR 
1.63,95% C. I. 1.10-2.41). Similar results have been found in a case-control 
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study in Canada with 382 cases and 625 controls having significant association 
among never married as compared to married men (OR 1.93, C. I. 1.08-3.44) 
(Fincham et al, 1990). The possible explanation is that single men may have 
unhealthy life style such as multiple sexual partners and more prone to acquire 
sexually transmitted diseases, which can lead to chronic infection and have some 
role in causation of prostate cancer (Fincham et al, 1990). 
Some previous studies, however, suggested negative association among the 
single or never married compared with married men (Harvei & Kravdal, 1997; 
Severson et al, 1989). However no association was found in several other 
studies (Harvei & Kravdal, 1997; Ramon et al, 2000; Severson et al, 1989). 
1.11 Conclusions 
The study achieved overall very good response rate for both cases and controls. 
Age was used as a confounding factor in the present study, as it was known 
priori confounding factor in prostate cancer epidemiological studies. Study 
population was homogenous with the majority of study population was 
Caucasian (>95%). Social class distribution is not associated with prostate 
cancer risk (p for trend 0.23). Nearly 50% of the cases and controls had 
achieved high education and quarter of study subjects has no education. No risk 
is associated with education level. Being single appeared to be a risk factor for 
prostate cancer (OR 1.63,95% C. I. 1.10-2.41). 
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2 Background and design of the study 
The Study of Gene 
-Environment Interactions in Prostate Cancer is an ongoing 
and a large scale case-control study. The study is in collaboration between the 
University of Nottingham (epicentre), Warwick and the Institute of Cancer 
Research UK. The study began in 1999 and sets out to investigate 
environmental exposures associated with risk and also to explore genetic 
components involved in disease aetiology. The data collection was divided in to 
two phases, the first phase collection focussed on young onset cases (560 
years) and began in March 1999 and in December 2004, data set was frozen for 
the purpose of interim analysis, review/modify questionnaire, simplify/improve 
data collection process. The second phase started in December 2007 and data 
was frozen once again in September 2009. This was done to assess new leads 
of both genetics and environmental exposures. The second phase extended the 
collection to cover subjects at all ages. It is the data collection of age equal to 
or greater than 60 that the author was fully responsible for the whole 
processes, for the age less than 60 two other research staff was responsible. 
The third phase is proposed to start in year 2010. 
2.1 Ethical approval and funding 
The study has been ethically approved by the Trent Multi Research Ethics 
Committee MREC/99/4/013(Mar) and 07/MRE04/29. There were main funding 
streams to support all epidemiological data collection and control biological 
sample collections including the Prostate Cancer Research Foundation (PCRF), 
the Cancer Research UK (CR UK). For the genetic part of the study, the study 
partner, the ICR was responsible for case blood collections and further genetic 
analysis. The work is funded by the Cancer Research UK grant C5047/A3354. 
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2.2 Data collection 
Data consists of epidemiological data which are collected using self administered 
questionnaire and biological samples including toe nail clippings and 18 ml blood 
samples. 
Details of data collection of both phases are described below 
2.2.1 Subjects identification in the first phase 
2.2.1.1 Case 
First phase cases were identified from the British Association of Urological 
Surgeon's (BAUS) database and the Royal Marsden Hospital, London. These 
patients registered with the UK Genetic Prostate Cancer Study (UKGPCS) (see 
Figure 2-1). The BAUS database is a nationwide cancer registry for urologists 
who have notified urological cancers to the BAUS organisation. If cases had 
been diagnosed with prostate cancer from January 1997 to September 2004 and 
were 5 60 years of age they were eligible for the study. The General practice 
(GP) of each of the eligible cases was then identified and approached. 
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Figure 2-1 UKGPCS recruitment centres 
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Criteria for case recruitment 
Inclusion Criteria 
" 
Age : 560 years at diagnosis. 
" 
Men diagnosed with primary prostate cancer (Histologically confirmed). 
" 
Currently living in the UK. 
" 
Able to understand the information sheet and give informed consent 
directly or via an interpreter. 
Exclusion criteria 
" 
Age >60 years at diagnosis. 
" 
The consultant or GP in charge considers that it would be inadvisable, for 
some reason, not to contact them e. g. too ill to complete the 
questionnaire. 
" 
The subject's English is inadequate to understand the information provided 
and no translator is available. 
2.2.1.2 Controls 
Men aged <_ 60 years without any history of prostate cancer were selected as a 
control for the first phase of study. They were randomly selected from GP 
practices where cases were registered. Controls were matched by age and 
geography. Controls were only excluded by GPs if they are too ill or unwilling to 
participate. 
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2.2.2 Subject identification in the second phase 
2.2.2.1 Case 
Second phase cases were identified from The Royal Marsden Hospital, London. 
These patients registered with the UK Genetic Prostate Cancer Study (UKGPCS). 
The list of cases had been received through series of case downloads from the 
Royal Marsden Hospital, London. These cases are either referral cases or had 
been notified by their consultant to the study team at the Royal Marsden 
Hospital. 
Inclusion criteria 
" 
Men diagnosed with primary prostate cancer at any age. 
" 
Histological confirmed diagnosis. 
" 
Currently living in the UK. 
" 
Able to understand the information sheet and give informed consent. 
Exclusion criteria 
9 The consultant or GP in charge considers that it would be inadvisable, for 
some reason, not to contact them e. g. too ill to complete the 
questionnaire. 
" 
The subject's English is inadequate to understand the information 
provided and no translator is available. 
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2.2.2.2 Control 
Age-frequency-matched men who were randomly selected from the GP practices 
without any history of prostate cancer. All participants have to be able to 
understand the information sheet and give informed consent. Exclusion 
criteria for controls were identical as for cases. In addition, who were 
ineligible or who were unwilling to participate were recorded and further remove 
from the working database. 
2.2.3 The recruitment procedure 
2.2.3.1 Case recruitment for the first phase 
The initial approach to GPs was made to explain the study and seek their co- 
operation. If they were willing to take part in the study, the study group would 
arrange patient information sheets and consent forms to be dispatched to 
practices. The invitation letter was signed by the GP and printed on practice 
headed paper. All documents, including the invitation letter, patient information 
sheet, consent form and one reminder were sent out via GP practices until the 
consent was given or if no reply was received within 4 weeks, no further follow- 
up was made. Patient consent forms were returned to the epicentre; and 
personal information including study ID, NHS number, name, date of birth, and 
contact details was then be recorded onto database. Once patients consented to 
fill the questionnaire and provide biological samples including blood, toe nail 
clippings, the questionnaires were sent to participants and blood kit and plastic 
vial was sent to the practice and with the arranged phlebotomist of the practice, 
the blood sample was taken and sent back to the research team at the Royal 
Marsden Hospital. Toenail samples were sent back to the epicentre. 
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2.2.3.2 Case recruitment for the second phase 
The Royal Marsden hospital were in charge of identifying and getting consent 
from eligible cases, taking blood samples and notifying epicentre if the patients 
gave consent to provide questionnaire data. Data was sent to epicentre through 
secure FTP server. Personal information including study ID, NHS number, name, 
date of birth, date of blood collection and contact details was recorded on the 
epicentre database. 
As the UKGPCS consent form only covers blood sample collection and permission 
to participate in epidemiological study, a separate invitation letter together with 
the patient information sheet and consent form was sent out from epicentre. 
One reminder was sent via epicentre, if no reply was received within 4 weeks, no 
further follow-up was made. Consent form includes: 
1. Completing the study questionnaire 
2. Giving a toenail clipping sample (optional) 
3. Providing the blood sample (optional) 
4. Giving the permission for the study group to access their medical records 
(optional). 
Once the consent form was received, a written instruction to explain the 
procedure, a copy of the questionnaire and/or a plastic vial/bag for toenail 
sample collection together with a self-addressed envelope for returning 
questionnaire and toenail clipping sample were sent. 
A telephone helpline was provided at the back of the questionnaire to help clarify 
any further queries regarding the study (see the appendix). If 
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questionnaire/toenails were not received within four weeks, one reminder was 
sent without further follow-up. 
Blood collection for cases was carried out by Research team at the Royal 
Marsden Hospital, London. 
2.2.3.3 Control recruitment procedure 
For both phases of data collection, there were similar approaches only the 
second phase controls were sought locally within the Nottingham area as well as 
nationally. Initially, the study was designed to use individual-matched controls 
(matched on age within five years and GP surgery). However, due to low 
response rate of GP practices, an alternative approach was introduced later on 
by selecting GPs from ten representative areas (one GP per one area) in the 
country to help identify age-frequency matched controls. Practices were asked 
to randomly select health controls with no prostate cancer history from their 
patient list. Initial approach was made by GP and participants were invited to fill 
out the study questionnaire, to give 2x9 ml of blood sample (optional) or give 
toenail clipping samples (optional) for further analysis. All blood samples were 
taken at GP practice then posted to the Royal Marsden Hospital (first phase) or 
the epicentre (second phase) on the same day or the next working day. All 
samples were logged and kept at 
-70°c secured deep freezer. 
It is noted that the study had offered to cover administrative costs for each 
practice. As mentioned above, controls selection was expanded to cover local 
area in Nottinghamshire. The reason is that the study applied a newly developed 
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computer program aiming to help saving GP time/workloads and as it was done 
locally, any technical problems could be sorted out in person very quickly to 
make sure the program functioned well. The procedure is described below. 
The Nottingham centre 
Controls from city of Nottingham had been selected from GP electronic records 
using series of Medical" Read" codes. The Read Codes cover a wide range of 
clinical terms from signs and symptoms, diagnostic tests, drug appliances, 
treatment and therapies received to diagnosis. A list of codes was set up to 
identify both prostate cancer patients and healthy control based on Read Codes 
versions 2 and 3. A computerised programme compatible with the GP practices 
working system EMIS and System One had been designed to generate a list of 
potential control subjects. 
The list was then passed onto the GP for further checking/confirmation of their 
well-being. After GP validation, any subjects that were not suitable were 
removed from the database. Invitation letters were generated automatically 
from the list at the practice using installed letter template that accompanied with 
the program. All documents were then packed and sent out from the practice to 
each individual. Once subject sent their consent form back to the researcher; 
the next steps followed the same procedures as described above. 
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2.2.4 Blood collection for local controls (Nottinghamshire area) 
After receiving questionnaire, the letter was sent to the participant (along with a 
blood sample collection pack together with an instruction letter to practice 
nurse/phlebotomist) to book an appointment for blood collection with their GP 
practice. 
To facilitate the phlebotomist at different GP practice in Nottingham and to help 
other prostate study running simultaneously by the study group such as Benign 
Prostatic Hyperplasia study, the author had taken phlebotomy course at King's 
Mill hospital, Mansfield for seven days; this was carried out to comply with the 
UK regulations. A separate honorary, contract was obtained to work as 
phlebotomist. 
Blood samples were sent back to study base in Nottingham, from there, samples 
were sent back to the Royal Marsden Hospital for DNA extraction and genetic 
analysis. 
2.2.5 The study questionnaire 
The Questionnaire covers a wide range of topics and took no longer than 45 
minutes to complete. It was well received by the target population and no 
complaint was raised during the study period. Information under the following 
broad headings from cases and controls using a structured questionnaire 
designed for this study are collected. 
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0 Demographic features 
9 Occupation 
" 
Hormone markers 
" 
Smoking habits 
9 Sexual behaviour 
" 
Sunlight exposure 
" 
Family history 
" Physical activity 
" 
General health and medication including diagnostic X-ray exposure 
" 
Anthropometric measures 
" 
Diet 
The second phase questionnaire was slightly modified from the previous one 
particularly the radiology section (details are described in methodology section of 
chapter 3). 
2.3 Data entry 
Data from the first phase was already entered and cleaned. For the second 
phase data entry database was created in Microsoft Access. Data was then 
entered in Microsoft access database and then transferred to Microsoft Excel. 
Data was checked thoroughly using filters in Excel. As data were entered by 
different people, data input was re-checked for quality control purpose. Data 
was checked to exclude any error using Microsoft Excel by re-entering randomly 
selected questionnaires and compare them with the actual data. Less than 0.5% 
error was found, which is negligible for large dataset like this. After that data of 
first and second phase was merged taking in account the difference in 
questionnaires of both phases. Social class coding was manually cross checked 
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by an expert. Recoding of variables was the next important step to make the 
analyses easier and flawless. 
2.4 Power and sample size calculation 
Sample size and power was calculated using power and sample size programme 
(PS) version 3.0.7. The total number of cases and controls in the study are 
1112 and 1872 respectively. This setting will have 80% power to detect odds 
ratios of 1.4,1.3,1.2 or the same power is also able to detect risk reduction 
with odds ratios of 0.6,0.7 and 0.8 when the exposure rates in controls are at 
10%, 20% and 30% respectively. Alpha level was set at 0.05 for the 
calculations (see Figure 2-2). 
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Figure 2-2 Detectable Odds ratio 
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2.5 Data analysis 
For statistical analysis, SPSS (Statistical Package for the Social Sciences) version 
16 was used. To compare the demographic characteristics of cases and controls, 
such as age and ethnicity, univariate logistic regression were performed. For 
social class, education and marital status, multiple logistic regression was 
performed. 
For all other environmental exposures, unconditional logistic regression was used 
to generate odds ratios and 95% C. Is. 
To assess for a trend in prostate cancer risk across the categories test for linear 
trend was performed, considering selected exposures as continuous variables. 
The methodology and analysis pattern for gene and environmental interaction 
will be mentioned in chapter five. 
2.6 Confounding factors 
Age and social class were previously tested when the interim analyses were 
undertaking and since then both factors have been consistently fitted in a model 
as confounding factors throughout all analyses of the study. Age was included 
as a continuous variable whereas social class was fitted as a categorical variable. 
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2.7 Literature search 
Searches were done using the "Pubmed" search engine. The topics of review 
include prostate cancer and its potential risk and protective factors including 
family history, X-rays and DNA repair genes involved in the X-ray repair, 
hormone markers including baldness, hand pattern and acne and also gene and 
environmental interaction for DNA repair genes involved in the X-ray repair, acne 
and baldness. 
45 
Chapter 3 Family history 
46 
3 Literature review 
3.1 Family history and prostate cancer risk 
The majority of cases of prostate cancer are not due to an inherited 
predisposition to develop the condition (about 75%) and are known as sporadic 
cases. In these cases damage to the genes occurs due to exposure to various 
environmental factors after birth (NCI, 2008). These genes are known as low 
penetrance genes (Shields & Harris, 2000). Another group of prostate cancer is 
known as familial (25%), with a family having more than one person affected 
with prostate cancer with no definitive pattern of inheritance. The aetiology of 
familial cancer varies from familial exposure to different environmental and 
dietary factors, polygenic inheritance, low penetrance single gene and to chance 
alone (Walsh & Partin, 1997). 
Data from previous epidemiological studies are very persuasive suggesting 
family history as a strong and established risk factor for developing subsequent 
prostate cancer and it is now considered as one of the strongest hereditary 
cancers (Witte, 2009). Results from several case-control and cohort studies are 
consistent and suggested a strong association of family history with prostate 
cancer. Highly significant associations were found with first degree relatives 
especially father and brother(s) having prostate cancer. All these studies 
showed two to six times increased risk of acquiring prostate cancer with positive 
family history. A border line risk is also evident with second degree relatives 
(See Table 3-1 (Cerhan et al, 1999; Isaacs et al, 1995; Kalish et al, 2000; 
Mettlin et al, 1995; Spitz et al, 1991). 
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According to the UK genetic prostate cancer study (UKGPCS) and several other 
studies, tendency towards developing prostate cancer has a genetic component, 
but the genes that have been shown to be involved in hereditary prostate 
cancers are not thought to be mutated in sporadic cancers (Gelmann & 
Gelmann, 2003). These genes affecting familial cases are known as high 
penetrance genes (Shields & Harris, 2000). Mutations in high penetrance 
susceptibility genes greatly increases the risk of prostate cancer as compared 
with low penetrance polymorphisms but as the low penetrance polymorphisms 
are more common they may therefore be more prevalent in the population 
(Porkka et al, 2004). 
Very small numbers (about 5-10%) of the cases of prostate cancer have an 
obvious strong genetic predisposition, but those who are diagnosed at a younger 
age are more likely (Crawford & Crawford, 2003; Gibbs et al, 1999). A 
hereditary prostate cancer is subtype of familial cancer with a Mendelian 
inheritance pattern of distribution and has an autosomal dominant trait (Carter 
et al, 1992; Tavtigian et al, 2001; Walsh & Partin, 1997). It has a faulty copy of 
one of the cancer protective genes that usually control cell division and growth 
and passed through the family line (NCI, 2008; Walsh & Partin, 1997). 
According to Cancer Research UK, family history of breast cancer is also an 
important risk factor for prostate cancer. It is mainly due to BRCA1 and BRCA2 
genes both are risk related with breast and prostate cancer (Cancer Research 
UK, 2010b). However Kalish et al didn't find any association between prostate 
cancer risk and family history of breast cancer (Kalish et a/, 2000). 
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3.2 Genetics of prostate cancer 
Cancer is a disease that occurs when cell division gets out of control, may be due 
to impairment of a DNA repair pathway, the transformation of normal gene into 
oncogene or due to the malfunction of tumour suppressor gene. The Majority of 
genetic mutations take place after exposure to environmental carcinogens, but 
some mutations have genetic predisposition to cancers (Porkka et al, 2004). 
3.2.1 Genes involved in predisposition and progression of prostate 
cancer 
According to different linkages studies several genetic loci have been found to be 
associated with prostate cancer predisposition, these include HPC1 at 1g24-q25 
(Smith et al, 1996). It is evident from previous studies that chromosome 1g24- 
q25 is linked with the families where prostate cancer is diagnosed at an early 
age ( 65 or less), male to male transmission and at-least five or more affected 
family members (Singh et al, 2000). PCAP at 1g42.4-q43 (Berthon et al, 1998) 
has also been linked with early onset (age 60 or less) (Singh et al, 2000). HPCX 
at Xq27-q28, suggests X-liked inheritance of prostate cancer (Xu et al, 1998), 
CAPB at 1p36, showing links between both families with high risk of prostate 
cancer and brain cancer (Gibbs et al, 1999), HPC20 at 20q13, provides very 
strong evidence in familial lines without male to male transmission (Berry et al, 
2000), 8p22-23 prostate cancer susceptible genes may have a possible role in 
the genetic inheritance of prostate cancer and in prostate cancer pathogenesis 
(Xu et al, 2001). There is strong evidence to suggest that variations ELAC2 at 
17p have increased the risk of prostate cancer (Tavtigian et al, 2001). It is 
evident from results of a study involving 5q, 7q, 19q that there may be some role 
of genes present on these candidate regions in progression of prostate cancer 
(Witte et al, 2000). From these chromosomal regions only three genes have 
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been identified (Porkka et al, 2004). The First is ELAC2 (MIM 605367) from the 
HPC2, locus. The second is RNASEL (MIM 180435) from the HPC1, locus but is 
as yet to be definitively confirmed (Ikonen et al, 2003), and the third is MSR1 
(macrophage scavenger receptor 1) gene located at 8p22-23 (Porkka et al, 
2004). According to the results of a study conducted by Nupponen, these three 
genes do not appear to be mutated in sporadic prostate cancer (Nupponen et al, 
2004) (see Table 3-2). 
The genetic analysis from the UKGPCS study as one part of this present study 
(included subjects only age<60) suggested that seven loci are associated with 
prostate cancer on chromosomes 3,6,7,10,19, and x and confirmed 
association of common loci with prostate cancer at 8g24 and 17q. Also three 
new loci have been identified as having candidate susceptibility genes: MSMB, 
LMTK2 and KLK3 (Eeles et al, 2008). 
Table 3-2 Genes involved in predisposition and progression of prostate 
cancer 
Genes and loci Description Justification/ Limit OF Ref 
Detectlon(LOD) 
HPC1 at 1q24-q25 Hereditary prostate cancerl 5.43 (Smith et a/, 
1996) 
PCAP at 1q42.4-q43 Predisposing for Cancer 40-50% of French & (Berthon et al, 
Prostate German Families linked 1998) 
HPCX at Xq27-q28 hereditary prostate cancer X- 4.6 (Xu et al, 1998) 
linked 
CAPB at 1p36 Cancer Prostate and Brain 3.22 (Gibbs et al, 
1999) 
HPC20 at 20g13 Hereditary prostate cancer20 2.69 (Berry et a/, 
2000) 
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Genes and loci Description Justification/ Limit OF 
Detection(LOD) 
Ref 
ELAC2 at 17p EIaC homolog protein 2/ Maximum 2-point LOD (Tavtigian et al, 
Heredity prostate cancer score at 4.5 at marker 2001) 
protein 2 D17S1289 and Maximum 
3-point LOD score at 4.3 
at marker D17S1289 and 
D17S921 
5q, 7q, 19q (P=0.0002), (P=0.0007), (Witte et a/, 
(P=0.0004) 2000) 
LOD: Is the log of the odds of linkage and LOD >3.0(loglo 3.0+1000 to I odds of linkage). LOD of <- 
2.0 is evidence against linkage of 100 to one (Singh et al, 2000) 
. 
Several studies have reported familial association between prostate cancer risk 
among male relatives of female patients with breast cancer (Chen et a/, 2008; 
Goldgar et al, 1994; Rodriguez et al, 1998; Tulinius et al, 1992). Germline 
mutation in BRCA1 and BRCA2 genes are responsible for inherited predisposition 
of breast cancer. Families of the carriers of these genes have an increased risk 
of prostate cancer (Edwards et al, 2004; Edwards et al, 2003; Ford et al, 1994; 
Sigurdsson et al, 1997), but the risk of developing prostate cancer is more likely 
with BRCA2 mutations than with BRCA1 mutations (Cancer Research UK, 2010b; 
Edwards et al, 2003; Mitra et al, 2008). 
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3.3 Hypotheses and aims 
Hypotheses 
1. Prostate cancer risk is increased with positive family history of prostate 
cancer. 
2. Prostate cancer risk is increased with positive family history of breast 
cancer. 
Based on above hypotheses following are the aims: 
Aims 
1. To evaluate the association between first degree relatives (father and 
brother) of the proband with prostate cancer on prostate cancer risk. 
2. To assess the association between first degree relatives (father and 
brother) with prostate cancer and prostate cancer risk among the young 
age group (<60 years). 
3. To investigate the role between history of breast cancer in a family 
(mother, sister and daughter) and risk of prostate cancer. 
3.4 Methodology 
To investigate the strength of familial factors in prostate cancer and the 
association between family history of breast cancer, the first step was to create 
dichotomous variable with family history of any cancer vs. no cancer in family. 
However, considering first degree relatives as an important risk factor as evident 
from previous epidemiological studies these variables had been filtered using 
Microsoft Excel and "exposed" group (only those with father and brother had 
had prostate cancer) vs. "unexposed" group. The unexposed group is defined by 
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i) subjects who reported none of their family members are affected with 
cancer of any type 
OR 
ii) subjects who reported their first degree relatives affected with other 
cancers but not prostate cancer. 
iii) subjects with 2nd or 3rd degree relatives members in their family affected 
with other cancers including the prostate cancer. 
To evaluate the effect of family history with first degree relatives on young-onset 
prostate cancer, controls age <60 years were selected and analysis was done. 
A new variable has been created for looking at the risk of prostate cancer with 
family history of breast cancer within first degree relatives, by selecting female 
first degree relatives such as mother, sister and daughter (exposed) vs. 
(unexposed) all other cancers in all other relatives including the breast cancer. 
3.4.1 Definitions of variables 
3.4.1.1 First degree relative (exposed) 
First degree relative (exposed) was defined as biological father and brother who 
had developed prostate cancer. 
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3.4.1.2 Family history of breast cancer (exposed) 
Family history of breast cancer was defined as biological mother, sister and 
daughter suffering from breast cancer. 
3.5 Analysis 
Multiple logistic regression models were used to-estimate odds ratios and 95% 
confidence intervals. Potential confounders such as age and social class were 
controlled for in the multivariate analyses. 
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3.6 Results 
3.6.1 Family history of prostate cancer in first degree relatives 
Table 3-3 shows distribution values and risk estimates when first degree 
relatives (father and brother) affected with prostate cancer. 
Table 3-3 Distribution and odds ratios for family history in the probands 
with prostate cancer 
-all ages 
first degree 
relatives 
Case (%) Control (%) ORt 95%CI Lower-upper P-value 
unexposed 734(70.0) 1701(94.9) 1.00 
exposed 314(30.0) 91(5.1) 7.93 6.17-10.20 <0.001 
Total 1048(100.0) 1792(100.0) 
Taajustea tor age ana social class 
The results showed a highly significant increased risk (OR 7.93,95% C. I. 6.17- 
10.20) among subjects whose first degree relatives are affected with prostate 
cancer compared to those who either don't have any family history of cancer or 
they have family history of other cancers including prostate cancer. The latter is 
only valid in the second or third degree relatives but not in the first degree 
relatives. 
3.6.2 Family history of prostate cancer in first degree relatives age <60 
Table 3-4 shows value and estimated risk of family history of prostate cancer 
age<60 
Table 3-4 Estimated risks for family history in the probands with 
prostate cancer age<60 
first degree 
relatives <60 yrs 
Case (%) Control (%) ORt 95%CI Lower-upper P-value 
unexposed 232(57.9) 553(94.4) 1.00 
exposed 169(42.1) 33(5.6) 12.55 8.35-18.86 <0.001 
Total 401 (100.0) 586 (100.0) 
tadjusted for age and social class 
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The risk estimate shows a highly significant association between family history of 
prostate cancer in first degree relatives and prostate cancer risk in age <60 
years as compared to risk in all ages (OR 12.55 compared to 7.93 ). 
3.6.3 Family history of breast cancer in first degree relatives 
Table 3-5 shows value and estimated risk of prostate cancer with family history 
of breast cancer. 
Table 3-5 Estimated risks for prostate cancer with family history of 
breast cancer 
Family History Case (%) Control (%) ORt 95%CI Lower-upper P-value 
No 930(88.6) 1638(91.5) 1.00 
Yes 120(11.4) 152(8.5) 1.39 1.07-1.79 <0.01 
Total 1050(100.0) 1790(100.0) 
tadjusted for age and social class 
The results showed a lower risk (OR 1.39,95% C. I. 1.07-1.79) for those who 
have family history of breast cancer in their first degree relatives compared to 
those who either don't have any family history of cancer or they have family 
history of other cancers and breast cancer but not in the first degree relatives. 
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3.7 Discussion 
3.7.1 Family history of prostate cancer with affected first degree 
relatives 
The results showed a highly significant association between prostate cancer in 
first degree relatives and prostate cancer risk (OR 7.93,95% C. I6.17-10.20). 
The results of this study are consistent with the several case-control and cohort 
studies. For example Australian study showed six times increased risk of 
prostate cancer with affected first degree relatives (Mettlin et al, 1995). In a 
Swedish study (RR 3.2,95% C. 1.2.1-5.1) was found with either father or 
brother affected by prostate cancer. Results from a case-control study 
conducted in Montreal, Toronto and Vancouver between 1989- 93 showed strong 
association between those who have at-least one blood relative(father or 
brother) affected and prostate cancer (RR 3.32,95% C. 1.2.18-5.05 ). Another 
case-control study by Spitz et al, also reported positive association (OR 2.41, 
95% C. I. 2.24-2.66) (Spitz et al, 1991). 
Cerhan et al, in their cohort study reported increased risk of developing prostate 
cancer in those whose father or brother had suffered from prostate cancer(RR 
3.2,95% C. I. 1.8-5.7)(Cerhan et al, 1999). Our results are also consistent with 
the findings of Chen and colleagues, who have recently demonstrated that a 
family history of prostate cancer in both father and brother doubled the risk of 
developing prostate cancer (RR 2.3,95%C. I. 1.76-3.12) (Chen et al, 2008). 
In most of these studies risk was inversely proportional with age of diagnosis, 
such a study conducted by Lesko et al, showed a fivefold increased risk in 
probands younger than 60 years. Our results also showed highly significant risk 
(OR 12.55,95%C. I. 8.35-18.86) among the subjects age <60 years with 
positive family history of prostate cancer. 
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Taken together, these results provide a strong body of evidence that family 
history is one of the important risk factor of prostate cancer. 
3.7.2 Family history of breast cancer with affected first degree relatives 
This study also demonstrated an association between history of breast cancer in 
family and prostate cancer (OR 1.39,95% C. 1.1.07-1.79). There is growing 
body of evidence on the role of family history of breast cancer and risk of 
development of prostate cancer among the male members of the family, 
especially when first degree relatives like mother or sister are affected (Chen et 
al, 2008; Goldgar et al, 1994; Rodriguez et al, 1998; Tulinius et al, 1992). For 
example, a case-control study conducted by Rodriguez et al, suggested similar 
increased risk to the present study that in the mother and sister with breast 
cancer (RR 1.16,95% C. 1.1.01-1.33 ) (Rodriguez et al, 1998). 
Also, results from cohort studies showed increased risk of prostate cancer, if first 
degree female relatives such as mother or sister had breast cancer. For 
example, Chen et al suggested a similar increased risk (RR 1.22,95% C. I. 1.08- 
1.38) (Chen et al, 2008). But Kalish et al in their study found no association of 
prostate cancer with the family history of breast cancer (RR 1.18,95% C. I. 0.51 
to 2.43) (Kalish et al, 2000). 
One of the important limitations of case-control study is recall or memory bias 
(Coughlin, 1990). Especially when it is self reported and for recalling for some 
chronic illness like cancer, where natural history of illness is remains obscured 
until full blown disease is evident. However, information for first degree 
relatives is more reliable than second or third degree relatives. A Swedish case- 
control study of 356 cases and 712 controls was conducted to assess the 
reliability of self-reported family history of prostate cancer, results found it a 
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reliable method to measure the true incidence of prostate cancer in immediate 
family members (Bratt et al, 1999). 
3.8 Conclusion 
The findings from these two analyses suggested that family history with first 
degree relatives with prostate cancer is a strong risk factor in prostate cancer 
and a family history of breast cancer appeared to be a lower risk factor in its 
development. 
Family history appeared to be a strong risk factor in all ages, and showed the 
importance of genetics in the aetiology of the disease, not only in the young but 
also that it can have an influence at any age. 
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Chapter 4 Radiation 
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4 Literature review 
4.1 Radiation 
Radiation is termed ionising when it has the capacity to penetrate and deposit its 
energy in the tissue such that an electron will be removed from its orbit. 
Ionising radiation is divided in to two major groups, Electromagnetic radiations: 
X-rays and gamma rays and Particular radiation: alpha, beta particles (electrons) 
and protons (Fajardo L-G et al, 2001; Park, 2005). 
4.1.1 Units of radiation 
There are different ways to measure radiation potency through SI units 
(international system of Units): 
1- Coulomb per kilogram(C/Kg): is the unit of exposure. 
2- Gray (Gy): is the unit of absorbed dose. 
3- Sievert (Sv): the unit indicates the degree of potential danger to health as 
it is the measure of absorbed dose, for X-rays Gy=Sv (Park, 2005). 
As all forms of radiation do not have the same biological effect per unit of energy 
absorbed, the idea of dose 
, 
equivalent (H) has been introduced and the 
equivalent dose in Sv is equal to the absorbed dose in Grays multiplied by a 
quality factor Q which is corresponding radiation weighting factor (which 
depends upon the density of ionisation produced in the tissue by the radiation) 
iSv=1000 mSv=100rem (Cardis et al, 2005; Park, 2005). 
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Ionising radiation is one the important risk factor in the development of many 
cancers (Myles et al, 2008). Studies on animal models to see the effect of 
radiation as a carcinogen were started soon after World War II and showed 
strong evidence of radiation carcinogenesis followed by the evidence from 
various epidemiological studies in the human population. These studies proved 
radiation as a "universal carcinogen" (Little, 2000). High dose radiation is 
proven risk factor for developing many cancers and has adverse effects on 
genetic makeup; however we know little about the effect of low-dose ionising 
radiation such as diagnostic, therapeutic, occupational or natural. Low dose 
radiation should be more concern as these are more common than high dose 
exposures (Shore, 2009). 
4.1.2 Biological effects of radiation 
It is now evident from several epidemiological and molecular studies that 
radiation can cause a wide range of DNA lesions including damage to nucleotide 
bases, cross-linking and DNA single- and double- strand breaks (DSBs) and the 
latter class of damage is potentially cytotoxic (Little, 2000). Bhatti and his 
colleagues demonstrated in their study that even low dose radiation i. e. 5OmGy 
and lower can cause chromosomal damage; especially "translocations" the 
intermediate biomarker of cancer risk and can cause harmful health effects 
including cancer (Bhatti et al, 2010; Sigurdson et al, 2008). The results from a 
collaborative cohort study conducted in fifteen countries included 407,391 
nuclear industry workers to estimate the cancer risk following prolonged 
exposure to low doses of ionising radiation showed significant association 
between radiation dose and different types of cancers such as lung and multiple 
myeloma and all-cause mortality (Cardis et al, 2007). 
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4.2 X-rays/ Diagnostic Medical Radiography 
The largest man-made source of radiation exposure in the general population is 
diagnostic X-rays. Worldwide diagnostic radiological exposures contribute about 
14% of total exposure annually from all sources (Berrington de Gonzalez et al, 
2004). X-rays were first discovered by Wilhelm Konrad Roentgen, a professor of 
Physics in his laboratory at New Physical Institute of University Of Wurzburg on 
8`h November 1895(Rontgen, 1972). It is one of the most important seminal 
discoveries in the field of medicine. X-rays have short wave lengths and hence 
have the ability for deep penetration (Park, 2005). They have important roles in 
the diagnosis of many health problems and have a wide range of applications 
from simple chest X-ray to forensic procedures (Brailsford, 1946; Frenz & Mee, 
2005). X-rays, however, have energy capable of causing ionisation in targeted 
tissue leads to harmful biological effects (Armstrong & Wastie, 2001). 
Figure 4-1 First ever human X-ray by Rontgen(his wife's hand also 
showing wedding ring) (Rontgen, 1972). 
The UK population is subjected to a lower annual per capita dose of X-rays 
(0.38mSv) as compared to other developed countries with similar health system 
(see Table 4-1). This may be due to health policy which avoids unnecessary X- 
ray exposure and lower doses as compared to other countries (Hart & Wall, 
2004). 
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Table 4-1 International comparison of annual per caput effective dose 
from medical radiology 
Country Time period Annual per caput effective dose(mSV) 
Germany 1990-1992 1.9 
France 
- 
1.0 
Switzerland 1998 1.0 
Canada 
- 
0.94 
Russia 
- 
0.9 
Australia 1996 0.8 
Norway 1993 0.8 
Poland 
- 
0.8 
Bulgaria 
- 
0.75 
Portugal 1991 0.71 
Sweden 
- 
0.68 
Romania 
- 
0.61 
Netherlands 1998 0.52 
USA 
- 
0.5 
Ukraine 1994 0.5 
Finland 
- 
0.45 
Spain(regional) 1990 0.4 
UK 2001/2002 0.38 
Denmark 
- 
0.36 
Taiwan 1993 0.23 
Brazil 
- 
0.09 
Malaysia 1994 - 0.05 
Taken from the article "UK population dose from medical X-ray examinations" with the permission 
from author (Hart & Wall, 2004). 
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4.3 X-rays and cancer 
Although the potential carcinogenic effect was recognized soon after the 
discovery of X-rays by Roentgen in 1895, the first ever observed radiation 
induced cancer noticed was a skin lesion in the form of an ulcer to Clarence 
Madison Dally (assistant of Thomas Edison) in 1902 and he is the first person to 
die of radiation induced cancer in 1904 (Fajardo L-G et al, 2001; Little, 2000). 
Marie Curie and her daughter Irene are thought to have died of complications 
resulting from radiation exposure and cause of death may have been due to 
leukaemia (Little, 2000). Although diagnostic X-ray procedures are of high 
benefit to human-kind, they also show some risk of developing cancer. 
Berrington de Gonzalez et al, reported that the UK has the lowest annual 
frequency of diagnostic X-rays and that Japan has the highest. About 0.6% (700 
cases of cancer/year) of the cumulative risk of cancer at age 75 years could be 
attributed to diagnostic X-rays in the UK (Berrington de Gonzalez et al, 2004). 
Though there is no reliable data available proving diagnostic radiography as a 
cause of cancer, the National Health Institute had added X-rays to the list of 
carcinogens in their eleventh report on carcinogens. They reported that nearly 
fifty five percent of global radiation exposure is a result of exposure to diagnostic 
radiography. In their report, it has also been added that childhood exposure 
may lead to leukaemia and thyroid cancer and exposure in women during 
pregnancy may lead to breast cancer and congenital malformation in the foetus, 
if the procedure was carried out during first trimester of pregnancy (Kay & 
Chronicle, 2005). 
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Track analysis studies of X-rays and their interaction with DNA provides evidence 
of DNA cluster damage which can produce DSBs (Little, 2000). There is a wide 
range of different diagnostic radiological procedures available ranging from 
simple chest X-ray to highly advanced imaging procedures, however there is no 
standard cut-off points available for radiation dose, and there is also no 
suggested standard value available for the dose of diagnostic X-rays, which can 
induce cancer (Brenner et al, 2003; Kalender, 2000). 
Tracy Hampton in her article "Researchers examine long-term risks of exposure 
to medical radiation" labelled radiation "double edge sword", as it is used for 
both the diagnosis and treatment, but can cause subsequent health problems 
including cancer. The major health risk of diagnostic radiography is the 
development of cancer, which might develop soon after the exposure or later in 
life, however, the exact mechanism is still not clear as to how these low dose 
ionising radiations can cause cancers. One theory " The bystander effect " is a 
phenomenon in which radiation-damaged cells may send mutation signals to 
neighbouring cells that then become malignant themselves (Hampton & 
Hampton, 2006). Other theories suggest sub-lethal damage to cells which then 
carry mutational damage. 
When looking at acute dose response relation with cancer incidence, Brenner et 
at found that those subjects who exposed to radiation doses ranging from 5- 
100msv show increased risk for solid cancers (p value =0.05) as compared 
to dose less than 5msv. It shows a definite dose response relationship (Brenner 
et a!, 2003). Many studies suggested that the earlier and frequent the exposure, 
the greater chance of developing cancer (Bassal et a!, 2006; Berrington de 
Gonzalez et a!, 2004 ; John et al, 2007; Miller et al, 1989). 
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4.4 Low dose diagnostic radiations and prostate cancer risk 
Our study group was the first group to report the results of preliminary analysis 
on association of certain types of diagnostic radiological procedures and early 
onset prostate cancer risk. The study investigated five radiological procedures 
involving the lower trunk of human body; barium enema, barium meal, IVP, 
hip/pelvic and leg/thigh. Since there was no information available on possible 
deliverable dose to prostate gland of these procedures, the study presented the 
estimated average dose, as shown in Table 4-2. The dose for leg/thigh X-ray 
was not shown as exposure was considered to be negligible (Myles et al, 2008). 
Table 4-2 Mean minimum and maximum estimates of the dose to the 
prostate gland 
Examination Mean minimum/mSv Mean maximum/mSv 
Barium enema 10 25 
Barium meal 0.2 0.4 
IVP 3 4 
HIP/pelvic 2 5 
Taken from the article "Diagnostic radiation procedures and risk of prostate 
cancer" with the permission from author (Myles et al, 2008). 
The analysis included 431 cases and 409 controls. The results suggested that 
exposed to barium enema and hip/ pelvic X-ray at 5 years prior to diagnosis 
were positively associated with early onset prostate cancer (OR 2.06, 
95%C. I. 1.01-4.20 and OR 2.23,95% C. I. 1.42-3.49 respectively) (Myles et al, 
2008). 
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The subsequent work was carried out by Hussain (2009). The analysis was 
based on the extended interim dataset of 831 cases and 1298 controls (age 
560) and included the same five radiological procedures; barium meal, barium 
enema, IVP, hip/pelvic X-ray and leg/thigh X-ray. The purpose of the study was 
to confirm the previous findings with the larger dataset. The results suggested 
increased risk of early onset prostate cancer with hip/pelvic X-ray >5yrs before 
diagnosis OR 1.89,95% C. I. 1.16-3.09, >10yrs before diagnosis OR 1.92,95% 
C. I. 1.09-3.36, with upper leg/thigh X-ray >5yrs before diagnosis the OR 1.90, 
95% C. I. 1.05-3.45, >10yrs OR 2.16,95% C. I. 1.10-4.25 and >20yrs OR 2.46, 
95% C. I. 1.10- 5.50. Barium enema was no longer associated with early onset 
prostate cancer risk. 
In this chapter, the analyses of all these five procedures are carried out with the 
extensive larger dataset particularly with the inclusion of subjects with all ages 
together and with the different approaches to data filtering. 
4.5 Hypotheses and Aims 
Hypotheses 
There is an association between exposure to low-dose ionising radiations 
(diagnostic medical radiations) and prostate cancer risk. 
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Based on above hypothesis following are the aims: 
Aims 
1. To investigate the association between diagnostic radiation procedures 
and prostate cancer occurring at any age. 
2. To assess the independent effect of different X-ray procedures and 
prostate cancer risk. 
4.6 Methodology 
The analysis includes data from the first phase (used by Myles and Hussain) 
(Hussain, 2008/2009; Myles et al, 2008), and the second phase (the author's 
collection). It is noted that in both phases questionnaires differed slightly from 
each other. In the first phase questionnaire, it was asked whether subject had 
had any of the procedures including barium meal, barium enema, IVP, hip/pelvic 
X-ray and upper leg/thigh X-ray, how many times and if so only the first date of 
each procedure was recorded. In the second phase, questionnaire was modified 
by including more procedures such as Cr scan, MRI, angiograms etc, and more 
detailed on date(s) of each procedure and reason for each. 
Since data are slightly different, the main analyses include 5 procedures that 
were previously reported and this was done in view of two main reasons, firstly 
to have a larger number which increase power particularly with the further 
statistical analysis of gene and environment interaction on X-ray exposure and 
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DNA repair genes (see Chapter 5). Secondly, the larger sample size will allow 
the analysis of exposure to any individual procedure alone without confound with 
other procedures with enough power to detect any significant associations. 
In sum, the study analyse 1112 cases and 1872 controls. 
4.6.1 Coding procedures 
To investigate the individual and independent effect of each procedure, the 
following was carried out. 
1. Only subjects reported having had that procedure one time in life and not 
the others are included. The dichotomous variable is then created as 
exposed subjects (exposed to particular individual diagnostic X-ray one 
time and never had any other procedures) and non-exposed subjects 
(never had procedures). The time of having the procedure was not taken 
into account so it could either be before or after diagnosis in case group 
and either before or after receiving questionnaire in control group). 
2. To measure the relevant time period of the procedure that could 
potentially effect prostate cancer risk, the data was filtered and new 
variable was created for. The exposed group consisted of subjects who 
reported had the procedure once and the timing of that procedure was 
greater than five, ten and fifteen years prior to their diagnosis date in 
case group and to their receiving questionnaire in control group. The 
non-exposed group consisted of subject who reported never had any 
procedures during their lifetime.. 
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4.7 Analysis 
Unconditional logistic regression was performed to obtain odds ratios and 
confidence intervals. All analyses were adjusted for age and social class. 
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4.8 Results 
4.8.1 X-rays 
4.8.1.1 Barium meal 
Table 4-3 below shows the distribution and risk estimates of barium meal. 
Table 4-3 Distribution and odds ratios of barium meal 
Barium meal Case (%) Control (%) ORt 95%CI Lower-upper P-value 
Never had any 
procedure 
204(85.7) 852(87.1) 1.00 
Barium meal once 34(14.3) 126(12.9) 1.19 0.78-1.82 0.43 
Total 238(100.0) 978(100.0) 
tadjusted for age and social class 
The results showed no association between barium meal and prostate cancer risk 
(OR 1.19,95% C. I. 0.78-1.82). 
Result on barium meal five, ten and fifteen years prior to diagnosis and prostate 
cancer risk is presented in Table 4-4. 
Table 4-4 Distribution values and odds ratios of barium meal >5,10 & 
15 years 
Barium meal Case (%) Control (%) ORt 95%CI Lower-upper P-value 
>5years 
Never had any 
procedure 
204(87.6) 852(88.6) 1.00, 
Once and >5years 
prior to diagnosis 
29(12.4) 110(11.4) 1.15 0.73-1.82 0.54 
Total 233(100.0) 962(100.0) 
-Continue- 
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Barium meal Case (%) Control (%) ORt 95%CI Lower-upper P-value 
> 10yea rs 
Never had any 
procedure 
204(87.6) 852(88.6) 1.00 
Once and >10years 
prior to diagnosis 
29(12.4) 110(11.4) 1.15 0.73-1.82 0.54 
Total 233(100.0) 962(100.0) 
> 15yea rs 
Never had any 
procedure 
204(87.6) 852(88.6) 1.00 
Once and >i5years 
prior to diagnosis 
29(12.4) 110(11.4) 1.15 0.73-1.82 0.54 
Total 233(100.0) 962(100.0) 
tadjusted for age and social class 
There was no significant link between prostate cancer and having been exposed 
to barium meal at more than five, ten and 15 years before the diagnosis (All 
confidence intervals include 1). 
4.8.1.2 Barium enema 
Figures from the table below show distribution and risk estimates of barium 
enema and prostate cancer risk. 
Table 4-5 Distribution and odds ratios of prostate cancer relative to 
barium enema exposure 
Barium enema Case (%) Control (%) ORt 95%CI Lower-upper P-value 
Never had any 
procedure 
204(95.8) 852(96.3) 1.00 
Barium enema once 09(4.2) 33(3.7) 1.17 0.55-2.51 0.69 
Total 213(100.0) 885(100.0) 
tadjustea for age ana social class 
Results support no association between exposure to barium enema and prostate 
cancer risk (OR 1.17,95% C. I. 0.55-2.51). 
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Table 4-6 illustrates distribution and risk estimates of barium enema five, ten 
and fifteen years prior to diagnosis and prostate cancer risk. 
Table 4-6 Distribution and odds ratios of barium enema >5,10 & 15 
years 
Barium enema Case (%) Control (%) ORt 95%CI Lower-upper P-value 
>5years 
Never had any 
procedure 
204(98.1) 852(97.6) 1.00 
Once and >5years 
prior to diagnosis 
04(1.9) 21(2.4) 0.85 0.28-2.53 0.77 
Total 208(100.0) 873(100.0) 
>10years 
Never had any 
procedure 
204(98.6) 852(98.0) 1.00 
Once and >10 years 
prior to diagnosis 
03(1.4) 17(2.0) 0.78 0.22-2.73 0.69 
Total 207(100.0) 869(100.0) 
>15years 
Never had any 
procedure 
204(99.5) 852(98.6) 1.00 
Once and >15years 
prior to diagnosis 
01(0.5) 12(1.4) 0.41 0.05-3.26 0.40 
Total 205(100.0) 864(100.0) 
tadjusted for age and social dass 
A very small percentage of both case and control group reported exposed to 
procedure at all periods. Barium enema was not associated with prostate cancer 
risk at five, ten or fifteen years prior to diagnosis. 
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4.8.1.3 IVP (Intravenous pyelogram) 
The results on independent effect of IVP in relation to prostate cancer are shown 
in Table 4-7 
Table 4-7 Distribution and odds ratios of IVP and prostate cancer 
IVP Case (%) Control (%) ORt 95%CI Lower-upper P-value 
Never had any 
procedure 
204(95.3) 852(96.9) 1.00 
IVP once 10(4.7) 27(3.1) 1.49 0.70-3.17 0.31 
Total 214(100.0) 879(100.0) 
tadjusted for age and social class 
The proportion of cases and controls in the exposed group is similar. There is no 
association between IVP procedure and prostate cancer risk. 
Table 4-8 shows IVP five, ten and fifteen years prior to diagnosis and prostate 
cancer risk. 
Table 4-8 Distribution values and estimated risk of IVP >5,10 & 15 
years and prostate cancer 
IVP Case (%) Control (%) ORt 95%CI 
Lower-upper 
P-value 
>5years 
Never had any procedure 204(97.6) 852(97.8) 1.00 
Once and >5years prior to 
diagnosis 
05(2.4) 19(2.2) 1.11 0.40-3.06 0.84 
Total 209(100.0) 871(100.0) 
> 10yea rs 
Never had any procedure 204(99.0) 852(98.2) 1.00 
Once and >10years prior to 
diagnosis 
02(1.0) 16(1.8) 0.56 0.13-2.49 0.44 
Total 206(100.0) 868(100.0) 
-continue- 
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iVP Case (%) Control (%) ORt 95%CI 
Lower-upper 
P-value 
Never had any procedure 204(99.0) 852(98.8) 1.00 
Once and >15years prior to 
diagnosis 
02(1.0) 10(1.2) 1.09 0.23-5.14 0.92 
Total 206(100.0) 862(100.0) 
tadjusted for age and social class 
None of the results is statistically significant (all ORs are closed to one and all 
confidence intervals include 1). 
4.8.1.4 Hip and pelvic X-ray 
Distribution values and risk estimates of hip/pelvic X-ray are presented in table 
4-9 
Table 4-9 Hip and pelvic X-ray exposure and prostate cancer risk 
Hip/pelvic X-ray Case (%) Control (%) ORt 95%CI Lower- 
upper 
P-value 
Never had any procedure 204(88.7) 852(96.3) 1.00 
Hip/ pelvic once 26(11.3) 33(3.7) 3.15 1.81-5.47 <0.001 
Total 230(100.0) 885(100.0) 
tadjusted tor age and social class 
The results showed a significant increased risk among subjects that reported 
having hip/pelvic X-ray once compared to those who never exposed to the 
procedure (OR 3.15,95% C. I. 1.81-5.47). 
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The results on hip/pelvic X-ray exposure five, ten and fifteen years prior to 
diagnosis and prostate cancer risk are presented in Table 4-10 
Table 4-10 Hip and pelvic X-ray >5,10 & 15 years and prostate cancer 
risk 
Hip/pelvic X-ray Case (%) Control (%) ORt 95%CI 
Lower-upper 
P-value 
>5years 
Never had any 
procedure 
204(94.4) 852(98.2) 1.00 
Once and >Syears 
prior to diagnosis 
12(5.6) 16(1.8) 3.42 1.56-7.50 <0.001 
Total 216(100.0) 868(100.0) 
> 10years 
Never had any 
procedure 
204(95.3) 852(98.7) 1.00 
Once and >10years 
prior to diagnosis 
10(4.7) 11(1.3) 4.18 1.69-10.30 <0.001 
Total 214(100.0) 863(100.0) 
> 15yea rs 
Never had any 
procedure 
204(95.8) 852(99.1) 1.00 
Once and >15years 
prior to diagnosis 
09(4.2) 08(0.9) 4.69 1.77-12.47 <0.001 
Total 213(100.0) 860(100.0) 
tadjusted for age and social class 
There was a positive association between hip/pelvic X-ray exposure five years 
prior to diagnosis and prostate cancer risk with the odds ratio of 3 (p-value 
<0.001). Highly Increased risk of four times is observed amongst the subjects 
with history of hip/pelvic X-ray at ten and fifteen years prior to diagnosis and 
prostate cancer risk (p-value <0.001). 
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4.8.1.5 Upper leg and thigh X-ray 
Table 4-11 shows distribution and risk estimates on upper leg and thigh X-ray in 
relation to prostate cancer 
Table 4-11 Distribution and odds ratios of upper leg and thigh X-ray and 
prostate cancer risk 
U Leg & thigh X-ray Case (%) Control (%) ORt 95%CI 
Lower-upper 
P-value 
Never had any procedure 204(97.6) 852(97.4) 1.00 
Leg &thigh once 05(2.4) 23(2.6) 1.05 0.39-2.83 0.93 
Total 209(100.0) 875(100.0) 
tadjusted for age and social class 
The overall distribution is similar between cases and controls. There is no 
association between single exposure of upper leg and thigh X-ray and prostate 
cancer risk. 
Results on upper leg and thigh X-ray five, ten and fifteen years prior to diagnosis 
and risk of prostate cancer is illustrated in Table 4-12 
Table 4-12 Distribution and risk estimates of leg and thigh X-ray >5,10 
& 15 years 
U Leg & thigh Case (%) Control (%) ORt 95%CI Lower- 
upper 
P-value 
>5years 
Never had any 
procedure 
204(98.1) 852(98.3) 1.00 
Once and >5years prior 
to diagnosis 
04(1.9) 15(1.7) 1.14 0.37-3.52 0.82 
Total 208(100.0) 867(100.0) 
-Continue- 
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U Leg & thigh Case (%) Control (%) ORt 95%CI Lower- 
u er 
P-value 
Never had any 
procedure 
204(98.1) 852(98.7) 1.00 
Once and >10years 
prior to diagnosis 
04(1.9) 11(1.3) 1.58 0.49-5.09 0.44 
Total 208(100.0) 863(100.0) 
> 15yea rs 
Never had any 
procedure 
204(98.1) 852(98.7) 1.00 
Once and >15years 
prior to diagnosis 
04(1.9) 11(1.3) 1.58 0.49-5.09 0.44 
Total 208(100.0) 863(100.0) 
raalustea ror age and social class 
None of the results was statistically significant and the adjusted OR ranged from 
1.14-1.58. 
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4.9 Discussion 
The study analysed 1112 prostate cancer cases and 1872 healthy controls. The 
main exposures were five individual diagnostic medical procedures. The results 
suggested that subjects who were exposed to hip/pelvic X-rays only once in their 
lifetime regardless of timing (OR for time non-specified 3.15,95% C. I. 1.81- 
5.47) are at greater risk of developing prostate cancer. This finding supports the 
priori hypothesis in that any insult from the low dose radiation to the prostate 
gland conveys a risk. When time of exposure was filtered by 5,10 and 15 years 
prior to diagnosis in the case group (or to receiving questionnaire in control 
group), the risks are greater (>5years OR 3.42,95% C. I. 1.56-7.50, >10years 
OR 4.18,95% C. I. 1.69-1.30 and >15 years OR 4.69,95% C. I. 1.77-12.47). 
These results though suggested that being exposed to hip/pelvic X-ray only one 
time date back as far as more than 15 years prior to diagnosis increase risk 
greater than being exposed during 5 or 10 years prior to diagnosis, the 
increased risk could be due to recall bias particularly in case group. 
To authors' knowledge the study group is the first to investigate an association 
between low dose ionising radiation from diagnostic radiological procedures and 
prostate cancer risk. Thus the discussion focuses on the results of different 
phases of the study including the results of first phase of study on diagnostic 
radiation procedure and young-onset prostate cancer risk (age560) published in 
2008 and the subsequent analysis by Hussain (Hussain, 2008/2009). 
In the article by Myles, the sample size consisted of 431 young-onset prostate 
cancer cases and 409 age frequency matched controls. Due to small sample 
size, the exposed group for each diagnostic X-ray procedure was defined by 
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subjects who reported ever had a procedure and date at first procedure was 
recorded and further filtered by 5,10,20 years prior to diagnosis in case group 
and receiving questionnaire in control groups. This was carried out to test a 
priori hypothesis if there was any suggested evidence between diagnostic 
medical X-ray procedures and early onset prostate cancer. The findings 
suggested positive associations with barium enema (OR at 5 years and 10 years 
prior to diagnosis was 2.06,95% C. I. 1.01-4.20 and 2.49,95% C. I. 1.07-5.78, 
respectively) and hip and pelvic X-ray (OR at 5 years prior to diagnosis was 
2.23,95% C. I. 1.42-3.49 and at 10 years prior to diagnosis 2.65,95% C. I 1.60- 
4.39 and 20 years prior to diagnosis 2.87,95% C. I. 1.47-5.62 respectively ) 
(Myles et al, 2008). 
The subsequent analysis reported by Hussain 2008/2009, with a larger dataset 
(831 cases and 1298 controls, age : 560) applied a more refined definition to the 
exposed group. The exposed group was defined by any subjects who reported 
having had one exposure of that particular procedure in a specific time period 
and further filtered according to exposure time (5,10,20 years prior to 
diagnosis). The results suggested that hip/pelvic procedure >5yrs before 
diagnosis OR 1.89,95% C. I. 1.16-3.09 and OR, 1.92 95% C. I. 1.09-3.36 if 
procedure >10yrs before diagnosis and upper leg/thigh X-ray >5yrs the OR 
1.90,95% C. I. 1.05-3.45, >10yrs OR 2.16,95% C. I. 1.10-4.25 and >20yrs OR 
2.46,95% C. I. 1.10-5.50 is a risk factor for early onset prostate cancer 
(Hussain, 2008/2009). The author concluded that there are 2 possible reasons 
to explain why these two results are different including different approaches for 
data cleaning/filtering of each procedure creating the much smaller number of 
cases as compared to controls in the second analysis. 
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This present study has largest sample size as compare to two others and 
including subjects with all ages. The reason to select all ages is to see the 
effect of radiation is exclusively in the young-onset prostate cancer, which is less 
prevalent and mostly familial but also seen in sporadic cases which have an older 
age of onset and are more prevalent and because of old age they might have 
exposed to more doses and might have cumulative effect. The different 
approach (to the first and the second analysis) to define exposed group is 
applied to reduce any confounding/co-effects of other procedures. Thus subjects 
will only be eligible to the analysis if they exposed to one procedure only and 
also further refine the period of having had the procedures 5,10 and 15 years 
prior to diagnosis or receiving questionnaire. The analysis did not take into 
account any subjects who reported having had procedure more than one time 
because data on dates are incomplete (part of the dataset did not have details 
on date of subsequent procedure) thus it is impossible to justify if the 
subsequent procedures were carried out before or after diagnosis. The exposure 
at greater than 5,10 and 15 years prior to diagnosis were investigated in order 
to minimise any chances of being exposed through treatments/diagnosis. 
The stratified analysis was also performed in age : 560 as compare to >60, but 
the results were not significant and sample size was small in each age group. 
From the first, second to the present analyses, there are some key differences in 
each of these sub studies as study progresses over the period of 10 years of 
data collection such as larger sample size, inclusion of all age groups, a different 
methodology of defining variables. With the larger samples, the analyses of 
more refine exposures are viable hence this dataset allows the analysis of an 
independent effect of. a single X-ray procedure (without being confound with 
other procedures) and the results of hip/pelvic X-ray remains consistent 
throughout all 3 analyses regardless subject's age and the approach used'. 
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Brenner and colleagues reported that radiation dose ranging from 5-100msv 
increased risk for solid cancers as compare to dose less than 5msv (Brenner et 
al, 2003). Among these 5 procedures, only barium enema and hip/pelvic X-ray 
can potentially convey the maximum dose to prostate gland at 25msv and at 
5msv respectively. However, barium enema is a rare procedure as shown by 
only 4% of cases reported ever had barium enema. Hip/pelvic X-ray, on the 
other hand, is more common in study subjects (11% in case group). Thus it 
could be the small numbers of subjects that affected the null results of barium 
enema. Although barium enema was reported as a risk factor by Myles et al, 
however the subsequent analysis both by Hussain and by author did not show 
any associations. Hussain also pointed out that it could be due to smaller 
samples as the result of different approach use to define exposure group. This is 
also the case for this present analysis. The null associations in other 3 
procedures; IVP, barium meal and leg/thigh can be explained by either the rare 
event (IVP, leg/thigh X-ray-less than 5% of subjects in both procedures) and/or 
low dose of X-ray that although delivered to the prostate, did not harm the 
gland. 
Berrington de Gonzalez et al, found that cumulative radiation induced risk 
increases from forty years of age. The most common cancers associated with X- 
rays are bladder, colon, breast and leukaemia in both sexes and the highest risk 
procedures are CT scan, barium enema, hip and pelvic X-rays. It is also stated 
that risk of getting cancer depends upon dose, frequency and radiosenstivity of 
organ. Although this study explores, several other cancers, however, it did not 
investigate prostate cancer. But as it assess other hormonal cancers such as 
breast cancer and thyroid cancer, thus we have reason to believe that prostate 
cancer may be affected in a similar way (Berrington de Gonzalez et al, 2004). 
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Since hip/pelvic X-ray shows a strong risk, the author investigated further on the 
effect of cumulative dose of hip/pelvic X-ray which may suggest a dose-response 
association. This can only be examined by the author's data (the second phase 
thus limit the number of eligible subjects. Moreover, during data audit process, 
there are problems with incomplete information on dates of having had the 
exposure in a few subjects particularly if they reported having had exposed to 
any procedures more than 3 times, very few has completed date of each 
procedure. This has an effect on identify eligible subjects. When omitted these 
subjects, the sample size then became too small. 
There are very limited evidence from epidemiological studies that radiation 
exposure in particular X-ray can be the risk factor for prostate cancer. Long 
term follow-up studies of the United Kingdom cohort of ankylosing spondylitis 
patients who received X-ray treatment and United Kingdom Atomic Energy 
Authority (UKAEA) employees who have internal low-LET (linear energy transfer) 
radiation exposures found no strong evidence for radiation exposure as a risk 
factor for prostate cancer, this conclusion, was made on the lack of evidence for 
dose-response in these studies (UNSCER., 2006). In a retrospective study of 
prostate cancer in the United Kingdom Atomic Energy Authority employees, a 
strong association was found between exposure of radio-nuclides and prostate 
cancer risk (Atkinson et al, 1994), but according to Atkinson et al., 2004, there is 
less significant association between prostate cancer risk and radiation dose 
compared with previous studies (Atkinson et al, 2004). 
Several studies have been conducted on the survivors of Hiroshima and 
Nagasaki. The survivors are from the general population and of all age and 
gender. During first five years the first cancer observed was leukaemia followed 
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by variety of solid tumours within ten years, with the significant exception of 
pancreatic, prostate, uterine cancer and chronic lymphoblastic leukaemia. The 
cancers showing a steady rise are leukaemia, non-melanoma skin and bone 
cancer (Little, 2009). The possible explanation for high incidence of these 
cancers following the exposure high dose radiation may be the effect of radiation 
on rapidly multiplying tissues like blood and bone marrow cells and for skin 
cancer possibly due to direct penetration of radiation in skin. 
The results from several cohort studies remain inconclusive and do not suggest 
radiation as risk factor for prostate cancer (Carr et a!, 2002; Iwasaki et al, 2003; 
McGeoghegan & Binks, 2000a; McGeoghegan & Binks, 2000b). In the report 
from National research Council, National Academy of Science, Advisory 
Committee on Biological effects of ionising radiation (BEIR) of 1990 found only 
a week association between prostate cancer and radiation exposure (BEIR, 
1990). 
Another study conducted on 13,136 subjects of the Childhood Cancer Survivor 
Study revealed 83% of patients had received radiotherapy during their childhood 
cancer and 59% developed a secondary neoplasm in a previous radiotherapy 
field with a median elapsed time of 15 years. Although there is higher dose of 
radiation used for therapeutic purpose as compare to diagnostic radiography but 
one cannot exclude the chance of getting cancer later in life as evident from the 
results of this study that there are potential chances of developing prostate 
cancer with hip X-ray exposure greater than five years. 
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Since literature on epidemiological evidence of diagnostic procedures and 
prostate cancer risk are limited, it is therefore worth mentioning the example of 
other hormone dependent organs such as breast and their vulnerability to 
acquire cancer after radiography or radiotherapy or screening. The results from 
case-control study on medical radiation exposure and breast cancer risk from the 
family cancer registry showed increased risk of breast cancer in those women 
who had exposed to radiotherapy for other cancers (OR 3.55,95% C. I. 1.47- 
4.20) and X-ray chest for lung infection such as tuberculosis and pneumonia (OR 
2.49,95% C. I. 1.82-3.40) and (OR 2.19,95% C. I. 1.83-3.47). Risk was highest 
in women with several exposures start from young age and with genetic 
predisposition (John et al, 2007). Another study also revealed that exposure to 
low level ionising radiation such as X-ray chest at early age and with frequent 
exposures lead to breast cancer later in life (95 % C. I. 1.11-1.67; P=0.001) 
(Miller et al, 1989). 
In this study the stratified analysis with family history and age <60 years were 
also performed to see the difference in risk between genetically predisposed and 
those who are not. The results show no significant difference in both groups 
thus the results did not present here. 
This is the first case-control study evaluating the effects of different X-rays 
procedures on causation of prostate cancer, there are few limitations of this 
study: 
1- The possible recall bias because the data was based on self-reporting by the 
participants using self administered questionnaire. Case group are more 
likely to recall events more accurate than control group, this is evident by 
the more complete data in case group. Subjects with prostate cancer may 
feel it is more important and might relate it with some role in their cancer. 
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2- Data validation should be considered however due to time and resource 
constraints, records could not be verified in this present study. 
In summary hip and pelvic X-ray procedure showed increase risk of prostate 
cancer. 
4.10 Conclusions 
Findings of this study suggested increased risk of prostate cancer with exposure 
to hip/pelvic X-ray and explained the importance of low-dose ionising radiation in 
the aetiology of prostate cancer. 
4.11 Recommendations 
9 This study provides rationale for large scale case-control studies along 
with some better tool/assessment of investigating exposure history, as 
self reported history might lead to recall bias. A validation study 
particularly for case-control study should be considered. 
9 Future study with completed information on diagnostic medical procedures 
would allow the calculation of lifetime cumulative dose. 
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Chapter 5 Hormone markers 
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5 Literature review 
5.1 Androgens 
Androgens play an important role in the growth and function of male 
reproductive organs such as testis and prostate and in the development of 
secondary sexual characteristics (Hsing et al, 2002). Androgens are male sex 
hormones formed by the testis and adrenal glands, and also from some 
peripheral tissues like skin and the prostate (Hsing, 2001). It has been 
postulated that they play a role in growth and progression of prostate cancer, 
but this association remains obscure in most epidemiological studies, possibly 
due to methodological issues (Platz et al, 2004). There are two main forms of 
androgens, firstly testosterone, of which about 90% of it is formed from 
androstenedione and secreted by the Leydig cells of the testis and 5-10% from 
adrenal glands and which is the major circulating androgen in adult male. The 
other is its metabolite, 5 alpha-dihydrotestosterone or dihydrotestosterone 
(DHT) mainly metabolized by 5 alpha-reductase in the skin and prostate (65- 
75%) and nearly 25% secreted by testis, is mainly found in tissues (Hsing, 
2001; Soronen et al, 2004). There are two types of 5 alpha-reductase enzymes, 
type 1 enzyme is encoded by SRD5A1 gene and mainly found in hair and skin 
and type 2 encoded by SRD5A2 gene is mainly located in genital skin and 
prostate. This enzyme is responsible for irreversible conversion of testosterone 
to DHT within the prostate (Hsing, 2001) (see Figure 5-1). 
Though the precise mechanism of androgen action in prostatic carcinogenesis is 
still not clear, the following facts suggest an important role of androgens in 
prostate cancer aetiology, the response of prostate cancer to hormonal therapy, 
the rare incidence of prostate cancer in eunuchs, regression of tumour after 
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androgenic ablation and the observation that prostate cancer never develops in 
men castrated before puberty and in individuals who are deficient in 5 alpha- 
reductase (Bosland, 2000; Hsing et al, 2002; Kirby & Patel, 2009). To 
understand the exact role of androgenic hormones in prostatic carcinogenesis 
Hsing et al, suggested setting up large-scale multidisciplinary investigations by 
incorporating molecular genetics, histopathology, biochemistry and 
endocrinology in epidemiological studies (Hsing et al, 2002). 
Figure 5-1 Spatial distribution of types 1 and 25 alpha-reductase 
(Steers, 2001). 
Typo Ii 
5a-R. ductaae 
Type I 
5a"Reductase 
Sebaceous Glands 
Liver 
alp 
- 
Hair Follicle 
Beard 
Chest Skin 
Liver 
Prostate 
91 
5.2 Baldness (Androgenetic alopecia) 
Androgenetic alopecia (AGA) or male pattern baldness (MPB) is a very common 
condition characterized by a distinct pattern of hair loss from the scalp (Hillmer 
et al, 2005). Those who developed a marked alopecia soon after birth are more 
prone to develop alopecia on same areas in their adult life. Factors contributing 
to the pathogenesis of androgenic alopecia are androgens, endocrine stimulation 
by testis (and ovaries in females), genetic predisposition and aging. Though the 
most important factor is androgen dependency (Hamilton, 1951), a genetic 
predisposition which appears to be a polygenic is an important prerequisite for 
the phenotype (Hillmer et al, 2005). It has been suggested that AGA is 
associated with several other diseases such as coronary heart disease, insulin 
resistant disorders, benign prosatatic hyperplasia (BPH) and prostate cancer. 
Apart from androgens, hair growth can be affected by hormones such as thyroid 
and glucocorticoid (Gonzalez-Gonzalez et al, 2009; Lotufo et al, 2000; Trueb, 
2010). 
The structure of hair follicle is like a three-dimensional tube composed of 
epithelial cells (see Figure 5-2). 
Figure 5-2 Structure of hair follicle 
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Taken from http: //medicaldictionary. thefreedictionary. com/ /viewer. asDx. 
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There are three phases of hair follicle growth cycle, Anagen-(growth phase), 
Catagen-(short transitional phase), Tolegen-(resting phase) (see Figure 5-3). At 
the base of hair follicle are the dermal papillas which are believed to play a key 
role in controlling this cycle for growth and development of the hair follicle. 
Androgens act on the dermal papilla and regulate hair growth (Hibberts et al, 
1998). 
Figure 5-3 Hair follicle growth cycle 
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Taken from httl2: //www. google. co. uk/imcires? 
During literature review, a small number of genes have been found which appear 
to predispose to male pattern baldness and they will be discussed in details in 
Gene and Environmental interaction chapter (see chapter 6). 
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5.2.1 Baldness and prostate cancer 
Though the exact mechanism and relation between the development of AA/MPB 
and prostate cancer is still unknown, both share many common factors such as 
prevalence, aging, androgens and heritability (Hawk et al, 2000; Wright et al, 
2010). There are very few epidemiological studies that have addressed the 
association between AA/MPB and prostate cancer and results are inconsistent. 
The majority of studies showed non significant association between baldness and 
prostate cancer risk (Cremers et al, 2010; Demark-Wahnefried et al, 2000; 
Wright et al, 2010). On the other hand, only a few studies showed statistically 
significant association between both conditions (Giles et al, 2002; Hawk et a!, 
2000). 
In summary, androgens and genetics have some role in the aetiology of both 
conditions therefore there may be some relationship between androgenic 
alopecia/baldness and prostate cancer. 
5.3 Hand pattern 
Ancient civilizations recognised the study of the hand and its finger pattern in 
relation to health, longevity and personality traits. Even today, it remains an 
area of great interest amongst palmists, scientists and researchers. But it was 
only a decade ago that the second to fourth digit length (2D: 4D) was proposed 
as a marker of prenatal testosterone exposure. Since then several studies have 
been conducted to establish the association between 2D: 4D and human 
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behaviour, fertility, sexual orientation and different disease risks (McIntyre, 
2006). 
The 2D: 4D ratio is sexually dimorphic, lower in males than females meaning the 
4th digit is longer than 2"d digit and this pattern is associated with high levels of 
foetal testosterone, present at age 2 years and did not change at puberty 
(Lutchmaya et al, 2004; Voracek et al, 2005). Initially, the foetal differentiation 
into male phenotype is dependent on SRY gene on the Y chromosome. Which 
leads to the formation of foetal testis and the production of testosterone which 
starts at about 8 weeks of foetal life (Manning & Robinson, 2003). The Second 
and fourth digit ratio (2D: 4D) has been correlated with foetal growth, hand 
preference, sperm count, family size, high sports ability, autism, Asperger's 
syndrome, age at myocardial infarction (MI) and breast cancer (Fink et al, 2006; 
Lutchmaya et al, 2004; Manning et a/, 2003; Manning & Taylor, 2001b). 
According to Manning et al., 1998, low digit ratio in right hand is associated with 
high sperm count and increased level of testosterone concentration in men. 
High digit ratio in both men and women is due to high concentration of 
luteinizing hormone(LH), oestrogen and prolactin (Manning et al, 1998). 
The results of a report conducted on 255,116 participants in a BBC internet 
survey also showed lower mean 2D: 4D for right hand as compared to left in 
men, but lower in left hand than right in women (Manning et al, 2007). The data 
revealed that the sex difference in 2D: 4D ratio almost same in all races and is 
universal (Manning & Robinson, 2003). However it is also evident from other 
studies that, the mean 2D: 4D is higher in Whites, non- Chinese Asians and Mid- 
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Easterners and lower for Chinese and Blacks. These differences are also 
significant across sexual orientation but only in men, higher in homosexuals and 
bisexuals as compare to heterosexuals suggesting low prenatal testosterone 
exposure in former group (Manning et al, 2007). 
Though there is a growing body of evidence that many sex-dependent behaviour 
are associated with the 2D: 4D ratio. However, there is no direct evidence for 
this association and is entirely based on indirect evidence from the 
characteristics dependent on sex hormones such as congenital adrenal 
hyperplasia (a genetic disorder associated with high prenatal androgen), 
maternal smoking during pregnancy supposed to increase foetal testosterone 
and having sons with a low 2D: 4D, waist-hip ratio and 2D: 4D and polymorphism 
in X-linked androgen receptor gene resulting in increased sensitivity to 
testosterone (Manning et al, 2003; Manning et al, 2007). A study conducted on 
50 men (49 Caucasian, 1 Caucasian/Chinese) showed a positive association with 
CAG (Cytosine, Adenine and Guanine) number, that men with low 2D: 4D in their 
right hand have AR alleles with low CAG numbers (Manning et al, 2003). Twin 
studies suggest there is also a possible genetic role in addition to any prenatal 
environmental influence on this hormonally related skeletal ratio in both men 
and women (Gobrogge et al, 2008; Paul et a/, 2006). To author's knowledge, 
there is only one cohort study looking at digit ratio and prostate volume, PSA 
level, and the prostate cancer risk (Jung et al, 2010). No other case-control 
study investigates this marker and prostate cancer risk. 
In summary, the morphology of hand pattern (2D: 4D) arises in utero from the 
concentration of sex hormones, lower in men than in women meaning 2D length 
" 
is shorter than 4D length, and negatively associated to prenatal and adult 
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testosterone and related phenotypes such as sperm counts and positively 
associated with prenatal oestrogen. The inclusive link between second to fourth 
digit length and testosterone thus warrants the investigation of this marker with 
prostate cancer. 
5.4 Acne 
Acne or acne vulgaris is the most common skin disorder of the pilosebaceous 
unit (consists of sebaceous gland and hair follicles) affecting nearly 80% of 
young population aged 11-30 (Leyden, 1995; Toyoda & Morohashi, 2001). 
There is no standard classification for acne but it has been suggested that it 
classified in to non- inflammatory (open or closed comedones) and inflammatory 
(papules, pustules and/or nodules) forms (Bhambri et a/, 2009). Problems 
related with acne are disfiguration, permanent scarring, and psychological 
disturbances ranging from social phobias to clinical depression (Leyden, 1995). 
The Pathogenesis of acne is multifactorial and factors that can play an important 
role in the development of acne are genetics, androgens, sebum, immunity and 
bacterial infection (Mascaro, 2000). 
Acne is characterized by androgen stimulated increased sebum production 
(seborrhoea), abnormal desquamation of follicular epithelium, colonization of 
propionibacterium acnes (P. acnes) and inflammation (Toyoda & Morohashi, 
2001). P. acnes is a harmless commensal gram-positive anaerobic bacteria found 
in the sebaceous gland of the skin (Bruggemann et a/, 2004). ' 
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Acne appears at a time of steady increase in production of androgens, that is 
puberty. But most men and women with acne have normal androgen levels and 
it is thought to be due to hyper responsiveness of sebaceous glands to 
androgens (Cunliffe, 1980; Leyden, 1995). Most of the androgens are produced 
by testis and adrenals, they can also be produced by sebaceous glands from 
adrenal precursor hormone, dehydroepiandrosterone sulphate (DHEAS), but the 
main androgens that act on androgen receptors are testosterone and DHT. DHT 
is 5-10 times more active than testosterone to act on androgen receptors 
present in the sebaceous gland (Thiboutot & Thiboutot, 2004). Androgens 
increase sebum production, a critical factor in the development of acne (Leyden, 
1995). 
Although hormones are important in the development of acne, the mechanism of 
action of hormones in the pathogenesis of acne is not clear (Thiboutot & 
Thiboutot, 2004). However, evidence from different studies suggests that acne 
appears on administering androgens in castrated men or those who have genetic 
mutations in androgen metabolism. It is found that women with acne can be 
cured with antiandrogenic therapy and the oral contraceptive pill and acne is 
often associated with androgenic producing tumours of the adrenals and ovaries 
(Galobardes et al, 2005; Thiboutot & Thiboutot, 2004). 
The combined twin and nested cross-sectional study in women reported that 
acne is a inheritable disease with significant additive genetic effects. Until 
recently very few candidate genes have been identified and but those that have 
related to androgen and steroid metabolism. The sample size of these studies 
however was very small (Bataille et al, 2002). 
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5.4.1 Acne and prostate cancer risk 
It has generally been hypothesized that androgens have an important role in the 
aetiology of both acne and prostate diseases, though the exact mechanism is yet 
to be established. Acne was used a marker of excess male hormone in a case- 
control study conducted by Giles et al, observed association between acne and 
prostate cancer risk (Giles et a/, 2003). 
It is also well established that chronic inflammation can cause several human 
cancers. The emerging theory that P. acnes might be one of the causes of 
prostate cancer gives a new lead to several combined risk factors in the 
aetiology of both conditions (Sutcliffe & Platz, 2007). 
It is evident from several studies that nearly 20% of adult human cancers are 
due to chronic infection or inflammation. Many epidemiological, molecular and 
histopathological studies proved that inflammation plays an important role in 
prostate cancer pathogenesis but the exact cause of prostate inflammation is still 
not clear. There may be several reasons for prostatic inflammation and 
infectious agent could be one of them and there may be several infectious 
agents leading to chronic inflammation of the prostate (De Marzo et al, 2007b). 
In summary, three factors are common in the pathogenesis of acne and prostate 
cancer, androgens, P. acnes and heritability may play some role in the aetiology 
of both conditions. Therefore it is worth investigating the role of acne in 
development of prostate cancer. 
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5.5 Hypothesis and aims 
Hypothesis 
There is an association between male sex hormones surrogate markers and 
prostate cancer risk including balding, pattern of index to ring finger length and 
acne. 
Aims 
To assess the association between male sex hormones surrogate markers and 
prostate cancer risk including balding, pattern of index to ring finger length and 
acne. 
5.6 Methodology 
5.6.1 Grading of Baldness pattern 
Hamilton's classification of the pattern of baldness (Baran et al, 1991) was used 
(see section 3 in the questionnaire in appendix). There are seven grades of 
baldness from normal hair pattern to severe vertex baldness. Grade 1 was 
assigned for normal hair pattern, which was also used as reference category, 
grade 2 for frontal baldness and 3-7 for vertex baldness. The reason of merging 
all grades of vertex baldness is to make sample size stable in that category, 
because all other have only one grade and vertex baldness has five grades. This 
approach had been applied by many other studies (Demark-Wahnefried et al, 
1997; Giles et al, 2002). Subjects were asked to record their balding from the 
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pictures provided during their 20s, 30s and 40s. The analysis was performed 
with these individual ages and further with the subset with a positive family 
history of prostate cancer. For the latter, only significant results are presented 
here due to limitations on space (baldness at age 30) (see Table 5-2). 
5.6.2 Right hand pattern 
Subjects were asked to identify their finger length pattern on right hand as 
nearest to series of pictures depicted in the questionnaire. A clear instruction of 
how best to compare their hand with the pictures provided. There were three 
illustrations indicating: the index finger longer than the ring finger, the index 
equally as long as the ring finger and the index shorter than the ring finger. The 
latter was used as the reference category. 
5.6.3 Acne 
Subjects were asked to respond yes or no for the presence of acne at puberty, in 
their 20s and 30s. Acne during these periods was individually analysed to obtain 
odd ratios. 
To investigate an effect of prolonged acne since teens through to 20s and 30s, 
only subjects who answered all questions related to acne at teens, at 20s and at 
30s were eligible for the analysis. A further variable filter was applied to 
categorise them according to the duration of acne presence i. e. from teens only, 
teens to 20s etc. Subjects who reported never had acne were used as a 
reference category. 
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5.7 Analysis 
Unconditional logistic regression was used to generate odds ratios and 95% C. Is. 
To control for confounding, age and social class were added to the model; age 
was included as a continuous variable whereas social class was fitted as a 
categorical variable. 
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5.8 Results 
5.8.1 Pattern of baldness 
Results showing pattern of baldness at age 20,30 and 40 
Table 5-1 shows distribution and odds ratios of baldness and prostate cancer risk 
Table 5-1 Distribution and odds ratio of pattern of baldness at age 20, 
30, and 40 
#Baldness at 20 Case (%) Control (%) ORt 95%CI Lower-upper P-value 
No baldness 716(68.3) 1235(69.9) 1.00 
Frontal baldness 234(22.3) 361(20.4) 1.10 0.91-1.33 0.34 
Vertex baldness 99(9.4) 172(9.7) 1.02 0.78-1.33 0.88 
Total 1049(100.0) 1768(100.0) P for trend 0.58 
#Baldness at 30 
No baldness 429(40.6) 733(41.3) 1.00 
Frontal baldness 311(29.4) 559(31.5) 0.95 0.79-1.14 0.56 
Vertex baldness 317(30.0) 481(27.1) 1.13 0.94-1.36 0.20 
Total 1057(100.0) 1773(100.0) P for trend 0.25 
#Baldness at 40 
No baldness 201(18.4) 328(18.0) 1.00 
Frontal baldness 308(28.3) 602(33.0) 0.84 0.67-1.06 0.15 
Vertex baldness 581(53.3) 896(49.1) 1.07 0.87-1.31 0.55 
Total 1090(100.0) 1826(100.0) P for trend 0.18 
#No baldness (picture 1), frontal baldness (picture2), vertex baldness (picture 3-7) 
tadjusted for age and social class 
Results showed that the prevalence of baldness increased with advancing age. At 
the age 40, nearly 80% of cases and controls had some baldness. Those with 
frontal and vertex baldness are not at any greater risk compared to no baldness 
at any age (all confidence intervals include 1). 
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Cluster analysis of family history of prostate cancer in first degree 
relatives 
Cluster analysis was carried out to investigate an effect modification of family 
history on balding and prostate cancer risk. Only the results of balding at 30s 
show the significant association as presented below. 
Baldness at age 30s and risk of prostate cancer within familial cases 
Table 5-2 shows distribution and risk estimates on baldness at age 30s and 
prostate cancer among subjects with father and brother affected and not 
affected by prostate cancer. 
Table 5-2 Percentage and odds ratio of pattern of baldness at age 30 
within familial cluster 
First degree 
relative 
affected with 
prostate 
cancer 
#Baldness at 30 Case (%) Control (%) ORt 95%CI 
Lower- 
upper 
13- 
value 
No No baldness 293(41.9) 649(40.2) 1.00 
Frontal baldness 205(29.3) 519(32.1) 0.86 0.69-1.06 0.16 
Vertex baldness 201(28.8) 447(27.7) 1.01 0.81-1.25 0.96 
Total 699(100.0) 1615(100.0) P for trend 0.90 
Yes No baldness 115(38.1) 46(53.5) 1.00 
Frontal baldness 87(28.8) 18(20.9) 2.06 1.10-3.83 0.02 
Vertex baldness 100(33.1) 22(25.6) 1.85 1.03-3.31 0.04 
Total 302(100.0) 86(100.0) Pfortrend 0.03 
#No baldness (picture 1), trontal baldness (picturez), vertex baldness (picture 3-7) 
tadjusted for age and social class 
The pattern of baldness is almost the same in cases and controls with no family 
history of prostate cancer. While those with positive family history of prostate 
cancer, both frontal and vertex balding prevalence is greater in case group. Risk 
is slightly higher with frontal balding subjects as compared to vertex balding 
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subjects (OR 2.06,95% C. I. 1.01-3.83 and OR 1.85,95% C. I. 1.03-3.31) 
respectively with positive history of prostate cancer in the family. 
5.8.2 Right hand pattern 
Distribution values and odds ratios are shown in Table 5-3 
Table 5-3 Right hand pattern and prostate cancer risk 
Right hand pattern Case (%) Control (%) ORt 95%CI 
Lower-upper 
P-value 
Index shorter than ring 862(78.1) 1442(77.4) 1.00 
Index equal to ring 221(20.0) 368(19.8) 1.01 0.83-1.22 0.93 
Index longer than ring 21(1.9) 52(2.8) 0.63 0.37-1.07 0.09 
Total 1104(100.0) 1862(100.0) 
tadjusted for age and social class 
The result indicates risk reduction in subjects with index longer than ring finger 
with borderline statistically significant (p-value 0.09). 
5.8.3 Acne 
Acne at different ages in life was explored and the results are presented below. 
Acne at puberty 
Presence of acne during puberty is shown in Table 5-4 
Table 5-4 Acne during puberty and prostate cancer risk 
Acne at puberty Case (%) Control (%) ORt 95%CI Lower-upper P-value 
No 800(72.7) 1393(75.1) 1.00 
Yes 301(27.3) 461(24.9) 1.16 0.97-1.37 0.10 
Total 1101(100.0) 1854(100.0) 
aujusieu for age ana social class 
No association was observed with presence 
- 
of acne at ' puberty and prostate 
cancer risk (confidence interval includes 1). 
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Acne at 20s 
Acne at age 20s is shown in table 5-5 
Table 5-5 Acne at 20s and prostate cancer risk 
Acne at 20 Case (%) Control (%) ORt 95%CI Lower-upper P-value 
No 974(88.9) 1659(89.9) 1.00 
Yes 121(11.1) 187(10.1) 1.10 0.86-1.41 0.46 
Total 1095(100.0) 1846(100.0) 
raajustea tor age ana social class 
Results showed presence of acne at 20s is not associated with prostate cancer 
risk. 
Table 5-6 shows presence of acne from teen through 20s and 
-prostate cancer 
risk 
Table 5-6 Risk estimates of acne appearance from teen through 20s 
Teen through 20 Case (%) Control (%) ORt 95%CI Lower-upper P-value 
Never 800(73.3) 1393(75.5) 1.00 
Acne at teen but 
clear at 20s 
172(15.8) 266(14.4) 1.16 0.93-143 0.18 
Both at teen and 
20s 
119(10.9) 187(10.1) 1.11 0.86-1.43 0.42 
Total 1091(100.0) 1846(100.0) P for trend 0.21 
raajustea Tor age ana social class 
The results showed that there is no risk difference amongst those who have had 
acne from teen through 20s to those who never have had acne. There is no 
trend of increasing risk across categories (P for trend 0.21). 
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Acne at 30 
Acne at age 30s is shown in table 5-7 
Table 5-7 Acne at 30s and prostate cancer risk 
Acne at 30 Case (%) Control (%) ORt 95%CI Lower-upper P-value 
No 1026(95.4) 1725(97.1) 1.00 
Yes 49(4.6) 52(2.9) 1.59* 1.06-2.39 0.03 
Total 1075(100.0) 1777(100.0) 
tadjusted tor age and social class 
A greater percentage of case reported having had acne in their 30s as compared 
to controls (4.6% as compared to 2.9%) and the result showed 60% risk 
increase as compared to those who reported never had acne. 
Presence of acne from teen through to age 30s and risk of prostate cancer is 
shown in Table 5-8. 
Table 5-8 Association between duration of acne appearance from teens 
through 30s and prostate cancer risk 
Teen through 30 Case (%) Control (%) ORt 95%CI Lower-upper P-value 
Never have acne 794(72.5) 1389(75.1) 1.00 
Presence of acne at 186(17.0) 291(15.7) 1.15 0.93-1.41 0.19 
puberty only 
Presence of acne at 71(6.5) 121(6.5) 1.01 0.74-1.39 0.93 
teen and 20s but 
not 30s 
Presence of acne at 44(4.0) 49(2.6) 1.60* 1.04-2.45 0.03 
teen, 20s and 30s 
Total 1095(100.0) 1850(100.0) Pfortrend 0.06 
tadjusted for age and social class 
Subjects who reported suffered from acne from puberty through to the age of 
30s are at greater risk as compared to subjects 
, 
who never had acne (OR 1.60, 
95% C. I. 1.04-2.45) (p-value=0.03). There is a borderline trend of risk increase 
across categories (p-value =0.06). 
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5.9 Discussion 
Male hormones are hypothesised to associate with prostate cancer therefore this 
study investigated selected surrogate markers of male hormones and prostate 
cancer risk. These markers are balding, finger length pattern and acne. 
5.9.1 Pattern of baldness 
The results showed no associations with either frontal or vertex baldness at any 
age and prostate cancer risk (all ORs are around 1). Similar findings were 
reported in a recent case-control study suggesting no statistically significant 
association between baldness and prostate cancer risk (OR 1.10,95% C. I. 0.89- 
1.34) (Cremers et al, 2010). Another case-control study using the same method 
for assessing the pattern of baldness (Illustration of the Hamilton classification) 
showed some association between early (age 30 ) and later (age 40) onset 
vertex baldness and prostate cancer risk, but these risks were, however not 
statistically significant (OR 2.44,95% C. I. 0.57-10.46) and (OR 2.11,95% C. I. 
0.66-6.73) respectively (Demark-Wahnefried et a/, 2000). Several other 
previous case-control studies also support the above results by showing no 
significant association between baldness and prostate cancer risk (Demark- 
Wahnefried et al, 1997; Hsieh et al, 1999; Oishi et al, 1989; Wynder et al, 
1971). 
A recent population-based case-control study showed negative association 
between baldness and prostate cancer risk. There was 29% risk reduction with 
hair loss at age 30 for prostate cancer cases (OR 0.71,95% C. I. 0.56-0.91) but 
no risk reduction for those who reported hair loss only at referent date (1 year 
prior to diagnosis in cases and a randomly assigned date that approximated the 
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distribution of cases diagnosis date for controls). The risk reduction is even 
greater with hair loss (all types) at age 30 in men aged >60 at referent date (OR 
0.55,95% C. I. 0.33-0.93) (Wright et al, 2010). In this study 999 cases and 942 
controls were analyzed, using different methodology for selection of controls, for 
assessing the pattern of baldness such as observing hair loss at age 30 and 
referent date and using show cards in person interview. The study did not use 
Hamilton classification and in their primary analysis they used three categories 
for assessing baldness such as little or no hair loss, loss at forehead only and 
loss at top of head and forehead (each class contain two pictures) and in their 
subsequent secondary analysis they used five categories, while using little or no 
hair loss as referent and other four as an independent categories. 
On the other hand, an Australian case-control study of 1446 cases and 1390 
controls found a significant increased risk between both frontal and vertex 
baldness and prostate cancer at age (60-69 years) (OR 1.80,95% C. I. 1.02- 
3.16; OR 2.91,95% C. I. 1.59-5.32 ) respectively. Combined effect of baldness 
vs. no baldness is also appeared to be significant (OR 1.95,95% C. I. 1.10-3.45) 
(Giles et al, 2002). The results of this study were different form present study 
may be due to differences in methodology. 
A prospective study conducted on 4,421 men age 25-75 years old without 
history of prostate cancer followed for 17-21 years found 421 incident cases of 
prostate cancer showing the greater age standardized incidence of prostate 
cancer among men with baldness and there was evidence of increased risk 
among baldness and prostate cancer risk (RR 1.50,95% C. I. 1.12-2.00) (Hawk 
et al, 2000). The possible explanation of the difference in results could be the 
study design and the use of different scale of measurement for baldness. 
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In this present study, there is very similar prevalence of hair patterns both 
frontal and vertex balding, in cases and controls. This could explain non 
significant findings. Male pattern baldness is a very common condition affecting 
nearly 25-30% of men by the age of 30 and 80% of all males by age of 80 years 
(Cancer Research UK, 2010a; Ellis et al, 2001). More common in Caucasians as 
compare to other races (Hamilton, 1951) with the highest prevalence of 30% 
occurring by the age 30 years (Kabai & Kabai, 2008). According to the figures 
from the NHS, UK, nearly 6.5 million men are bald in the UK and by age 60, the 
majority of men have some degree of hair loss (National Health Service, 2010). 
The analysis of the subset with a family history of prostate cancer in first degree 
relatives suggested statistically significant results for frontal and vertex baldness 
in those with positive family history (OR 2.06,95% C. I. 1.01-3.83 and OR 1.85, 
95% C. I. 1.03-3.31 respectively). These results indicate a genetic association in 
both balding phenotypes. To the author's knowledge there are no case-control 
studies reporting baldness as a risk factor in the aetiology of prostate cancer 
relative to the presence of prostate cancer in the family. But it is evident from 
genetic studies that family history and genetic factors play an important role in 
both conditions (Hawk et al, 2000). 
This study used self reported baldness using pictures present in questionnaire. 
This method was proved reasonably precise by a study conducted by Littman and 
White, 2005 (Littman & White, 2005). Taylor et al, 2004, also suggested self 
reporting as the method of choice in the absence of. trained staff for assessing 
baldness using Hamilton-Norwood classification (Taylor et al, 2004). This may 
be due to its cosmetic and social importance. 
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In conclusion, the results from this study supported no association between 
pattern of hair loss and prostate cancer risk at any age. There was, however, a 
positive association between baldness and prostate cancer risk in those with a 
positive family history of prostate cancer, suggesting a potential shared genetic 
role in the aetiology of both conditions which might influence hormonal 
mechanism. 
5.9.2 Right hand pattern 
The common phenotype of male finger pattern is index shorter than ring finger 
(approximately 77.4% in controls). This phenotype is used as reference. The 
result indicated a risk reduction, although not statistically significant, between 
men with index longer than ring finger and men with index shorter than ring 
finger (OR 0.63,95% C. I. 0.37-1.07). No association was found in men with 
ring equal to index finger as compared to men with index shorter than ring finger 
(OR 1.01,95% C. I. 0.83-1.22). 
The only study investigated the relationship between digit length pattern and 
prostate cancer is the Korean Cohort study. Jung et al, showed a significant 
negative association between digit ratio and PSA (r=-0140, p=0.007). Those 
with lower digit ratio had higher mean PSA level and had higher risk of prostate 
biopsy (OR 1.75,95% C. I. 1.07-2.84) and prostate cancer (OR 3.22,95% C. I. 
1.33.7.78) (lung et al, 2010). These results are consistent with the present 
study. 
In our previous analysis whereby 3 data sets from a series of prostate cancer 
studies conducted by our study group including "The Gene-environment 
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interaction study from the first (1999-2004) and second phase (2007-2009) " 
Gene-environmental interactions in prostate cancer" and "Prostate cancer: A 
case-control study of lifestyle and dietary factors using BPH and community- 
based controls "(1999-2002), a PhD thesis by Dr Artitaya Lophatananon, were 
merged to provide a large number with 1524 cases and 3044 population-based 
controls had shown the negative association between the hand pattern with 
index finger longer than ring finger (high 2D: 4D) and prostate cancer risk, 
indicative of a protective effect with a 33% risk reduction (OR 0.67,95% C. I. 
0.57-0.80) (Rahman et al, 2010) (article in press). In this present analysis, the 
author included only data from the Gene-environment interactions in prostate 
cancer study (both phase I and II) as the author was directly involved with the 
data collection/validation process and to make all analyses of all variables 
consistent throughout. This results in a smaller number of subjects, 1104 cases 
and 1862 controls. 
Pictures of the right hand were provided to aid the response as there is a greater 
sex difference in 2D: 4D on the right hand side than on the left hand (Williams et 
al, 2000). The procedure was particularly successful in terms of response rate 
(99% of eligible subjects responded to the question). 
It has been suggested that intra-uterine exposure of hormones has an impact on 
the development of other adult-onset diseases (Manning & Bundred, 2000) 
including a large study on finger pattern and osteoarthritis risk, where lower digit 
ratio was associated with osteoarthritis (Zhang et a/, 2008). In this study, digit 
lengths were physically measured on the hand radiographs using vernier 
callipers to allow for actual measures with a high degree of accuracy and 
repeatability. Although such an approach allows for an exact ratio to then be 
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calculated, it was considered impractical and unethical for this present study as 
hand radiographs were not available. Instead, we used a more pragmatic way to 
identify the pattern of 2nd and 4th finger by self reported comparison of the hand 
with pictures. The self-reported finger length, however, raises a possible 
concern over measurement error as discussed by Caswell and Manning. In their 
study, they used two different approaches to measure 2D: 4D including finger 
length measured from photocopies of the ventral surface of hands (photo 
2D: 4D) and self-reported finger length measured directly from the finger (S-R 
2D: 4D). The results suggested that S-R 2D: 4D showed more extreme values 
when compared to photo 2D: 4D. The authors, however, concluded that a large 
sample size would reduce the effect size of this and thus this possible error is 
unlikely to have a large effect in our study (Caswell & Manning, 2009). Another 
validation assessment was made by Zhang et. al. In their study, a questionnaire 
was used with hand pictures and this was compared with exact finger length 
measurements from radiographs. Both methods showed similar results with a 
lower digit ratio associated with increased risk of osteoarthritis of knee and hip 
(Zhang et al, 2008). 
The finger length relationship seen in our study is also in keeping with equivalent 
studies on breast cancer risk based on current understanding of the role of 
hormonal patterns in utero. Women with a high ratio of 2D: 4D (indicative of 
higher prenatal oestrogen exposure) are at greater risk of breast cancer. Women 
with the more "feminine" pattern of digit length (2D: 4D high - ring finger closer 
in length or shorter than the index finger), were also more likely to present at a 
younger age (Manning & Bundred, 2000). 
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Although finger length in humans has been studied for decades, its relationship 
with hormones has only been established only recently. In humans, the growth 
and pattern of digits and the differentiation of gonads is controlled by the 
homeobox genes HOXA and HOXD. Therefore, gonadal foetal products such as 
testosterone may influence finger morphology (Manning et al, 2003). Many 
studies have shown that a high concentration of testosterone, indicating high 
prenatal testicular activity was inversely related with 2D: 4D ratio (higher the 
prenatal testicular activity and lower the 2D: 4D ratio). The negative correlation 
between digit ratio and hormone profile has been used as a marker to predict 
offspring sex ratio and sporting ability (Manning et a/, 2002; Manning & Taylor, 
2001a; Robinson & Manning, 2000; Williams et al, 2000). 2D: 4D ratio is greater 
in the right hand compared with the left and has a higher sensitivity with foetal 
androgens than the left hand (Williams et al, 2000). Manning and colleagues 
demonstrated that high 2D: 4D ratio in male right hands was associated with 
germ cell failure (GCF) due to azoospermia or oligospermia with no motility. 
They also demonstrated that testosterone assays from 58 male subjects were 
inversely associated with 2D: 4D ratio in the right hand (p= 0.03). The 
association was absent in left hand (Manning et al, 2000). 
In summary, the indicative negative association suggested some potential role of 
lower prenatal activity of testosterone which showed some protection against 
prostate cancer later on in life. 
5.9.3 Acne 
The results indicate that acne at puberty and at age 20s is not a risk factor for 
the prostate cancer (OR 1.16,95% C. I. 0.97-1.37 and OR 1.10,95% C. I. 0.86- 
1.41, respectively). There was no trend of increasing risk with the presence of 
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acne from teens through to their 20s (p for trend 0.21). The results from a 
cohort study conducted on 11,232 male students in Glasgow University who 
participated in voluntary health checks reported history of acne participants 
during 1948-1968, contradicting the results of this study, showed that students 
with acne at a young age had higher risk of prostate cancer mortality than at a 
later age (hazard ratio=1.67,95% C. I. 0.79-3.55) (Galobardes et al, 2005). 
In the present study, men who reported suffering from acne in their 30s are at 
greater risk for developing prostate cancer (OR 1.59,95% C. I. 1.06-2.39) 
compared to men who never had acne. A test for trend suggests increasing risk 
of prostate cancer with the longer duration of acne "from puberty till age 30" (p 
for trend 0.06). Since acne is not exclusively related to high level of androgen 
and inflammation, this result supported that long term suffering from acne 
potentially indicatives prolonged and persistent high level of androgens is a risk 
factor for prostate cancer and/or may be suggestive the role of chronic 
inflammation in the causation of prostate cancer. 
To the author's knowledge, only a case-control study by an Australian group 
investigated the association between markers of body growth, size, changes 
including acne and prostate cancer risk on 1476 cases and 1409 controls. As 
they classified acne in different manner, it is not possible to compare results with 
present study, however, a negative association was found in their results of 
never had acne vs. ever had acne (OR 0.71,95% C. I. 0.52-0.97) and acne onset 
before puberty vs. never had acne (OR 0.67,95% C. I. 0.45-0.99). Results of 
acne after puberty vs. never had acne proved insignificant (Giles et al, 2003). 
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As mentioned in the literature review, another emerging theory is the role of 
inflammation in the causation of prostate cancer (De Marzo et al, 2007a; De 
Marzo et al, 2007b; Sutcliffe & Platz, 2007). It is evident from previous studies 
that chronic inflammation plays some role in the aetiology of cancers of many 
other organs such as oesophagus, stomach, colon, liver and urinary bladder. It 
is also evident from epidemiological studies that prostatitis and sexually 
transmitted diseases may increase the risk of prostate cancer (Sugar, 2006). 
There could be several reasons for prostatitis ranging from invasion of organ by 
microorganism to cell injury due to physical and chemical trauma, hormonal 
variations and dietary factors (De Marzo et al, 2007b; Vasto et al, 2008; 
Wagenlehner et al, 2007). A cohort study conducted at the Johns Hopkins 
Bloomberg School of Public Health revealed a possible role of P. acnes as a 
causative agent for acne in. the development of prostate cancer (RR. 1.70,95% 
C. I. 1.03-2.80) (Sutcliffe et al, 2007). Cohen et al in their study also found 
P. acnes in 35% samples of prostate cancer patient underwent radical 
prostectomy for localized tumour (P=0.007) (Cohen et al, 2005). 
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5.10 Recommendations 
9 For the hand pattern measurement of actual ratio between 2 digits are 
recommended. 
9 Bearing in mind the important role of hormones in baldness, defining hand 
pattern, acne with prostate cancer, there is a timely need for more large- 
scale multidisciplinary investigations incorporating molecular genetics, 
histopathology, biochemistry and endocrinology in epidemiological studies 
to further investigate how these conditions can be used as biomarkers for 
prostate cancer. 
9 In addition the role of P. acnes in the development of prostate cancer 
should be evaluated in a more detailed manner using inflammatory 
markers and by culturing biopsies taken for histopathological grading. 
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Chapter 6 Gene and environmental interaction in prostate 
cancer 
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6 Literature review 
It is suggested that cancer is not exclusively the outcome of endogenous or 
exogenous carcinogens but their interaction with genes is suggested to play a 
role in carcinogenesis. This may be particularly so in "sporadic" cancer which 
may be the result of exposure to environmental factor along with polymorphism 
in genes indicative of increased susceptibility (Kotnis et al, 2005). About 99.9% 
of Deoxyribonucleic acid (DNA) is identical in every human genome and only 
0.1% variation is responsible for inter-individual differences and exclusive 
phenotype of each individual. These small genetic variations in the genome are 
known as single nucleotide polymorphisms (SNPs) (Kotnis et al, 2005). The 
key concept of genetic research is to discover the association of sequence 
variation. with heritable phenotypes and SNPs which are considered the most 
common variations that may have functional significance (Smigielski et al, 
2000). 
The majority of chronic diseases are likely to be the outcome of gene and 
environmental interaction and the most suitable approach to investigate the 
association between multiple genes and environmental factors is a standard 
case-control study (Kellen et al, 2005). For gene-environmental interaction 
studies, there still is a shortage of good quality data sets. The results to date 
are varied and this is due to the requirement of a large sample size to allow such 
investigation. 
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Table 6-1 Rationale for the study of gene-environment interactions 
" 
Obtain a better estimate of the population-attributable risk for genetic and 
environmental risk factors by accounting for their joint interactions. 
" 
Strengthen the associations between environmental factors and diseases by 
examining these factors in genetically susceptible individuals. 
" 
Help to dissect disease mechanisms in humans by using information on 
susceptibility (and resistance) genes to focus on the biological pathways that 
are most relevant to that disease, and the environmental factors that are most 
relevant to the pathways. 
" 
Determine which specific compounds in the complex mixtures of compounds 
that humans are exposed to (such as diet or air pollution) cause disease. 
" 
Use the information on biological pathways to design new preventive and 
therapeutic strategies. 
" Offer tailored preventive advice that is based on the knowledge that an 
individual carries susceptibility or resistance alleles. 
Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews 
Genetics] (Hunter, 2005), copyright (2005). 
Taking forward the results of exposure analysis in previous chapters, two 
particular groups of genes were investigated further relating to X-ray damage, 
and hormone markers including balding and acne. The following literature 
describes the roles of these genes and their possible relationship to prostate 
cancer. 
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6.1 DNA repair genes 
6.1.1 DNA damage repair machinery 
DNA is commonly subjected to damage caused by endogenous as well as 
exogenous mutagens such as cigarette smoking, ionising radiation, ultra-violet 
rays and other chemicals. There are several genome stability pathways for the 
repair of damage to DNA due to different agents (Bulman et al, 2006). There 
are now more than 150 DNA repair genes directly involved in these repair 
pathways in humans (Agalliu et al, 2010). 
Different genes function within different pathways during DNA replication or DNA 
repair. These pathways include recognising and deleting the DNA lesions, giving 
tolerance to DNA damage, and providing protection from errors (Ronen & 
Glickman, 2001). If the damage remains unrepaired it may leads to apoptosis, 
unregulated cell growth and cancer (Goode et al, 2002). 
Different types of damage to DNA such as exposure to ionising radiation can 
cause oxidation and fragmentation of DNA bases. Subsequently, it affects the 
formation of DSBs (Bulman et al, 2006). It has been evident from animal 
studies that DSBs initially repaired by non-homologous end joining process which 
is prone to error. Cells with multiple DSBs may cause chromosomal 
rearrangements and several other major changes leading to radiation 
carcinogenesis (Little, 2000). 
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To perform a critical repair function, there are five different types of DNA repair 
pathways such as homologous recombination repair (HRR), non-homologous end 
joining (NHEJ), nucleotide excision repair (NER), base excision repair (BER) and 
mismatch repair (MMR) (Bernstein et al, 2002). DNA damage caused by ionising 
radiation is however, repaired by HRR and NHEJ pathways (Goode et al, 2002). 
These repair systems protect genome stability by repairing modified bases, DNA 
adducts, crosslinks and DSBs (Bulman et al, 2006). 
Although these two pathways are mainly involved in repairing insults caused by 
ionising radiations, we are also looking at genes involved in other pathways. 
6.1.2 DNA repair genes and prostate cancer risk 
DNA repair pathways play a vital role in retaining the genome stability by 
preventing and protecting DNA from injury. Damage to these pathways may 
lead to many cancers. With aging, there could be several different factors 
accumulated and may result in DNA damage such as oxidative stress, 
inflammatory process, exposure to different environment carcinogens and/or 
dwindling DNA repair capacity may increase the prostate cancer risk (Agalliu et 
al, 2010). 
In this chapter, DNA pathways are reviewed and after extensive literature 
searches, the following genes were selected to investigate further on the basis of 
their potential interactions between X-ray exposures and the selected single 
nucleotide polymorphisms. The summary of studies is depicted in table 6-2 (see 
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Table 6-2) and the summary of selected SNPs of these genes is illustrated in 
table 6-3 (see Table 6-3). 
A study conducted by Hirata et al, showed evidence that the chemokine 
CXCL12G801A polymorphism may be associated with prostate cancer risk, they 
studied this particular mutation on the basis of evidence from previous studies 
that chemokines have an important role in the metastasis of tumour cells (Hirata 
et al, 2007a). The XPD (Xeroderma Pigmentosum Group D) gene is mainly 
involved in nucleotide excision repair (NER) pathway, and it has been suggested 
that this gene has a vital role in environmentally induced cancers. Mutations in 
this gene may halt the important steps leading to removal of DNA adducts from 
the affected organ and especially polymorphism in XPD codon 312 which is 
associated with increased level of DNA adducts in breast cancer tissue (Rybicki 
et al, 2004). The XPC Lys939GIn (Xeroderma Pigmentosum Group C) is also 
works principally through the NER pathway, a pathway mainly responsible to fix 
bulky DNA adducts. It is evident from studies that XPC codon 939 polymorphism 
may be associated with increased risk of bladder and lung cancer and might be 
risk factor for prostate cancer (Hirata et al, 2007b). Ritchey et al, studied 
XRCC3 Thr241Met (X-ray repair cross completing group 3), which act through 
HRR pathway, a pathway responsible for repairing DSBs and found some 
association with prostate cancer risk, although they analysed the combined 
effect of environmental factor such as diet and genotype (Ritchey et al, 2005). 
Ritchey et al, also found some association of 
- 
MGMT (O-6-methylguanine-DNA 
methyltransferase) MGMT 
-Leu84phe&MGMT-11e143Va1 which act through direct 
damage reversal mechanism with prostate cancer risk (Ritchey et al, 2005). It is 
evident from several studies that XRCC1Arg399 Gln (X-ray repair cross 
completing group 1) genotype involved in BER pathway are associated with 
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increased prostate cancer risk (Hirata et al, 2007b; Ritchey et al, 2005; Rybicki 
et al, 2004), while Hirata et al (b) performed first study to see the association 
between polymorphism in XRCC1 Arg194Trp and found it to be a possible risk factor 
for prostate cancer (Hirata et al, 2007b). The XRCC7G6721T (X-ray repair cross 
completing group7) is one of the genes which acts through NHEJ pathway and it 
was found that polymorphism in this gene may be associated with glioma. In 
this study they investigated polymorphism XRCC7 and two other genes 
XRCC1Arg399 Gin, XRCC1 Argl94Trp and XPC codon 939 (mentioned above) and 
found no association of XRCC7 with prostate cancer risk (Hirata et al, 2007b). 
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Table 6-3 DNA repair genes and the SNPs analysed in this study 
X-ray Gene Description of the gene SNPs Reference 
CXCL12G801A chemokine (C-X-C motif) ligand rs 1801157 (Hirata et al, 
12 (stromal cell-derived factor 2007a) 
1) 
XPD Xeroderma Pigmentosum Group 
D 
XPD codon ASP312 rs1799793 (Ritchey et al, 
Asn 2005; Rybicki 
et al, 2004) 
XPD codon lys751 
rs13181 
Gln 
XPC Lys939Gln Xeroderma Pigmentosum Group rs2228001 (Hirata et al, 
C rs3731055 2007b) 
XRCC3 Thr241Met Involved in the homologous rs861539 (Ritchey et al, 
recombination repair (HRR) 2005) 
pathway of double-stranded 
DNA, thought to repair 
chromosomal fragmentation, 
translocations and deletions 
MGMT O-6-methylguanine-DNA 
methyltra nsfe rase (Ritchey et al, 
MGMT-Leu84phe rs12917 2005) 
MGMT-Ile143Val rs2308321 
XRCC1 X-ray repair cross completing 
group 1 (Hirata et al, 
XRCC1 Arg194Trp rs1799782 2007b; 
Ritchey et al, 
2005; Rybicki 
XRCC1-Arg399 Gln rs25487 et al, 2004) 
XRCC7G6721T X-ray repair cross completing rs7003908 (Hirata et al, 
group? 2007b) 
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6.2 Genes related to sex steroid hormones 
6.2.1 Genes related to balding and prostate cancer 
It is evident from the previous studies that androgens play an important role in 
the development of baldness but it is also evident that genetic predisposition 
may also have some role in the aetiology of baldness (Hamilton, 1951; Hillmer et 
al, 2005). Although the genetic basis for baldness remains unclear, the following 
facts may be of importance: the genes encoding 5 alpha-reductase isonzymes 
(SRD5A1 and SRD5A2) or genes encoding enzymes that act in the earlier stages 
of the androgen pathway such as 30-hydroxysteroid dehydrogenase appear to 
have a role. A study by Ellis et al in 2001, revealed a significant association 
between AGA/MPB and androgen receptor (AR) gene polymorphisms (Stul) in 54 
young and 392 older cases of baldness and 107 older controls without baldness 
with AGA. The AR gene StuI was found in 98.1% of young bald men age 18-30 
(p=0.0005) and in 92.3% of older men >_50 years with baldness (p=0.000004) 
and found only in 76.6% of 107 controls >_50 years without baldness. The AR 
exon 1 triplet repeat polymorphisms CAG and GGC (which have also an 
association with prostate cancer) were also prevalent in bald men (p=0.03) (Ellis 
et al, 2001). In their recent large population-based Caucasian cohort study they 
also found strong association between androgen receptor gene SNP (rs6152) 
with baldness (p=0.0001), but no association was found with polyglutamine CAG 
or polyglycine GGN triplet repeat (p=0.13) (Ellis et al, 2007). The results from 
the study by Hilimer et at suggested that for early onset AGA, genetic variation 
in the androgen receptor gene is the key requirement and for functional effects 
there is possible role of a polyglycine-encoding GGN repeat in exon 1. They also 
suggested a maternal line of inheritance for AGA due to X-chromosomal location 
of AR (Hillmer et al, 2005). 
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Hillmer et al, in their genome-wide association study(GWAs) in 296 subjects with 
baldness and 346 population based control, investigated thirty SNPs and found a 
strong association for five SNPs on chromosome 20p11 (Hillmer et al, 2008). 
In another genome-wide association study on 1125 men with baldness, the 
authors found new susceptibility locus at 20p11 (rs1160312) with increased risk 
in the Twin UK cohort and also with Icelandic and Dutch cohort. In their 
combined analysis, the results were also highly significant (Richards et al, 2008). 
It is evident from previous studies that sex hormones particularly androgens play 
an important role in the growth of the prostate and may be associated with 
prostate cancer carcinogenesis (Platz et al, 2005; Travis et al, 2009). Twin 
studies suggest an inherited component for serum concentration of sex 
hormones; however, there is limited epidemiological evidence about the steroid 
hormone gene variants in prostate cancer aetiology. Travis et al, studied genetic 
variations at the CYP19A1 locus in relation to prostate cancer risk and with 
circulating steroid hormone concentrations in men in the Breast and Prostate 
Cancer Consortium (BPC3), a large collaborative prospective study. BPC3 aimed 
to investigate role of the common variants in CYP19A1 by targeted resequencing 
and dense genotyping; selected haploytype-tagging single nucleotide 
polymorphism (htSNP) in U. S. and European whites, Latinos, Japanese 
Americans, and native Hawaiians. - The results of this study found no association 
with prostate cancer risk (Travis et a/, 2009). 
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Table 6-4 Genes and selected SNPs in association with baldness and 
prostate cancer risk. 
Hormone Gene SNPs Reference 
Chromosome 20p11 rs2180439 (Hillmer et al, 2008) 
Chromosome 20p11 rs1998076 (Hillmer et al, 2008) 
Chromosome 20p11 rs1160312 (Richards et al, 2008) 
Chromosome 20p11 rs11603132 (Richards et al, 2008) 
CYP19A1 rs2414096 (Travis et al, 2009) 
6.3 Hypothesis and aims 
Hypothesis 
There are possible interactions between environmental exposures including low 
dose diagnostic radiation, balding, acne and selected single nucleotide 
polymorphisms. 
Aims 
1. To assess prevalence of sixteen selected SNPs in study population. 
2. To explore risk estimates of subjects who carry these alleles. 
3. To explore potential gene-environment interactions between: 
- 
Medical radiation exposure and DNA repair genes. 
- 
Genes involved in androgen pathways (particularly for baldness). 
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The selection of SNPs in this study was based on following criteria: 
An extensive review was carried out for 150 DNA repair genes and balding genes 
and those selected genes and their SNPs were based on their associations with 
prostate cancer risk in previous studies. 
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6.4 Methodology 
DNA extraction from 5 ml blood samples was commercially prepared by Gen 
Probe Company and subsequently DNA were deposited with the study partner at 
the Royal Marsden Hospital (RMH). Since DNA extraction process was carried 
out in batches throughout the period of data collection which is still ongoing thus 
not all of study subjects in this study had their DNA extracted by the time of 
genetic analysis request. To prepare DNA for SNPs analysis, the list of study 
subjects were sent to the researcher at the RMH, DNA samples of 633 cases 
(57%) and 1438 (77%) controls were successfully matched and ready for 
genotype. 
6.4.1 SNPs analysis 
SNPs analysis was out sourced with the KBiosciences who specialise in low 
volume DNA analysis (5 nanograms DNA in 75 micro litre of sample 
normalisation). Eleven SNPs from seven DNA repair genes and four SNPs for 
baldness were identified. Two other suggested genes were steroid hormone 
genes, however only one SNP result was received. The other SNP result (of acne 
gene) showed only one genotype (G: G), and was therefore excluded from 
analysis. 
In total, 11 SNPs from 7 DNA repair genes and 5 SNPs from 2 genes related to 
balding were analysed (see Table 6-3 and Table 6-4). 
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6.4.2 SNPs statistical analysis 
Frequency statistics were run to check genotype prevalence in each SNP, then 
each genotype as a trichotomous variable was transformed into numeric e. g. if 
one SNP has genotype G: G, G: A and A: A, they were transformed into 1,2 and 
3 (the most common allele was recoded as 1 and was used as reference 
category). All missing values and samples which were failed at genotyping 
process were re-coded as 9 and 99 respectively and were considered as missing. 
ORs of each SNPs was obtained by running unconditional logistic regression. 
6.4.3 Interaction analyses 
Botto and Khoury suggested different ways of analysis such as combining gene 
and environmental interaction and analysing separate (case or control only) and 
joint analysis (multiplicative or additive interaction)(Botto & Khoury, 2001). 
They also suggested that the best way to present interaction is by creating a 
two- by- four table which summarises both gene and environmental factors in 
dichotomous variable (Botto & Khoury, 2001; Kellen et al, 2005). 
The following explains the operational details for creating variables for gene and 
environmental interaction. 
To assess the effect of genotype and environmental interaction on prostate 
cancer risk, dichotomous variables were created from both genotype and 
environmental exposure. For genotype, a new dichotomous variable was created 
by keeping the most common genotype as 1; while two other alleles were 
merged into one group and labelled as 2. 
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For environmental exposures, there are two main exposures in the GE analysis 
including diagnostic radiation exposure and markers of male hormones, 
dichotomous variables were created for both exposures. However, the scheme 
of coding was slightly differed from the previous chapter due to the requirement 
of large sample size for Gene and environment interaction analysis. The 
following describes the process involved in creating the exposure variables for 
GE analysis. 
6.4.4 Diagnostic X-ray procedure 
As previously reported, hip/pelvic X-ray procedure appeared to be a strong risk 
factor for prostate cancer not only in this present study but also in our two 
previous interim data analysis by Myles and Hussain (Hussain, 2008/2009; Myles 
et al, 2008) 
. 
The first approval was made by using hip/pelvic X-ray for the 
exposure analysis as presented in chapter 4 (for recalling coding scheme see 
chapter 4 page 71). However, while filtering variables to create categories for 
subjects with presence on both exposure and gene, the sample size was too 
small in most of the newly created dichotomous variables. A further approach 
was therefore applied by creating a new dichotomous variable so called 
"universal hip and pelvic X-ray" taking into account only two categories of 
subjects including ever had hip/pelvic X-ray in life time and never had hip/pelvic 
X-ray at all. 
Since one of the a-priori hypotheses was that a diagnostic radiation insult to the 
prostate gland could potentially lead to prostate cancer, an interaction between 
the exposure of any X-ray procedures during subjects' lifetime on prostate 
cancer risk and X-ray DNA repair gene polymorphisms was investigated. A 
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dichotomous variable "Universal X-ray" was created. Subjects were categorised 
into two groups; ever had any of 5 procedures and never had any procedures at 
all. 
6.4.5 Balding 
This variable was investigated in 2 ways, firstly at each decade (20s, 30s and 
40s) and secondly by scoring overall balding. A dichotomous variable for balding 
at age 20s, 30s and 40s was created; subjects with balding (by merging frontal 
and vertex baldness) and subjects with no balding at that particular age. For the 
overall balding variable, a new dichotomous variable "universal baldness" was 
created by recoding subjects into subjects with no baldness versus subjects with 
baldness occurring at any age. 
Once both exposure and gene variables had been coded into dichotomous, all 
included subjects were classified according to their presence/absence of both 
variables. The basic layout was as follows: 
Table 6-5 Shows basic layout for a case-control study assessing the 
effect of a genotype and environmental factors (Botto & Khoury, 2001) 
Genotype Environmental Cases Controls OR Contrast Main Information 
factors 
+ + A B ah/bg A A vs. D Joint genotype and 
environmental factor 
vs. none 
+ C D ch/dg B B vs. D Genotype alone vs. 
None 
- 
+ E F eh/fg C C vs. D Environmental factor 
alone vs. None 
- 
G H 1 D Common reference 
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Botto and Khoury described several advantages of this two-by-four table 
including the fact that it displays primary data clearly, helps efficiently to 
calculate risk estimates alone and for joint exposure, highlights sample size 
issues, attributable fractions can be calculated alone for each individual exposure 
and for the joint exposure, case only and control only. Risk estimates can be 
calculated easily and multiplicative and additive models of interactions can also 
be obtained (Botto & Khoury, 2001). 
From the table, to assess the separate effect of exposures (in the absence of 
gene), odds ratios were computed by EH/FG and to calculate risk for genetic 
polymorphisms in the absence of exposure, odds ratios were computed by 
CH/DG. For joint effect (presence of both gene and exposure), the risks were 
computed by AH/BG. All of these formulae are shown in column 5th of the table 
(column label as "Odd ratio"). 
Multiplicative interaction is the ratio of the joint effect to the product of the 
independent effects. To assess multiplicative interaction, the following formula 
was used [OR = A/ (B*C)]. All analyses was performed by logistic regression 
and adjusted for age, social class and family history. 
In summary, the gene and environment interaction analysis consisted of 633. 
cases and 1438 controls. Subjects were classified according to presence or 
absence of their genes and their exposure. A2 by 4 cross tabulation table was 
created. Subjects with most common variant and not exposed to exposure were 
used as reference category. 
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6.5 Results 
6.5.1 DNA repair genes 
Prevalence of selected SNPs (X-ray DNA repair genes) is presented in table 6-6. 
Table 6-6 Distribution of seven DNA repair genes (eleven SNPs) 
polymorphism and prostate cancer risk 
Gene name Selected 
SNPs 
Genotype Cases 
(%) 
Controls 
(%) 
ORt 95%C. I. P 
CXCL12G801A rs G: G 412(67.2) 935(66.1) 1.00 
1801157 G: A 186(30.3) 426(30.1) 1.04 0.83-1.30 0.76 
A: A 15(2.4) 53(3.7) 0.59 0.32-1.10 0.10 
XPD A: G 274(45.0) 631(45.1) 1.00 
XPD codon ASP312 rs1799793 G: G 281(46.1) 604(43.1) 1.10 0.88-1.37 0.39 
Asn A: A 54(8.9) 165(11.8) 0.77 0.53-1.11 0.17 
G: T 290(46.8) 654(47.0) 1.00 
XPD codon1ys751 
i 
rs13181 T: T 257(41.5) 556(39.9) 1.00 0.81-1.25 0.98 
G n G: G 73(11.8) 182(13.1) 0.77 0.55-1.08 0.13 
XPC Lys939GIn rs2228001 C: A 281(46.3) 674(48.9) 1.00 
A: A 220(36.2) 489(35.5) 1.06 0.84-1.33 0.65 
C: C 106(17.5) 214(15.5) 1.23 0.92-1.64 0.17 
rs3731055 G: G 616(99.7) 1420(99.2) 1.00 
G: A 02(0.3) 12(0.8) 0.63 0.14-2.86 0.55 
XRCC3 Thr241Met rs861539 T: C 292(47.7) 639(45.4) 1.00 
C: C 243(39.7) 571(40.5) 0.97 0.78-1.21 0.80 
T: T 77(12.6) 199(14.1) 0.80 0.58-1.11 0.19 
MGMT rs12917 C: C 491(79.4) 1077(76.9) 1.00 
MGMT-Leu84phe T: C 119(19.3) 305(21.8) 0.82 0.63-1.06 0.13 
T: T 08(1.3) 19(1.4) 0.86 0.35-2.15 0.75 
MGMT-IIe143VaI rs2308321 A: A 452(73.4) 1036(73.7) 1.00 
G: A 152(24.7) 346(24.6) 1.09 0.86-1.39 0.47 
G: G 12(1.9) 24(1.7) 1.14 0.53-2.46 0.73 
XRCC1 C: C 528(86.4) 1246(87.4) 1.00 
XRCC1 Arg194Trp rs1799782 C: T 78(12.8) 171(12.0) 0.90 0.66-1.24 0.53 
T: T 05(0.8) 09(0.6) 1.17 0.35-3.89 0.80 
rs25487 G: A 282(45.3) 630(44.7) 1.00 
XRCC1-Arg399 Gin G: G 265(42.6) 570(40.5) 1.03 0.83-1.28 0.80 
A: A 75(12.1) 208(14.8) 0.79 0.57-1.09 0.15 
XRCC7G6721T rs7003908 A: A 270(44.6) 627(45.6) 1.00 
C: A 269(44.5) 614(44.6) 1.10 0.89-1.38 0.38 
C: C 66(10.9) 135(9.8) 1.15 0.80-1.64 0.46 
tadjusted for age, social class and family health 
137, 
Prevalence of genotype in all polymorphisms is similar in both case and control 
groups, none of the allele mutations is associated with prostate cancer risk (all 
confidence interval include 1). 
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The exposure to universal hip/pelvic X-ray alone was a strong risk factor for 
prostate cancer for all 11 selected SNPs, odds ratios ranging from 1.49-2.20 and 
p-value between 0.03-<0.001. 
Subjects who carried allele mutation of XRCC3 Thr241Met gene (rs861539) also 
showed a significant risk reduction (OR 0.77,95% C. I. 0.59-1.00) (p- 
value=0.05). 
Statistically significant joint effects (presence of both polymorphism and 
hip/pelvic x-ray exposure) were observed in 9 out of 11 selected SNPs including 
rs1801157 (CXCL12G801A), rs1799793 (XPD codon ASP312 Asn), rs13181 (XPD 
codon lys751 Gln), rs2228001 (XPC Lys939GIn), rs861539 (XRCC3 Thr241Met), 
rs2308321 (MGMT-Ilel43Val), rs1799782 (XRCC1 Arg194Trp), rs25487 
(XRCC1Arg399 Gln) and rs7003908 (XRCC7G6721T) (for ORs and C. Is see Table 
6-7). Odds ratio for joint effect between SNP rs3731055 (XPC Lys939Gln) and 
universal hip/pelvic X-ray could not be calculated as sample size is zero in case 
group. 
There was no evidence of joint effect between SNP rs12917 (MGMT-Leu84phe) 
and universal hip/pelvic X-ray and prostate cancer risk (OR 1.32,95% C. I. 0.82- 
2.11). 
142 
Multiplicative interaction between DNA repair genes, hip-pelvic x-ray 
and prostate cancer risk 
Table 6-8 shows risk estimates for multiplicative interaction between DNA repair 
genes and universal hip/pelvic exposure in prostate cancer 
Table 6-8 Multiplicative interaction between DNA repair genes (SNPs) 
and prostate cancer with universal hip/pelvic exposure 
DNA SNPs OR 95% Cl p-value ORt 95% CI p-value 
rs1801157 0.86 0.54-1.38 0.54 0.78 0.47-1.29 0.33 
rs1799793 0.94 0.60-1.48 0.80 0.93 0.57-1.53 0.79 
rs13181 1.01 0.64-1.58 0.98 0.91 0.56-1.48 0.71 
rs2228001 1.77 1.13-2.78 0.01 1.66 1.02-2.71 0.04 
rs3731055 0.00 0.00 1.00 
rs861539 1.24 0.80-1.95 0.34 1.54 0.95-2.51 0.08 
rs12917 0.74 0.43-1.28 0.28 0.71 0.39-1.28 0.25 
rs2308321 1.02 0.62-1.68 0.93 1.03 0.60-1.76 0.92 
rs1799782 1.59 0.82-3.07 0.17 1.88 0.91-3.86 0.09 
rs25487 0.89 0.57-1.39 0.60 0.86 0.53-1.39 0.53 
rs7003908 0.81 0.52-1.27 0.35 0.71 0.44-1.17 0.18 
tadjusted for age, social class and family health 
The multiplicative test of interaction between universal hip/pelvic X-ray and DNA 
repair genes SNPs showed significant interaction with modest increase risk only 
for SNP rs2228001 (XPC Lys939GIn gene) (OR 1.66,95% C. I. 1.02-2.71). 
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The results showed that the independent effect of environmental exposure was a 
risk factor for prostate cancer for six SNPs and ORs were ranging from 1.34-1.71 
and p-value=0.06-<O. 001. 
Individuals carrying the variant allele of SNP rs7003908 (XRCC7G6721T) without 
environmental exposure are at modest risk for getting prostate cancer (OR 1.45, 
p-value =0.03). 
The joint effects of both gene and environmental exposure were only significant 
with rs2308321 (MGMT-IIel43VaI) (OR 1.46,95% C. I. 1.05-2.02) and 
rs7003908 (XRCC7G6721T) (OR 1.48,95% C. I. 1.08-2.03). 
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Multiplicative interaction between DNA repair genes, universal X-ray and 
prostate cancer risk 
Distribution and risk estimates of multiplicative interaction between SNPs (DNA 
repair genes) and prostate cancer with universal X-ray exposure are shown in 
table 6-10 
Table 6-10 Multiplicative interaction between SNPs (DNA repair genes) 
and prostate cancer with universal X-ray exposure 
SNPs OR 95% CI p-value ORt 95% CI p-value 
rs1801157 0.88 0.58-1.33 0.54 0.92 0.58-1.43 0.70 
rs1799793 0.83 0.56-1.24 0.36 0.84 0.55-1.29 0.42 
rs13181 1.35 0.90-2.00 0.14 1.21 0.79-1.85 0.39 
rs2228001 1.43 0.96-2.12 0.08 1.35 0.88-2.07 0.17 
rs3731055 
rs861539 1.14 0.77-1.69 0.52 1.33 0.87-2.04 0.19 
rs12917 0.73 0.46-1.17 0.20 0.78 0.47-1.31 0.35 
rs2308321 0.97 0.62-1.51 0.89 1.08 0.66-1.74 0.77 
rs1799782 0.89 0.50-1.59 0.70 0.89 0.47-1.67 0.72 
rs25487 1.12 0.84-1.48 0.45 1.08 0.79-1.47 0.63 
rs7003908 0.67 0.45-1.00 0.05 0.60 0.39-0.93 0.02 
tadjusted for age, social class and family health 
A negative multiplicative interaction was seen in SNP rs7003908 (XRCC7G6721T) 
(OR 0.60,95% C. I. 0.39-0.93). 
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6.5.2 Genes related to baldness 
Prevalence of selected SNPs in the study subjects is presented in table 6-11 
Table 6-11 Distribution of genotype from two Hormone genes (five 
SNPs) and prostate cancer risk 
Gene name Selected 
SNPs 
Genotype Cases 
(%) 
Controls 
(%) 
ORt 95%C. I. p- 
value 
Chromosome 
20p11 
rs2180439 T: C 306(50.1) 687(49.1) 1.00 
T: T 202(33.1) 483(34.5) 0.94 0.74-1.19 0.61 
C: C 103(16.9) 228(16.3) 0.98 0.72-1.33 0.88 
Chromosome 
20p11 
rs1998076 G: A 306(50.6) 683(48.9) 1.00 
G: G 200(33.1) 491(35.2) 0.89 0.70-1.13 0.33 
A: A 99(16.4) 222(15.9) 0.92 0.67-1.25 0.59 
Chromosome 
20p11 
rs1160312 G: A 297(49.7) 710(50.6) 1.00 
A: A 158(26.5) 395(28.2) 0.89 0.69-1.15 0.38 
G: G 142(23.8) 298(21.2) 1.01 0.77-1.34 0.93 
Chromosome 
20p11 
rs11603132 G: A 309(50.4) 649(46.8) 1.00 
A: A 205(33.4) 482(34.8) 0.83 0.65-1.06 0.13 
G: G 99(16.2) 255(18.4) 0.82 0.60-1.10 0.18 
CYP19A1 rs2414096 G: A 337(54.0) 719(51.5) 1.00 
A: A 140(22.4) 352(25.2) 0.87 0.67-1.13 0.28 
G: G 147(23.6) 324(23.2) 0.90 0.69-1.17 0.43 
tadjusted for age, social class and family health 
The distributions of genotypes are very similar between cases and controls. 
None of the allele mutations is associated with prostate cancer risk. 
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Baldness at age 30s showed an increase risk in the absence of allele mutation 
(SNP rs11603132, OR 1.34,95% C. I. 1.01-1.78) however the result was no 
longer statistically significant in the full adjusted model (when age, social class 
and family history of prostate cancer were adjusted for). 
f 
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Multiplicative interaction between genes related to balding, balding and 
prostate cancer risk 
Risk estimates in multiplicative interaction for baldness and sex steroid hormone 
genes in prostate cancer 
Table 6-13 Multiplicative interactions between baldness and sex steroid 
hormone genes in prostate cancer 
Baldness SNPs Age OR 95% C. I p value ORt 95% CI p value 
rs 2180439 
20s 0.90 0.77-1.07 0.23 0.93 0.78-1.10 0.38 
30s 0.97 0.83-1.13 0.68 0.96 0.81-1.13 0.59 
40s 0.89 0.73-1.08 0.24 0.90 0.71-1.12 0.34 
rs1998076 
20s 0.88 0.75-1.02 0.10 0.89 0.75-1.06 0.19 
30s 0.89 0.78-1.02 0.10 0.92 0.79-1.08 0.31 
40s 0.90 0.77-1.07 0.24 0.95 0.78-1.16 0.62 
rs1160312 
20s 0.93 0.81-1.07 0.30 0.95 0.83-1.10 0.51 
30s 1.00 0.88-1.14 0.99 1.07 0.93-1.24 0.35 
40s 1.04 0.86-1.27 0.68 1.06 0.86-1.31 0.60 
rs11603132 
20s 0.95 0.81-1.12 0.56 0.89 0.73-1.07 0.22 
30s 0.94 0.81-1.09 0.40 0.92 0.78-1.08 0.31 
40s 0.86 0.71-1.03 0.09 0.86 0.71-1.05 0.14 
Steroid 
hormone SNP 
Age OR 95% C. I p value ORt 95% CI p value 
rs2414096 
20s 1.03 0.84-1.28 0.75 1.06 0.84-1.35 0.61 
30s 1.13 0.92-1.40 0.25 1.12 0.89-1.41 0.34 
40s 0.95 0.76-1.19 0.65 0.97 0.76-1.23 0.77 
tadjusted for age, social class and tamily health 
There was no multiplicative interactions for all five SNPS (all confidence intervals 
include 1). 
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6.6 Discussion 
The purpose of this work was to explore the prevalence of polymorphisms in 
DNA repair and hormonal genes in the study population and to investigate how 
genetic and environmental factors might jointly influence the risk of developing 
prostate cancer. The analysis consisted of 633 cases and 1438 controls. The 
genetic factors examined included seven DNA repair genes polymorpisms, 
CXCL12G801A (rs 1801157), XPD codon ASP312 Asn (rs1799793), XPD codon 
lys751 Gln (rs13181), XPC Lys939GIn (rs2228001 rs3731055), XRCC3 
Thr241Met (rs861539), MGMT-Leu84phe (rs12917), MGMT-Ile143Vai 
(rs2308321), XRCC1 Arg194Trp (rs1799782), XRCC1Arg399 Gln (rs25487), 
XRCC7G6721T (rs7003908) and baldness genes Chromosome 20p11 
(rs2180439, rs1998076, rs1160312, rs11603132) and steroid hormone gene 
CYP19A1 (rs2414096). 
To the author's knowledge, this is the first study looking at both polymorphisms 
in DNA repair genes and genes related to balding and their interactions with 
exposures on a large scale case-control study. 
6.6.1 DNA repair genes 
The prevalence of polymorphisms was similar for both cases and controls and 
risks for subjects with these possible risk alleles were not different from subjects 
with common allele. Previous studies reported similar findings. A case-control 
study conducted on 167 cases and same number of control by Hirata et at, 
2007a, found G: G (54.0%) was the most, common variant followed by G: A 
157 
(38.0%) and A: A (8.0%) in CXCL12 G801A polymorphism in their controls, 
which is similar to our study G: G (66.1%) 
, 
G: A (30.1%) and A: A (3.7%), 
however the distribution in cases and controls was different to the present study. 
They too suggested none of the gene alleles were associated with prostate 
cancer risk. However, when two alleles were combined (GA+AA), the prevalence 
was higher in prostate cancer cases as compared with controls and a modest risk 
was observed (OR 1.58, C. I. 1.03-2.43) (Hirata et al, 2007a). The difference in 
results might be due to difference in ethnicity (Japanese origin), smaller size of 
study participants and different methodological approach. 
Rybicki et al, conducted a study on 637 cases and 480 controls out of 506 
Caucasians sibships identified through a brother with prostate cancer, to see the 
effect of XPD codons 312 and 751 polymorphisms on prostate cancer risk. They 
found moderate risk with XPD codon 312 Asn allele when two copies of the allele 
were present (OR 1.59,95% C. I. 1.01- 2.51) (Rybicki et al, 2004). These 
results were not in keeping with the results of the present study. However 
Ritchey found no effect of XPD codons 751 genotype on prostate cancer risk 
(Ritchey et al, 2005). Another case-control study comprising 118 cases and 132 
age matched controls from South Australia, found no association between XPD 
codon 312 Asn and prostate cancer risk (Dhillon et a/, '2009). 
Hirata et al, 2007b, in their small scale case-control study based on 165 cases 
and 165 controls conducted in Japan, found no association between XPC 
Lys939GIn polymorphism and prostate cancer risk. These results are-similar 
with the results of present study (Hirata et al, 2007b). 
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The results from a population-based case-control study conducted on 162 
prostate cancer cases and 251 age (5 year interval) and frequency matched 
controls in Shanghai, China, found the same prevalence in both cases and 
controls for XRCC3 
-Thr241Met polymorphism. No genotype was associated 
with prostate cancer risk; these results are in accordance with the present study. 
The results from the same study for MGMT-84 polymorphism found a different 
pattern of distribution among the cases and controls as compare to present 
study. C: T genotype with 22.4% prevalence in cases and 13.0% in controls 
appeared to be a risk factor for prostate cancer (OR 1.95, C. I. 1.15-3.30). Our 
results suggested that C: T allele is more prevalent in our controls (22%). 
For MGMT-143 polymorphism, the most common genotype was A: A with very 
similar prevalence in cases and controls. No significant association was found 
between prostate cancer risk and any of genotype. These results are consistent 
with the results reported by Ritchey and colleagues(Ritchey et al, 2005). 
For XRCC1 genes, the findings suggested no association with prostate cancer 
risk. The results of pooled data from two case-control studies (1,457 cases and 
1,351 controls) conducted by Agalliu, et at. found no association between 
prostate cancer risk and 28 SNPs in nine DNA repair genes including XRCC1 
(Agalliu et al, 2010). However, other previous studies suggested an association 
of these variant alleles with prostate cancer. Ritchey et al, found almost similar 
distribution-of variant genotypes in both case and controls in XRCC1-399 and 
A: A genotype was associated with prostate cancer risk (OR 2.18,95% C. I. 0.99- 
4.81) (Ritchey et al, 2005). Hirata et al, suggested XRCC1-Arg399GIn and T-A 
haplotype of XRCC1 Arg194Trp might have some role in prostate carcinogenesis 
(Hirata et al, 2007b). Furthermore, they reported a potential interaction, 
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between XRCC1 codon 399 On allele and XPD codon 312 Asn allele when both 
alleles were present in homozygous states (OR 4.81,95% C. I. 1.66-13.97) 
(Rybicki et al, 2004). 
For XRCC7 gene, the findings are similar to those reported by Hirata and 
colleagues. Hirata et al, 2007b, found almost identical distribution of genotype 
in cases and controls with XRCC7 G6721 and found no association between gene 
polymorphism and prostate cancer (Hirata et a/, 2007b). 
6.6.1.1 GE interaction (DNA repair genes, universal hip and pelvic X- 
ray and prostate cancer) 
The multiplicative test for interaction between universal hip/pelvic X-ray and 
DNA repair genes SNPs showed a significant increased risk only for SNP 
rs2228001 (XPC Lys939GIn) in prostate cancer risk (OR 1.66,95% C. I. 1.02- 
2.71). To date, there is no study reporting an interaction between this particular 
SNP and hip/pelvic X-ray exposure thus this is the first study to report an 
interaction between these two components. 
, 
It is evident from previous studies 
that this particular DNA repair gene plays important role in removing bulky DNA 
adducts and it's polymorphism is associated with cancers such as bladder and 
lung and might therefore be risk for, prostate cancer, (Hirata et al, 2007b). 
Kotnis et al, stated that there could be range of susceptibilities with additive or 
multiplicative interaction of each allele, those have always a minute genotypic 
risk (Kotnis et al, 2005). 
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6.6.1.2 GE interaction using universal X-ray 
Analyses were conducted using universal X-ray exposure as an environmental 
factor and DNA repair genes. Results of individual and joint effects of each SNP 
(DNA repair genes) and environmental risk factor and the possible risk of 
prostate cancer were provided in Table 6-9. Table 6-9 shows that independent 
effect of environmental exposure appeared to be a risk factor for prostate cancer 
in most SNPs rs1801157 (CXCL12G801A), rs1799793 (XPD ASP312 Asn), 
rs12917 (MGMT-Leu84phe), rs2308321 (MGMT-Ile143Val), rs1799782 (XRCC1 
Arg194Trp) and rs7003908 (XRCC7G6721T) and ORs were ranging from 1.27- 
1.71 and p-value=0.06-<O. 001. 
Multiplicative interaction of SNP rs7003908 (XRCC7G6721T) and "universal X- 
ray" assessment was appeared to show a negative association (OR 0.60,95% 
C. I. 0.39-0.93). To date, there have been two studies looking at this SNPs 
mutation in association with cancer but none has investigated further the 
interactions with environment exposures. The first study conducted by Wang et 
al, showed an association of XRCC7G6721T with glioma (Wang et al, 2004) in 
subsequent study Hirata et al, 2007b, looked at XRCC7G6721T in connection 
with prostate cancer but found no association (Hirata et al, 2007b). The only 
explanation that could be offered for this negative association is that when 
multiplicative effects was calculated, the joint effect was used as numerator and 
separate effect from both gene and exposure was used as denominator. The 
fact that these risk estimates are very similar particularly the risk of joint effect 
could contribute to the negative multiplicative effect. 
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In sum, little is known of a direct effect of DNA repair capacity on prostate 
cancer risk but there is a growing body of evidence that environmental exposure 
to toxins leads to formation of DNA adducts in prostate and with faulty DNA 
repair machinery may lead to prostate carcinogenesis (Rybicki et al, 2004). 
Therefore hip/pelvic X-ray exposure might play a role in a same way by either 
affecting DNA repair capacity which can lead to translocations, gene 
rearrangements, amplifications and deletion (Ritchey et al, 2005) or by help 
formation of DNA adducts in prostate. 
Most of the previous studies were just looking at polymorphism in DNA repair 
genes and its effect on prostate cancer not the gene-environment interaction 
and risk of prostate cancer. In this study, the author demonstrated the potential 
roles of DNA repair genes and their interaction with low dose radiation in 
prostate cancer including X-ray repair cross completing group7 and Xeroderma 
Pigmentosum Group C. Further studies using large sample sizes are warranted. 
6.6.2 Genes related to Baldness 
There was no effect of all five variant genotypes and prostate cancer risk. 
For SNP rs11603132, baldness appeared to be a risk factor for prostate cancer at 
age 30's (OR 1.34,95% C. I. 1.01-1.78). , There was no evidence for a joint 
effect between baldness at any other age and SNPs (rs 2180439, rs1998076, 
rs1160312, rs11603132). The results from the fully adjusted model showed a 
non-significant multiplicative interaction between both baldness at any age and 
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the SNPs (rs2180439, rs1160312, rs1998076, rs11603132, rs2414096) with 
prostate cancer risk. 
There is no case-control study on interactions of these genes and balding factors 
available to compare results of the present study with. Most of the previous 
studies have investigated SNPs role in direct relation to baldness. The case- 
control study by Hillmer et al, found significant association between rs2180439 
(OR 1.82,95% C. I. 1.45-2.30) and baldness in their genome wide association 
study (GWAS) and also reported an OR of 2.17 with 95% C. I. 1.70-2.78 in their 
replication analysis however after combined studies (the German samples from 
GWAS+ replication analyses), they found highly significant association between 
rs2180439 and baldness (p=2.67.10'15). The results also suggested that 
rs1998076 showed a significant risk increase both with GWAS (OR 1.90,95% 
C. I. 1.50-2.41) and with replication analysis (OR 2.13,95% C. I. 1.66-2.73). 
They found rs1998076 as the best SNP (p=1.3=10-7) located outside the 
androgen receptor locus (AR) (Hillmer et al, 2008). 
For steroid hormone gene CYP19A1 (rs2414096), there is only one study looking 
at mutation of CYP19A1 and prostate cancer risk. The study included 8,166 
prostate cancer cases and 9079 age and ethnicity matched controls and results 
suggested that germ line variation in CYP19A1 htSNPs were responsible for 
significant difference in sex steroid hormone concentrations in men but they did 
not have measureable effects on prostate cancer risk (Travis et al, 2009). 
Previous studies showed that CYP19 gene plays an important role in the 
biosynthesis of the most active biological oestrogen, the oestradiol. It has been 
postulated that polymorphisms of CYP19 could increase oestradiol level and have 
some role in breast cancer risk (Mucci et al, 2001). 
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In summary, no association was found with baldness genes, baldness and 
prostate cancer risk. 
6.7 Conclusion 
This study has identified gene and environment interactions between two 
mutations of DNA repair genes including XPC and XRCC7, low dose ionising 
radiation and prostate cancer risk. This observation, if further substantiated, has 
the potential to make substantial contribution to our understanding the roles of 
genetic susceptibility in prostate cancer. 
6.8 Recommendations 
As linkage studies lack power to detect alleles with moderate effects on risk, a 
large scale case-control studies are more efficient and the hypotheses supported 
by such evidence can then be further investigated in cohort studies and clinical 
trials. 
Studies on molecular level for identifying individuals with higher risk carrying 
genetic polymorphisms with reduced DNA repair capacity should be identified 
and this could help in cancer prevention by targeting those individuals. 
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Chapter 7 Summary of work 
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This thesis forms part of the study of Gene-Environment Interactions in Prostate 
Cancer. The study was a population based case-control study. Cases were 
recruited from a variety of prostate cancer centres and controls were sourced 
from general male population and were age and geographically matched. The 
study sets out to investigate exposures associated with risk and also to explore 
genetic components involved in disease aetiology and their interactions. The 
Trent Multi Ethics approval was obtained. Exposures data were collected using 
self completed questionnaire. 18 ml Blood samples and toe nail clippings were 
also collected. Data of 1112 prostate cancer cases with symptomatic prostate 
cancer of all ages and 1872 population-based controls were analysed. 
The study obtained a good response rates, 85.0% in case group and 74.4% in 
control group. The study population were predominantly Caucasian (>95%). 
The median age for cases and controls were 60 years and 59 years respectively 
suggesting good age matching between cases and controls. Furthermore, social 
class and education level distributions were similar between the two groups. 
These general demographic factors indicate that the study design was good. 
This thesis presents results with two main parts, environmental factors and 
genetic factors. 
For environmental factors, the results suggested that probands with positive 
family history of prostate cancer in first degree relatives were at greater risk 
compared to those with no family history of any cancer. A slightly lower risk, as 
compared to prostate cancer proband, was observed when the proband had a 
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family history of breast cancer in first degree relatives. The findings suggest 
strong genetic components in the development of prostate cancer. 
The findings on X-ray exposure suggested that hip/pelvic X-ray increased the 
risk of developing prostate cancer. These results indicate that low dose 
radiations delivered to the anatomical site of the prostate gland are a potential 
cause prostate cancer later on in life. 
Balding of any ages was not associated with prostate cancer risk overall 
however, an investigation of baldness in the subset of subjects with a positive 
family history of prostate cancer indicated that baldness was a risk factor for 
prostate cancer in this subgroup, suggesting a combined genetic role in the 
aetiology of both the conditions. 
The results of hand pattern (second digit length (2D) compare to fourth digit 
length (4D) showed that men with index finger longer than ring finger (high 
2D: 4D) indicative of higher oestrogen at conception were less likely to develop 
prostate cancer as compared to men with index finger shorter than ring finger 
(low 2D: 4D) indicative of higher testosterone at conception though the results 
were borderline statistically significant. This finding suggests the role of prenatal 
androgenic influences on prostate cancer risk later on in life. 
Acne appeared at age 30 and presence of acne from teens through to age 30s 
showed an increased risk. This suggested a possible role of prolonged exposure 
to high levels of androgens and/or chronic inflammatory process in prostate 
carcinogenesis. 
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For the genetic investigations, low penetrance genes may be in part responsible 
for about 90% of cases (10% are inherited with high penetrance genes) were 
targeted and subsequently identified based on previous associations reported. 
Eleven selected single nucleotide polymorphisms (SNPs) from seven genes 
involved in DNA repair pathways and five selected SNPs from two genes involved 
in balding were analysed. The risk estimates of each SNPs was obtained and 
none of these SNPs showed any significant association with prostate cancer. The 
multiplicative interaction analysis on hip/pelvic X-ray suggested one SNP 
(rs2228001) of Xeroderma Pigmentosum Group C (XPC DNA repair gene) 
showed a modest risk increase. In contrast, the multiplicative analysis of 
universal X-ray exposures suggested negative associations between DNA repair 
genes (X-ray repair cross completing group? (XRCC7G6721T rs7003908), X-ray 
exposures and prostate cancer risk. No interaction was observed between 
balding, balding gene mutations and prostate cancer risk. 
This research was based on analysing the large UK case-control data set of many 
novel potential risk factors for prostate carcinogenesis including environmental 
and genetic factors. This large dataset allows not only the better power to 
detect any significant associations of exposures but also the investigation of 
gene and environment interactions. The newly identified environmental risk 
factors include low dose medical diagnostic radiological procedure, acne and 
balding in subjects with positive prostate cancer family history. The finding on 
gene and environment interaction suggested that subjects who carry the 
mutation allele on XPC DNA repair gene are at greater risk of developing 
prostate cancer, however, subjects who carry X-ray repair cross completing 
group7 allele mutation and who were exposed to low dose radiation are less 
likely to develop prostate cancer. This is the first study to look at DNA X-ray 
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repair and potential candidate hormone marker gene polymorphisms and their 
interactions with exposures. 
The findings of this study provide several new leads in the field of cancer 
epidemiology of prostate cancer which could be applied further to investigate the 
aetiology of prostate cancer. The findings from gene and environmental 
analyses provide new means of evaluating prostate cancer and many other 
cancers and better understanding of potential combined effects of gene and 
environmental effects on human cancer. The completion of whole genome 
project includes various populations around the world will allow the identification 
of a much wider range of SNPs and genes. This will enable future work to 
expand SNPs selection according to study population and extend the 
investigations stated here on the effects both alone and in combination of 
genetic and environmental factors in prostate cancer aetiology. 
This work has indicated some new leads in prostate cancer aetiology that should 
be further investigated in other large epidemiological studies. The Gene- 
environment interaction work has also demonstrated the potential of such an 
approach but required very large sample sizes that would be provided by 
prostate cancer case-control study consortia. Such consortium has recently 
been established (Collaborative Oncological Gene-environment Study-COGs) to 
which these data have been contributed and the lead identify in this dissertation 
and others will be investigated further in due course. 
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National Research Ethics Service 
Trent Research Ethics Committee 
Derwent Shared Services 
Laurie House 
Colyear Street 
Derby 
DE1 11-I 
Telephone: 01332 868 905 
Facsimile: 01332 868 930 
06 June 2007 
Professor Kenneth Muir 
Professor in Epidemiology 
University of Nottingham 
Division of Epidemiology and 
Public Health School of 
Community Health Sciences 
Queen's Medical Centre. 
NOTTINGHAM 
NG7 2UH 
Dear Professor Muir 
Full title of study: Investigation of Environmental, Lifestyle and Genetic 
Risk Factors for Prostate Cancer in Younger Men 
REC reference number: 07/MRE04/29 
Thank you for your letter of 23 May 2007, responding to the Committee's request 
for further information on the above research and submitting revised 
documentation. 
The further information has been considered on behalf of the Committee by 
the Chair. Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical 
opinion for the above research on the basis described in the application 
form, protocol and supporting documentation as revised. 
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Ethical review of research sites 
The Committee has designated this study as exempt from site-specific 
assessment (SSA. There is no requirement for any Local Research Ethics 
Committees to be informed or for site-specific assessment to be carried out 
at each site. 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions 
set out in the attached document. You are advised to study the conditions 
carefully. 
This research Ethics Committee is an advisory committee to East Midlands Strategic Health Authority 
The National Research Ethics Service (NRES) represents the NRES Directorate within 
the National Patient Safety Agency and Research Ethics Committees in England 
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Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document Version Date 
Application Version 5.3 05 April 2007 
Investigator CV Version 2 01 January 2007 
Covering Letter 05 April 2007 
Questionnaire: F1001 Reminder Version 1 01 March 2007 
Questionnaire: Gene-Environment 
interactions In Prostrate Cancer 
Revised 5th Draft 06 February 2007 
Letter of invitation to participant P3001- Introduction 
study 
procedures- Version 1 
01 March 2007 
Letter of invitation to participant 2- F1003 
- 
Control 23 May 2007 
Participant Information Sheet: P2002 
- 
Controls 2 23 May 2007 
Participant Information Sheet: P2001 
- 
Cases 2 23 May 2007 
Participant Consent Form: F1002 Reminder Version 1 01 March 2007 
Participant Consent Form: P2004 
- 
UKCPCS 
Cases 2 
23 May 2007 
Participant Consent Form: P2003 
Consultants/GP-Cases/Controls 2 23 May 2007 
Response to Request for Further Information 23 May 2007 
Letter to nurses 
- 
P3002, Instructions for blood 
sample taking Version 1 
01 March 2007 
Headed Paper 2 
Headed Paper I 
Evidence of Insurance letter, Marsh Ltd Version 1 23 October 2006 
Letter from Medical Research Council 19 October 2004 
Letter from The Prostate Cancer Research 
Foundation 
01 February 2006 
Procedures Manual Version 1 04 April 2007 
Invitation Letter- P1002, Obtaining permission to 
contact consultant cases 
Version 1 01 March 2007 
Invitation Letter-P1001, UKGPCS Cases Version 1 01 March 2007 
Invitation Letter 
- 
P1002a, Consultant/GP Cases Version 1 01 March 2007 
Letter to consultant/GP 
- 
C1002 Version 1 01 March 2007 
Letter to GP 
- 
C1001, Instructions for controls 
selection 
Version 1 01 March 2007 
Letter to Consultant 
- 
00001, Initial Approach Version 1 01 March 2007 
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R&D approval 
All researchers and research collaborators who will be participating in the 
research at NHS sites should apply for R&D approval from the relevant care 
organisation, if they have not yet done so. R&D approval is required, whether or 
not the study is exempt from SSA. You should advise researchers and local 
collaborators accordingly. 
Guidance on applying for R&D approval is available from 
httg: //vvww. rdforum. nhs. uk/rdform. htm. 
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Statement of compliance 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees (July 2001) and 
complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
Feedback on the application process 
Now that you have completed the application process you are 
invited to give your view of the service you received from the 
National Research Ethics Service. If you wish to make your views 
known please use the feedback form available on the NRES 
website at: 
https: //www. nresform. org. uk/AppForm/Modules/Feed back/EthicaiReview. a 
SDX 
We value your views and comments and will use them to 
inform the operational process and further improve our 
service. 
071MRE04129 Please quote this number on all correspondence 
With the Committee's best wishes for the success of this project 
Your sincerely 
Dr Robert Bing 
Email: jill. marshaliUalderwentsharedservices. nhs. uk 
Enclosures: Standard approval conditions [SL. AC2] 
Copy to: Professor Kenneth Muir, Division of Epidemiology and Public Health, 
University of Nottingham 
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ID number 
Official use only 
R The University of 
Nottingham 
Gene-Environment Interactions in 
Prostate Cancer ". 
This study is being conducted by the Division of Epidemiology and Public Health, 
University of Nottingham, Institute of Cancer Research and the Royal Marsden 
Hospital NHS Trust. We are investigating factors that may be involved in the 
occurrence of prostate disease. 
We would be very grateful if you could complete this questionnaire. This should only take 
about 30-45 minutes and we hope you will find it interesting. Your information will be 
treated in the strictest confidence. 
Please DO NOT write your name anywhere on the questionnaire. You will be identified 
only by the unique ID number at the top of this page. 
Please return the completed questionnaire at your earliest convenience in the enclosed 
prepaid envelope 
- 
no stamp is reate 
Thank you for your help. 
Dr Aneela Rahman (Researcher) Tel: 0115-8230495 
Study Team from The University of Nottingham 
Prof. Ken Muir (Principal Investigator) 
Dr Artitaya Lophatananon (Research Officer) 
Dr Aneela Rahman (Researcher) 
Ms Jo-Fen Uu (Research Officer) 
Study Team from The Institute of Cancer 
Research/The Royal Marsden Hospital 
NHS Trust 
Dr Rosalind Eeles (Principal Investigator) 
Prof. Douglas Easton (Co- Investigator) 
Prof. David Deamaley(Consultant Oncologist) 
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ID Number 
use only 
p, s. - ,. ý, »... ,w,.. <.. ýýzr.. -. ,.. t... "., .. a.,..,., r. ,.. x.. srýv 
. _r . 
_=ýý _. ý. ýt^vrrn -, ý«ý. w, r :° . ý, - ý,.. + ri. eY«w. 
--Section "', 1: About-you 
We would like to ask about your personal details. 
1) Date of birth 
Qoiao/ao 
Date Month Year 
2) Your marital status (p/ease tick the appropriate box) 
Q Married Q Widowed Q Single 
Q Divorced Q Separated Q Other, please specify 
.............. 
3) Please indicate which group you belong to (please tick the appropriate box) 
Q White Q Black- Caribbean 
Q Black- African Q Black- other 
Q Indian Q Pakistani 
Q Jewish Q Sephardic 
Q Ashkenazi Q Chinese 
Q Other, please specify ........ 
4) In which country were you born? (P/ease tick the appropriate box) 
Q UK Q Other, please specify 
................................................ 
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5) Have you always lived in the UK? (P/ease tick the appropriate box) 
Q Yes (go on to question 7) Q No (go on to question 6) 
6) How long have you been living in the UK? (P/ease specify number of years) 
......................... 
years 
7) What is the highest educational qualification you have obtained? 
(P/ease tick the appropriate box) 
Q None 
Q GCSEs, "0" levels or equivalent 
Q 
"A" Levels, higher or equivalent 
Q Higher or professional qualifications e. g. degree, HND 
Q Other, please specify 
......................................... 
ý. T .. « +- 
_ 
a, ^rcv ý ; -. ý aýý, ý 
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'< 
_ý.. n,, rr,. r-agsýr'""`u-; ý; wý. -aý 
Section 2: Employment 
This section is about the jobs you have had since you left school. 
8) Can you briefly describe all the jobs you have had for more than 1 Year. 
(Please start with your current job or your latest job). 
)ob title Full time (FT) Started Finished Self- Did you 
and description or (year) (year) Employed supervise 
of duties Part time (PT) (SE) any 
or others? 
Employed (Y or N) (E) 
1 
2 
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Job title 
and description 
of duties 
Full time (FT) 
or 
Part time (PT) 
Started 
(year) 
Finished 
(year) 
Self- 
Employed 
(SE) 
or 
Employed 
(E) 
Did you 
supervise 
any 
others? 
(Y or N) 
3 
4 
5 
6 
7 
9 
10 
11 
12 
13 
14 
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9) Have you ever been exposed to chemical substances in any of your jobs? 
Q Yes (please complete the table below) Q No (go on to Section3) 
Degree of Regularity Total From which job? 
Chemical substances (Y/N) exposure l. e. 1. e. daily, number -please give 
high, weekly of the fob number 
intermediate or years from the /ist 
background exposed above 
Paints/varnishes 
/lacquers 
Solvents/ 
degreasing agents 
Petrol/diesel/ 
hydrocarbons 
Weed killers/ 
herbicides 
Radiation 
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Section 
-"3:. YOUr hormones 
Evidence has suggested a possible relationship between male hormones 
and prostate disease. The effect of hormones can be seen physically, for 
example, pattern of hair loss, frequency of shaving, acne or hand pattern. 
In this section we would like to ask you about these factors at various 
ages. 
Please choose the NUMBER corresponding to the hair pattern nearest to your own at the 
ages below. Please select one answer to each question. If you can't remember precisely, 
please make your best estimate. 
b, ýýý. re 
1234 
ýýý, ýý 
567 
10) In your 20s F-j 11) In your 30s 
a 12) In your 40s Q 
13) From the picture below, could you please look at the index and the ring 
fingers on your right hand by putting your hand on the table and compare these 
to the patterns below. Please tick the appropriate box for the pattern that is 
nearest to your own. 
Right hand 
199 
Right hand 2 
El 
Right hand a 
El 
14) In your 20s, how often, on average, did you need to shave in order to keep 
clean shaven? 
Q Once a day Q Twice a day Q Every other day 
Q Less than every other day f7, Do not shave 
15) Did you have acne when you were young? 
Q Yes (if yes go on to question 16) Q No (go on to Section 4) 
16) Did you still have acne when you were: 
Yes No 
In your 20s 
QQ 
In your 30s 
QQ 
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Section 
- 
4: Smoking 
We would like to know a bit more about your smoking habit in this section. 
Please recall your smoking habits urior to your diagnosis 
17) How would you describe yourself? (Pease tick one box only) 
Q Current smoker, smoke daily (go onto Question 18) 
Q Current smoker, smoke occasionally (go on to question 18) 
Q 
Ex-smoker, don't smoke at all now (go on to question 21) 
Q 
Never smoked (yo on to Section 5) 
F~Smokers"o'nly 
18) In a day, I usually smoke (p/ease tick the box 
- 
you can tick more than one 
box and write down the number of cigarettes/ cigars or amount of pipe tobacco 
you smoke per day or per week) 
a Cigarettes number........ per day or number........ per week (go on to questions 19,20) 
Q Cigar number........ per day or number........ per week (go on to questions 19) 
Q Pipe amount 
........ 
per day or amount........ per week (yo on to questions 19) 
19) The cigarettes I normally smoke are: (Please tick appropriate box) 
Q High tar level Q Middle tar level Q Low tar level 
20) I have been a smoker for........ years (please write down a number and go to 
next section) 
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Ex-smokers only. I: 
21) 1 have been an ex-smoker for: (p/ease tick appropriate box) 
Q Less than a yearQ 1-3 years 
Q 4-10 years Q over 10 years 
22) When I was smoking, I used to smoke (please tick the box - you can tick 
more than one box and write down the number of cigarettes/ cigars or amount of 
pipe tobacco you smoke per day or per week) 
Q Cigarettes number........ per day or number......... per week 
Q Cigar number......... per day or number......... per week 
Q Pipe amount 
......... 
per day or amount......... per week 
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Section 
-, 
5 :, About sex 
-A 
The prostate gland is responsible for producing fluid that helps sperm to survive 
when they enter the female reproductive tract following ejaculation. Changes in 
the prostate gland may occur depending on how often you have sexual 
intercourse or masturbate. Some sexual activities may also be related to 
hormone levels or may lead to an increased risk of infection. To help us find out 
if there is an association between prostate changes and sexual activities we need 
to know about past and present sexual practices. 
We realise that this is a very sensitive subject but we would be very grateful if 
you could complete this section. Please answer these questions ONE if you 
feel able to do so. 
All your answers will be treated as STRICTLY CONFIDENTIAL AND NO 
INFORMATION WILL BE PASSED ON TO ANYONE OUTSIDE THE STUDY 
INCLUDING YOUR FAMILY DOCTOR. 
23) At what age did you first have sexual intercourse? (P/ease tick appropriate 
box) 
Q Never Q Under 15 years old 
El 15-19 years old Q 20-24 years old 
25-29 years old 
Q 30 years or older 
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24) How often on average did you have sexual intercourse? (Please tick one box 
and indicate yes or no, as appropriate) 
In your Neve 
Less 
than 
once a 
month 
Once to 
three 
times a 
month 
Once a 
week 
Two to 
three 
times a 
week 
Four to 
six times 
a week 
Daily 
Condom 
normally 
used 
r Yes No 
20s Q Q 
30s Q Q 
40s Q 
50s a Li 
25) In your lifetime, how many women in total have you had sexual intercourse 
with? (Please tick appropriate box) 
Q None Q One Q Two 
E] Three to five Ej Six to ten F7] Eleven to twenty 
More than twenty 
26) From your answer to question 25, how many of them would you have 
classified as your "partner" (i. e. someone you have/had sexual intercourse with 
once a week or more for a period of 3 months or longer). 
Q None Q One Q Two 
Q Three to five Q Six to ten 
Q More than twenty 
Q Eleven to twenty 
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27) In your lifetime, have you ever paid money to women for sexual intercourse? 
(P/ease tick appropriate box) 
Q Yes (go on to question 28) Q No (go on to question 29) 
28) Did you normally use condoms on those occasions? 
Q Yes Q No 
29) At what age did you first masturbate? (Please tick appropriate box) 
Q Never Q Under 15 years old 
Q 15-19 years old Q 20-24 years old 
Q 25-29 years old Q 30 years or older 
30) How often on average did you masturbate? 
Less 1-3 2-3 4-6 
than times times times 
once a 
a 
. 
Once a a a 
In your Never month 
mont 
h week week week Daily 
20s 
30s 
40s 
50s 
31) Overall, did you regard yourself has having a problem with sexual activity at 
different ages? (please tick appropriate box) 
In your 20s 
Q Yes Q No 
30s Q Yes Q No 
40s 
Q Yes Q No 
50s 
Q Yes Q No 
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32) In your 20s, 30s, 40s and 50s, did you encounter any of the following 
statement(s) that might have restricted you from sexual activity? (you can tick 
vmore than 1 statement) 
Statements 
In your 
20s 30s 40s 50s 
1. Were not in any relationships 
2. Your partner had physical/ emotional difficulties 
3. You suffered from the following conditions which 
restricted your sexual activity. 
( You can tick more than 1 box. ) 
Q Q Q Q 
- 
depression Li Li 
- 
diabetes (high blood sugar) 
- 
high blood pressure 
- 
arthritis or rheumatism 
- 
prostate cancer 
- 
enlarged or swollen prostate 
- 
back problem 1: 1 0 U Li 
- 
impotence / erectile dysfunction 
- 
lack of desire/ too tired 
- 
other, please specify 
................................................................................................. 
................................................................................................. 
Q Q Q Q 
33) In your lifetime, have you ever attended a sexually transmitted disease (STD) 
or special (VD) clinic? (Please tick appropriate box) 
Q Yes Q No 
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34) Have you ever been told by a doctor that you had any of the following 
conditions, even if it was a long time ago? (Please tick appropriate box) 
Gonorrhoea Q Yes Q No 
Syphilis Q Yes Q No 
Genital herpes Q Yes Q No 
Genital warts (ie. warts on your penis/anal area) E] Yes Q No 
Non-specific urethritis (NSU) Q Yes Q No 
Any other type of venereal disease Q Yes Q No 
35) Have you ever had sores or ulcers on your penis? 
Q Yes (go on to question 36) Q No (go on to Section 6) 
36) Have you ever had sexual intercourse while you had sores or ulcers on your 
penis? (Please tick appropriate box) 
QYes No 
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rion ti; out cL; fl xexposure 
There is growing evidence on the relationship between UV radiation exposure 
from sunlight and prostate diseases. Thus we would like to ask you questions 
about your skin colour and also lifetime sun exposure. 
Please tick appropriate box for each question: 
37) What type of complexion do you have? 
Q Oily Q Dry Q Combination Q Normal 
38) What is your skin colour when you are not sun tanned? 
Q Very fair Q Fair Q Medium 
Q Olive Q Very dark 
39) What happens when you stay in the sun too long? 
Q Painful, bad blistering and peeling 
Q Blistering followed by peeling Q Burns sometimes 
Q Rarely burns Q Never had burns 
40) On average looking back at the various stages of your life, in the daytime, 
how long were you out of doors during your working and non working hours? (If 
during the last 5,10 or 20 years you did not work please answer only non working 
time. ) 
*Please recall your sunlight exposure prior to your diagnosis 
In your Less 
than 1 
hour 
1-2 
hours 
3-4 
hours 
More 
than 5 
hours 
20s Working 
Non- working 
30s Working 
Non- working 
40s Working 
Non- working 
During the last 5 years* Working 
Non- working 
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41) On average looking back at the various stages of your life in the day time 
when outdoors, did you generally try one of the following? P/ease put v'under the 
activity. You can answer more than one activity. If you did not spend time 
outdoors at all, please put iunder the far right column 
* Please recall your activity prior to your diagnosis 
When outdoors, you........ 
Did not 
Always Wear very Wear Try to spend 
seek a sun little normal cover time 
In your tan summer yourself outdoors 
clothing up from at all 
the sun 
20s 
30s 
40s 
During the last 5 years* 
42) Did you use suntan oil, lotion or cream to protect your skin when you were 
out in the sun? Please tick V 
In your Always Sometimes Rarely Never 
20s 
30s 
40s 
During the last 5 years* 
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ction 7:. Ai t thbe health of your family 
Some prostate diseases may be hereditary. We would like to ask if any of your 
family have ever been diagnosed with prostate problems or any type of cancer. 
43) Have any male members of your family been told by a doctor that he 
has/had any of the following? (If there is no one, please go on to question 44) 
Identify relationship to you 
Yes (P/ease answer the following) 
fl A swollen or enlarged prostate 
(benign prostatic hyperplasia) 
Q Prostatitis (infection of the prostate) 
No (p/ease go on to question 44) 
Certain cancers are known to have a genetic or familial component. Please record 
below any cancers that you are aware of and that have occurred in your first degree 
relatives (parents, siblings or your children). 
44) Have any of your first degree relatives have cancer of any type? 
Yes (go on to question 45) Q No (go on to Section 8) 
45) If yes, please specify their relationship to you and type of cancer that they 
have (including vrostate cancer). 
Relationship to you Type of cancer Age at Date of birth 
diagnosis 
(if known) 
1 
2 
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a 
jiý 
p ý, 
Relationship to you Type of cancer Age at 
diagnosis 
(if known) 
Date of birth 
3 
4 
5 
6 
7 
8 
9 
10 
ýY µ Section 8: Ph sical activity-, ''' 
In this section we would like you to think about the physical activity you 
have undertaken in a typical day at various stages of your life. 
On average have you undertaken at least 30 minutes of moderate 
physical activity per day 
-either at home or at work. (These 
activities can be made up of many components, for example, moving a 
table, pushing a vacuum cleaner, bowling or playing golf). 
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* Please recall your activity prior to your diagnosis 
46) In your 20s Q Yes Q No 
47) In your 30s 
48) In your 40s 
49) During the last 5 years* 
Q Yes Q No 
Q Yes Q No 
Q Yes Q No 
Q Not applicable 
Q Not applicable 
Q Not applicable 
Q Not applicable 
On average have you undertaken 20 minutes or more of eneroetic activity at 
least 3 times per week whilst NOT at work. (These include, for example, keep fit, 
dancing or exercises, swimming or other brisk sport, long walks, jogging or 
running, hard work in a job at home or in the garden, cycling). 
* Please recall your activity prior to your diagnosis 
50) In your 20s Q Yes Q No 
51) In your 30s 
52) In your 40s 
53) During the last 5 years* 
Yes Q No 
Q Yes Q No 
Q Yes Q No 
Q Not applicable 
Q Not applicable 
Q Not applicable 
Q Not applicable 
ý,,.,. ý .. ,ýr, « . =. ýo,. ..,,..., mac. ý... ..... 
Section 9: Your general health and medication 
In this section we would like to know more about your general health, medication 
(use of steroids, hormone treatments, or pain killers etc), as well as any X-ray 
procedures you have ever had at various stage of your life time. 
Please recall your general health and medication prior to your diagnosis 
54) Have you had a vasectomy? 
Q Yes (go on to question 55) 
55) How old were you? QQ 
Q No (go on to question 56) 
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56) Have you ever taken any of the following? (If no please go on to question 57) 
Yes/No At 
age 
Treatment for Duration of 
use 
(mm/yy) 
Androgens or testosterone 
Anabolic steroids 
Oestrogen 
Cortisone not as a skin cream 
Cortisone or corticosteroids as a skin 
cream 
Thyroid drugs 
One of the questions researchers want to know is whether the exposure of 
medical diagnostic procedures such as X-ray, is associated with prostate disease. 
In order to answer this question, we will need to collect detailed information 
about any X-ray or radiological procedures you have ever had. 
Please recall any procedures you have had prior to your diagnosis 
57) Have you ever had any of the following x-ray procedures? (if yes, please give 
details with your best estimates) 
b N Details of procedure 
Procedure Yes/ 
um 
er of 
Purpose of x-ray 
No times At age / date and 
site (if applicable) 
1 
Barium meal 2 
f 
- 
i your 
. 
e. x rays o 
stomach taken after 3 
swallowin lass of a g g 
chalky liquid 4 
5 
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Numb Details of procedure 
Procedure Yes/ No 
tof imes At age / date 
Purpose of x-ray 
and 
site (if applicable) 
1 
Barium enema 
i. e., a special X-ray test 
2 
used to examine the 
large bowel(colon and 3 
rectum) 4 
5 
1 
Cholecvstoaram 2 
Le. x-ray of your gall 
bladder taken after 
3 
swallowing a glass of 
thick liquid 4 
5 
1 
2 
Kidney X-ray following 
i ti 
3 
an njec on 
4 
5 
1 
2 
X-ray of hand. 
shoulder or arms 
3 
4 
5 
1 
2 
X-ray of uQper leg o 
thigh 3 
4 
5 
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Numb Details of procedure 
Procedure Yes/ No er of times At age / date 
Purpose of x-ray 
and 
site (if applicable) 
1 
2 
X-rav of hies/pelvic 
region 
3 
4 
5 
1 
Lvmnhanaioaram 2 
/. e. x-ray taken of 
different parts of the 
3 
body after dye has been 
injected 4 
5 
1 
CAT scan 
- 
f I b d 
2 
. 
e. x your ray o o y 
taken inside a machine 
th i h t 
3 
ere e equ pmen w 
rotates around you 4 
5 
1 
NMR or MRI 
(magnetic resonance 
2 
imaging) Scan 3 
I. e. where you are put 
inside a large magnet 
4 
5 
di ti R 
1 
a oac ve 
or isotope injections 2 
with pictures or x-ray 
taken afterwards 
3 
4 
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Numb Details of procedure 
Procedure Yes/ of Purpose of x-ray No t imes At age / date and 
site (if applicable) 
5 
1 
2 
V enoaram 
i. e. x-rays of vein after 3 
e has been injected d y 
4 
5 
1 
Anaioaram or 
arterioqram 2 
I. e. an x-ray to view 
your heart or body 3 
blood vessels taken 
after a tube has been 4 
passed into your arm or 
groin 5 
58) Have you ever been told by doctor that you have/had any of the following 
conditions? 
Conditions Yes/No Age at diagnosis 
Diabetes 
Heart disease 
Hypercholesterolaemia (high blood cholesterol) 
High blood pressure 
Other please specify 
.................................................................... 
Some medications may be associated with prostate diseases. In order to study 
this question in detail, we would like to ask you some questions about your use 
of prescription or non-prescription painkillers in the past. 
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Please try to recall the time period prior to your diagnosis 
59) Have you ever regularly taken statin (e. g, Atorvastatin, Cerivastatin, 
Simvastatin) in the past 10 years? 
Q Yes (go on to question 60) Q No (go on to 
question 61) 
60) If Yes, could you please let us know 
(a) Which type of statin (or brand name) you have taken? 
............................................................................................................................ 
a. The dosage of pills or capsule? 
.................. 
mg or 
............... 
Ng 
b. Roughly how often do you take the medicine? 
...................................... 
c. For how many years have you been taking the medicine? 
.................. years 
d. Reason for taking statin? 
.................................................................................... 
61) Have you ever regularly taken any non-prescription painkillers bought over the 
counter from a -chemist or a supermarket in the last 10 YEARS? prior to your 
diaqn * 
(By regularly, we mean at least one tablet per week for more than three months) 
Q Yes (go on to question 62) Li No (go on to question 63) 
62) We would like to know more details about the painkiller(s) you have regularly 
taken. Could you please let us know: 
a) Which type of painkiller(s) you have taken? 
b) Do you recall the dose? 
c) Roughly how often do you take the tablets or medicine? 
d) For how many years have you been taking the tablets or medicine? 
e) For what reason do you take them? 
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Please provide the information in the table 
c) Average frequency 
b) Dose Tick one box per line d) Duration 
a) Name of Painkiller At least 
Dosage of once a At Number of e) Reason 
pills/capsules Never or month but least years of for taking 
or teaspoons less than not every once taking painkillers 
each time ea month day a day painkillers 
1 Aspirin or preparation 
containing aspirin eg 
Alka-Seltzer, Disprin 
2 Ibuprofen 
- 
e. g. 
Nurofen, Ibufen, Advil, 
Migrafen 
3 Paracetamol or 
preparation containing 
Paracetamol 
- 
eg 
Panadol, Co-proxamol, 
Co-codamol 
4 Other pain medication 
(please specify) 
.......................................... 
63) Do you have any side-effects if you take aspirin? 
Q Yes (go on to question 64) Q Don't know/ I don't use aspirin (go on to 
question 65) 
Q No (go on to question 65) 
64) Do the side effects make you stop taking aspirin? 
Q Yes (go on to question 65) 
Q No. I still take aspirin because 
........................................................................ 
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In this section, we would like you to think about the three most commonly used 
painkillers in various stages in your adult life. This includes painkillers available in 
pharmacy or supermarket (i. e., over the counter: OTC), as well as those 
prescribed by doctor. Please try to recall the period prior to your diagnosis 
65) Have you been taken any painkilling medication on a regular basis (at least 
once a week for more than three months) during your adult life, either prescribed 
by your GP or bought over the counter (OTC). 
Q Yes (go on to question 66) Q No (go on to section 10) 
66) If Yes, please can you give us more details 
A Painkiller 1 B Painkiller 2 C Painkiller 3 
In your No of No of No of 
Name From years Name From years Name From years 
used used used 
GP o GP o GP 
20s 0 0 
OTC OTC OTC 
GP o GP o GP 
30s 0 0 OTC OTC OTC 
GP o GP GP 
405 0 13 OTC OTC OTC 
GP GP 11 GP 
50s 11 13 OTC OTC OTC 
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Section, 10: Further details about you 'l 
In this section we would like to know more about your body size and body shape. 
This includes the changes of your weight or trouser size in the past years. Please 
give as approximate estimates if you can and 
67) Please can you tell me your current weight and height? 
My weight is........... Stones 
............. 
Pounds 
My height is............ Feet 
.................. 
Inches 
or 
.............. 
Kilograms 
or 
............... 
Centimetres 
68) What was your weight prior to your diagnosis? 
My weight was 
......... 
Stones........... Pounds or 
............. 
Kilograms 
69) What is your collar-size? 
1inches 
70) Please can you tell me your waist and your approximate hip circumference, 
either in inches or in centimetres? If you cannot remember your waist 
circumference, can you recall your trouser size (for example size 30)? 
Waist/ Trouser Size Hip 
inch cm inch cm 
In your 20s 
In your 30s 
In your 40s 
During the last 5 years before 
your diagnosis 
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Please select the shape you think you were at different ages. (Please write down 
the number you think you were). 
0 
71) In your 20s Q 
72) In your 30s Q 
73) In 'your 40s Q 
74) During the last 5 years Q 
(Before your diagnosis) 
Overall please select one of the descriptions below that suit you the most before 
your diagnosis (please write down number in the box) 
LApple 
shape- where your body fat is distributed mainly around your tummy area. 
2 Pear shape- where your body fat is distributed mainly on your hip and thigh. 
3. Ova/shape- where your body is distributed around your neck, your chest, your tummy 
area and also your thigh. 
4. Symmetric shape- where you are lean with no fat distribution around your body. 
75) My body shape was Q 
221 
123456789 
May we have your permission 
- 
To contact you if we need further information to resolve any queries? 
Q Yes Contact telephone number: 
................................................. 
Q No Email: 
.................................................................................... 
- 
To look at your medical record 
Q Yes Q No 
If you are planning to move house in the near future, please may we 
have your new address? 
My new address will be 
........................................................ 
.......................................................................... 
Post code..................... 
New telephone number (if known) 
................................................... 
E-Mail: 
..................................................................................................................... 
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Thank you very much once again for 
taking the time and trouble to fill in 
this questionnaire, your help is really 
appreciated and will be invaluable to 
this research project. 
Please return your answers in the pre paid 
envelope as soon as possib/e to.,, 
DrAneela Rahman 
Division of Epidemiology and Public Health 
School of Community Health Sciences 
Queens Medical Centre 
University of Nottingham 
Nottingham NG7 2UH 
Tel 0115-8230495 
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